

2017

REPORT OF THE
**AUSTRALIAN AND
NEW ZEALAND
NEONATAL NETWORK**



UNSW
SYDNEY

ANZNN

2017

REPORT OF THE AUSTRALIAN AND NEW ZEALAND NEONATAL NETWORK

Sharon S.W. Chow, Prudence Creighton,
Georgina M. Chambers and Kei Lui

ANZNN Executive:

Kei Lui (Chair)

Chad Andersen

Barbara Bajuk

Malcolm Battin

Georgina Chambers

Lucy Cooke

Koert de Waal

Andy Gill

Barbara Hammond

Jim Holberton

Christine Jorgensen

Natalie Merida

Jane Pillow

Victor Samuel Rajadurai

Jutta van den Boom



UNSW
SYDNEY

ANZNN

© Australian and New Zealand Neonatal Network 2019

This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced without prior written permission from the Australian and New Zealand Neonatal Network (ANZNN). Requests and enquiries concerning reproduction and rights should be directed to the Australian and New Zealand Neonatal Network at the National Perinatal Epidemiology and Statistics Unit, Level 4, Lowy Cancer Research Centre, UNSW Sydney, NSW 2052 Australia.

This publication is part of the Australian and New Zealand Neonatal Network annual reports series. A complete list of the ANZNN's publications is available from the Network's website < www.anznn.net >.

ISBN: 978-0-7334-3871-4

Suggested citation:

Chow, S.S.W., Creighton, P., Chambers, G.M., Lui, K. 2019.

Report of the Australian and New Zealand Neonatal Network 2017. Sydney: ANZNN.

Any enquiries about or comments on this publication should be directed to:

Australian and New Zealand Neonatal Network
At the National Perinatal Epidemiology and Statistics Unit
Level 4, Lowy Cancer Research Centre
UNSW Sydney
NSW 2052 Australia

Phone: +61 2 9385 9158

Email: anznn@unsw.edu.au

Published by the Australian and New Zealand Neonatal Network 2019

Designed and printed by Green Print Centre at UNSW Sydney

Please note that there is the potential for minor revisions of data in this report.
Please check the online version at < www.anznn.net > for any amendments.

Contents

Contents.....	iii
Acknowledgements	vi
Structure of this report	vii
Abbreviations	viii
Participating units and supporting staff.....	ix
1. Organisation of the ANZNN	1
History.....	1
Aims and objectives.....	1
Structure of the ANZNN.....	1
Registration criteria.....	2
Funding support	3
Data set variables	3
2017 Report of the Australian and New Zealand Neonatal Network.....	4
Babies born in Australia	5
Babies born in New Zealand	5
2. Babies registered to level III units	6
3. Mothers of level III registrants	9
Maternal age	9
Previous antenatal history	9
Assisted conception	9
Presenting antenatal problem	10
Antenatal corticosteroid use	11
Magnesium sulphate	12
Multiple gestation.....	13
Method of birth	13
Place of birth.....	14
Transport after birth to a level III NICU	15
Breastfeeding at discharge	15
4. Characteristics of level III registrants.....	16
Baby gender	16
Resuscitation in delivery suite	16
Apgar score at birth	16
Admission temperature	16

Indication for respiratory support.....	17
Exogenous surfactant.....	18
Type of assisted ventilation.....	19
Ventilation in babies born at less than 32 weeks gestation.....	21
Ventilation in babies born at 32 to 36 weeks gestation.....	21
Ventilation in babies born at term.....	21
Respiratory support.....	21
Nasal high flow therapy.....	22
Parenteral nutrition.....	23
Chronic lung disease.....	23
Pulmonary air leak.....	24
Neonatal sepsis.....	24
Retinopathy of prematurity.....	25
Intraventricular haemorrhage.....	27
Late cerebral ultrasound.....	28
Therapeutic hypothermia.....	29
Necrotising enterocolitis.....	29
Spontaneous intestinal perforation.....	30
Neonatal surgery.....	30
Congenital anomalies.....	31
Transfer from level III NICUs to other units.....	31
Length of stay until discharge home.....	32
Survival.....	33
5. Babies registered to level II units.....	35
Overview.....	35
Maternal, pregnancy and birth characteristics.....	36
Characteristics of level II babies.....	38
Eye examination.....	39
Cerebral ultrasound.....	39
Other morbidities.....	39
Level II transfers.....	39
Survival.....	39
6. Extremely preterm follow-up, 2011–2014 births.....	41
Introduction.....	41
Follow-up rate.....	41
Assessment and tools.....	43
Neurological outcome.....	43
Vision and hearing.....	44
Congenital anomalies.....	44
Developmental testing.....	45

Functional impairment	47
Moderate to severe functional impairment	48
Growth – weight, height and head circumference	49
Respiratory and gastrointestinal tract.....	52
APPENDICES	53
Appendix 1: Trends.....	53
Appendix 2: Data tables by birthweight	62
Appendix 3: Methods used in this report	70
Appendix 4: Confidentiality guidelines.....	71
Principles of ownership and maintenance of data.....	71
Conditions for data collection.....	71
Conditions for data security	72
Small numbers.....	72
Appendix 5: Minimum Data Set variables	73
Neonatal Minimum Data Set.....	73
Extremely Preterm Follow-up Minimum Data Set.....	85
Glossary	91
References	93
List of Tables	94
List of Figures	96

Acknowledgements

This is the twenty-second report of the Australian and New Zealand Neonatal Network (ANZNN), the tenth report in the current format and the sixth to include a report on 2 to 3-year follow-up. The ANZNN has endeavoured to retain the information provided in previous reports to allow comparative reporting over time. Details of the current format can be found under 'Structure of this report'.

We would like to acknowledge all the units involved in the provision of data for this report. The ANZNN greatly appreciates the contribution of all participating units and we thank them for their ongoing support together with our data managers for their hard work and attention to detail.

The ANZNN greatly values the time, effort and expertise of the members of the ANZNN Advisory Council and their conceptual, intellectual and financial contributions, all of which have helped make this network a respected and world-recognised organisation.

We thank the following members of the ANZNN Executive Committee for their commitment and guidance for all the activities of the ANZNN: Kei Lui (Chairperson), Chad Andersen, Barbara Bajuk, Malcolm Battin, Georgina Chambers, Lucy Cooke, Koert de Waal, Barbara Hammond, Andy Gill, Jim Holberton, Christine Jorgensen, Natalie Merida, Jane Pillow, Victor Samuel Rajadurai, and Jutta van den Boom.

Particular thanks to the ANZNN Data Collection and Operation Committee, namely Jim Holberton (Chairperson), Georgina Chambers, Liza Edmonds, Andy Gill, Timothy Hong, Rod Hunt, Caroline Karskens, Simon Lam, Peter Marshall, Karen Nothdurft and Victor Samuel Rajadurai. The Follow-up Subcommittee comprising of Liza Edmonds (Chairperson), Peter Anderson, Lex Doyle, Vanessa Ellison, Jim Holberton, Elizabeth Hurrion, Mary Sharp, Rachel Taufer and Crista Wocadlo were instrumental in advising the data collection and analysis for the Extremely Preterm Follow-up chapter.

We would also like to acknowledge Evelyn Karantonis for running the data validation queries and liaising with the audit officers and data managers at each participating unit to finalise the neonatal data for this report.

We thank Emerge Health (Australia) and Douglas Pharmaceuticals (New Zealand) for their ongoing support and for helping us to achieve our aims. We acknowledge our colleagues from the National Perinatal Epidemiology and Statistics Unit (NPESU) and the Centre for Big Data Research in Health for their continued support and encouragement.

Structure of this report

- Chapter 1:** This chapter presents the structure and organisation of the ANZNN together with some historical information related to its establishment. Also included is information on funding, selection criteria as well as a brief synopsis of level III registrants in Australia and New Zealand for 2017.
- Chapter 2:** ‘Babies registered to level III units’ provides information and characteristics on the ANZNN registrants in 2017 who are either born in a hospital with a level III unit or who are born elsewhere and then transferred to a level III unit within the first 28 days of life.
- Chapter 3:** ‘Mothers of level III registrants’ provides information on the mothers of level III registrants registered to the ANZNN in 2017.
- Chapter 4:** ‘Characteristics of level III registrants’ provides information about the babies admitted to a level III neonatal unit during 2017.
- Chapter 5:** ‘Babies registered to level II units’ provides information about babies registered to the level II special care baby units during 2017.
- Chapter 6:** ‘Extremely preterm follow-up, 2011–2014 births’ provides 2 to 3 year follow-up information about extremely preterm and/or extremely low birthweight babies registered to the level III neonatal units during 2011 to 2014.
- Appendices:** Appendix 1 presents 10-year trends.
Appendix 2 presents data tables by birthweight for 2017.
Appendix 3 describes the methods employed for this report.
Appendix 4 contains confidentiality guidelines, and conditions for data collection, use and security.
Appendix 5 presents the Minimum Data Sets for the ANZNN.

Abbreviations

ANZNN	Australian and New Zealand Neonatal Network	IQR	interquartile range
APH	antepartum haemorrhage	IUGR	intrauterine growth restriction
CI	confidence interval	IVF	in vitro fertilisation
CLD	chronic lung disease	IVH	intraventricular haemorrhage
CP	cerebral palsy	MgSO ₄	magnesium sulphate
CPAP	continuous positive airway pressure	NEC	necrotising enterocolitis
CRIB	Clinical Risk Index for Babies	NHMRC	National Health and Medical Research Council
ECMO	extracorporeal membrane oxygenation	NICU	neonatal intensive care unit
g	gram	NPESU	National Perinatal Epidemiology and Statistics Unit
GIFT	gamete intra-fallopian transfer	O ₂	oxygen
GMFCS	gross motor function classification system	PCR	polymerase chain reaction
HFOV	high frequency oscillatory ventilation	PMA	post menstrual age
HMD	hyaline membrane disease	PPROM	preterm pre-labour rupture of membranes
ICD-10-AM	The International Statistics Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification	PVL	periventricular leukomalacia
IPPV	intermittent positive pressure ventilation	ROP	retinopathy of prematurity
		SD	standard deviation
		UNSW	University of New South Wales
		WHO	World Health Organization
		WPPSI	Wechsler Preschool and Primary Scale of Intelligence

Participating units and supporting staff

Level III nurseries:

Australia

New South Wales

Children's Hospital at Westmead

(NICU & special care beds: 23)

Nadia Badawi (Co-director), Alison Loughran-Fowlds (Co-director), Rob Halliday, Caroline Karskens, Christine Jorgensen

John Hunter Hospital

(NICU & special care beds: 43)

Paul Craven (Director), Koert de Waal, Javeed Travadi, Rebecca Glover, Lynne Cruden, Larissa Korostenski, Susanne Wooderson, Alissa Argomand

Liverpool Health Service

(NICU & special care beds: 31)

Jacqueline Stack (Director), Ian Callander, Kathryn Medlin, Amanda Beasley

Nepean Hospital

(NICU & special care beds: 37)

Lyn Downe (Director), Vijay Shingde, Basiliki Lampropoulos, Jacqueline Furey, Mee Fong Chin

Royal Hospital for Women

(NICU & special care beds: 44)

Kei Lui (Director), Lee Sutton, Vikki Biggs, Diane Cameron, Christine Rodrigues

Royal North Shore Hospital

(NICU & special care beds: 27)

Mary Paradisis (Director), Jennifer Bowen, Martin Kluckow, Amy Sparks, Lyn Barnes

RPA Women and Babies

(NICU & special care beds: 34)

Ingrid Rieger (Director), Nick Evans, David Osborn, Crista Wocadlo, Shelley Reid

Sydney Children's Hospital

(NICU & special care beds: 4)

Andrew Numa (Director), Janelle Young

Westmead Hospital

(NICU & special care beds: 44)

Melissa Luig (Director), Mark Tracy, Melissa Ross, Tracey Anne Goyen, Jane Baird

Neonatal Intensive Care Units' (NICUS) Data Collection

(New South Wales and Australian Capital Territory)

Barbara Bajuk, Janette Tommasi, Sara Sedgley, Mark Leckie

Australian Capital Territory

The Canberra Hospital

(NICU & special care beds: 29)

Hazel Carlisle (Director), Allana Carter, Judith Smith

Victoria

Mercy Hospital for Women

(NICU & special care beds: 58)

Dan Casalez (Director), Jim Holberton, Elizabeth Noble, Emily Burke

Monash Medical Centre

(NICU & special care beds: 64)

Alice Stewart (Director), Elizabeth Carse, Kenneth Tan, Rose Li, Marie Hayes

Royal Children's Hospital

(NICU & special care beds: 34)

Rod Hunt (Director), Jo Brooks

Royal Women's Hospital

(NICU & special care beds: 60)

Carl Kuschel (Director), Lex Doyle (Professor of Neonatology), Alison Martin, Melissa Drew, Frances Darmanin

Tasmania

Royal Hobart Hospital

(NICU & special care beds: 26)

Tony De Paoli (Director), Peter Dargaville, Karen Butterley

Queensland

Gold Coast Hospital

(NICU & special care beds: 33)

Peter Schmidt (Director), Timothy Hong, John Hyland

Mater Mothers' Hospital

(NICU & special care beds: 79)

Pita Birch (Director), Elizabeth Hurriion, Karen Nothdurft, Leith Poulsen

Royal Brisbane and Women's Hospital

(NICU & special care beds: 71)

Pieter Koorts (Director), David Cartwright,
Anja Lipponer

The Townsville Hospital

(NICU & special care beds: 44)

Guan Koh (Director), Gary Alcock,
Louise McIlldowie

South Australia

Flinders Medical Centre

(NICU & special care beds: 35)

Peter Marshall (Director), Vanessa Ellison

Women's and Children's Hospital

(NICU & special care beds: 49)

Chad Andersen (Director), Andy McPhee,
Michael Stark, Cindy Golding, Ros Lontis

Western Australia

King Edward Memorial and Perth Children's Hospitals

(NICU & special care beds: 137)

Karen Simmer (Director and Professor of
Neonatal Medicine), Rolland Kohan, Steven
Resnick, Mary Sharp, Rebecca Thomas, Corrado
Minutillo, Shripada Rao, Andy Gill, Jane Pillow,
Damber Shrestha

Northern Territory

Royal Darwin Hospital

(NICU & special care beds: 25)

Charles Kilburn (Director of Perinatal Services),
Rakesh Seth, Deborah Ribbon, Connie Yui

Newborn emergency transport services

Newborn & paediatric Emergency Transport Service (NETS, NSW)

Andrew Berry (Director)

Paediatric Infant Perinatal Emergency Retrieval (PIPER, Victoria)

Michael Stewart (Director)

Neonatal Retrieval Service (NeoRESQ, Queensland)

Lucy Cooke (Director)

Newborn Emergency Transport Service of Western Australia (NETS, WA)

Jonathan Davis (Director)

SAAS MedSTAR Kids (South Australia)

John Craven (Director)

New Zealand

Christchurch Women's Hospital

(NICU & special care beds: 41)

Adrienne Lynn (Director), Nicola Austin, Brian
Darlow (Professor of Paediatrics), Trish Graham

Dunedin Hospital

(NICU & special care beds: 16)

Liza Edmonds (Director), Frances McCaffrey

Middlemore Hospital

(NICU & special care beds: 38)

Lindsay Mildenhall (Director), Maisie Wong,
David Hou

National Women's Health (at Auckland City Hospital)

(NICU & special care beds: 46)

Mariam Buksh (Director), Malcolm Battin,
David Knight, Sabine Huth

Waikato Hospital

(NICU & special care beds: 41)

David Bouchier (Director), Phil Weston,
Deborah Harris, Arun Nair, Claire West

Wellington Regional Hospital

(NICU & special care beds: 40)

Vaughan Richardson (Director), Keith Fisher,
Helen Miller, Harshad Patel, Bronwyn Cook,
Jackie Chin-Poy, Claire Jacobs

Singapore*

KK Women's and Children's Hospital*

(NICU & special care beds: 32)

Bin Huey Quek (Director), Victor Samuel
Rajadurai, Kee Thai Yeo, Rowena Dela Puerta

Hong Kong*

Prince of Wales Hospital*

(NICU & special care beds: 82)

Alan So (Director), Simon Lam, Peggy Chan,
Xuelian Wang

*data not included in this report

Level II nurseries:

Australia

New South Wales

Blacktown Hospital

(Special care beds: 24)

Anjali Dhawan (Director), Therese Freeman,
Jessica Lagos

Campbelltown Hospital

(Special care beds: 15)

Raymond Chin (Director), Lauren Rodgers,
Catherine Allgood, Fiona Kite

Gosford District Hospital

(Special care beds: 25)

Philip Watt (Director), Adam Buckmaster, Kerry
Field, Jane Wardle

St George Hospital

(Special care beds: 8)

Bob Fonseca (Director), Anne Hurst, Beverley
Lewis

The Maitland Hospital

(Special care beds: 8)

David Rogers (Director), Jessica Crombie

Tamworth Hospital

(Special care beds: 6)

Genaro Domingo (Director), Therese Madden

Wagga Wagga Base Hospital

(Special care beds: 7)

John Preddy (Director), Dianne Webb

Wollongong Hospital

(Special care beds: 20)

Susie Piper (Director), Ian Wright, Sylvia Lees

Victoria

Sunshine Hospital

(Special care beds: 21)

Clare Collins (Director), Martin Wright, Thao
Lu, Jennifer Francis, Rosalynn Pszczola

The Northern Hospital

(Special care beds: 15)

Wei Qi Fan (Director), Ann Hood, Barbara
Risshitelli

Queensland

Cairns Hospital

(Special care beds: 22)

Neil Archer (Director), Sue McMahon

Logan Hospital

(Special care beds: 16)

Jan Cullen (Director), Pamela McErlean, Angela
Geraghty

Mackay Base Hospital

(Special care beds: 8)

Jacinta Tobin (Director), Kerry Topping

Redcliffe Hospital

(Special care beds: 10)

Simon Grew (Director), Marlon Radcliffe,
Meredith Shallcross

Redland Hospital

(Special care beds: 8)

Dougie Thomas (Director), Greg Pallas,
Pamela McErlean, Wendy Bostock

Sunshine Coast University Hospital

(Special care beds: 27)

Lizelle Weber (Director), Tom Hurley,
Tonya Gibbs, Janet Rowley

Tasmania

Launceston General Hospital

(Special care beds: 12)

Chris Bailey (Director), Jennifer James, Robyn
Morey, Frances McCarroll, Christine Coker

Northern Territory

Alice Springs Hospital

(Special care beds: 8)

Deborah Fearon (Director), Marion Bates

New Zealand

Gisborne Hospital

(Special care beds: 6)

Shaun Grant (Director), Heinrich Stander,
Graeme Lear, Barbara Reid

Hawkes Bay Hospital

(Special care beds: 12)

Oliver Grupp (Director), Jenny Corban,
Kay Hodson, Mercy Jenson

Lower Hutt Hospital

(Special care beds: 12)

Sarah Mills (Director), Debbie Bashaw,
Anne Mitchell

Nelson Hospital

(Special care beds: 10)

Peter McIlroy (Director), Nathalie Robinson,
Maureen Higgs

North Shore Hospital

(Special care beds: 12)

Jutta van den Boom (Director), Karen Boyle,
Susan Law

Palmerston North Hospital

(Special care beds: 17)

Jeff Brown (Director), Amy Hinder, Misty Curry

Rotorua Hospital

(Special care beds: 10)

Stephen Bradley (Director), Jacquie Koberstein,
Gaye France, Leanne Turvey

Southland Hospital

(Special care beds: 6)

Ian Shaw (Director), Paul Tomlinson,
Liz Hanning-Baird

Taranaki Base Hospital

(Special care beds: 8)

John Doran (Director), Jane Bocock

Tauranga Hospital

(Special care beds: 10)

Hugh Lees (Director), Heather McAlley,
Anna Hayns

Timaru Hospital

(Special care beds: 3)

Mick Goodwin (Director), Bid Esler, Mark Liddy

Wairau Hospital

(Special care beds: 4)

David Bond (Director)

Whanganui Hospital

(Special care beds: 4)

David Montgomery (Director), Barbara
Hammond

Whakatane Hospital

(Special care beds: 5)

John Malcolm (Director), Chris Moyes,
Margret Norris, Lee Willetts, Katherine Dumauual

Whangarei Area Hospital

(Special care beds: 8)

David Barker (Director), Ransford Addo, Janine
Whale, Merophy Brown, Georgia Kidd

Waitakere Hospital

(Special care beds: 12)

Jutta van den Boom (Director), Debbie Daniel,
Susan Law, Stefanie Smith

ANZNN Program and Secretariat**National Perinatal Epidemiology and
Statistics Unit (NPESU)**

Georgina Chambers (Director), Sharon Chow,
Prudence Creighton, Evelyn Karantonis

1. Organisation of the ANZNN

History

A prospective audit of high-risk infants commenced in 1994 with all level III neonatal intensive care units (NICUs) in Australia and New Zealand contributing data on babies from 1 January 1995. One of the member level II units became a level III unit in 2014 and an NICU in Singapore joined in 2016 followed by an NICU in Hong Kong in 2017, bringing the total of NICU members to 31. For the purposes of this report, data submitted by the Singaporean and Hong Kong NICU members have not been included.

In 1998, all the level II units in New Zealand joined the Network and began contributing data. The level II unit in Tasmania, Australia joined in 1999 and level II units within Australia continue to join with a total of eighteen units contributing data in 2017.

Aims and objectives

The ANZNN clinical quality registry aims to improve the care of high-risk newborn infants and their families in Australia and New Zealand by enabling benchmarking and so collaborative audit, plus facilitating research.

This is achieved through the following objectives:

- provide a core data set that will:
 - provide information on neonatal outcomes, adjusted for case mix and disease severity, to participating neonatal units to assist with quality improvement
 - identify trends and variations in morbidity or mortality
 - assist with the identification of areas of priority for research
 - enhance the ability to carry out multicentre studies and randomised controlled trials through collaboration
- monitor the clinical indicators for perinatal care and improving clinical practice while maintaining national standards of evidence-based care
- monitor the use of new technologies, e.g. high flow/oxygen air usage by patient type and outcome
- achieve consistency in national data collections.

Each year, an annual report of the ANZNN clinical quality registry is published as part of the *Report of the Australian and New Zealand Neonatal Network* series.

Structure of the ANZNN

The ANZNN is located in the National Perinatal Epidemiology and Statistics Unit (NPESU) within the University of New South Wales (UNSW Sydney). The arrangement is managed under a memorandum of understanding (MOU) between the ANZNN and UNSW Sydney.

The governance structure of the ANZNN (Figure 1) consists of the Advisory Council, the Executive Committee, and the Data Collection and Operations Committee. The Advisory Council is the governing body of ANZNN and includes the directors (or their nominee) of each participating unit, the academic neonatologists and neonatal nurses in the region. The Director of the NPESU, who is the data custodian for the ANZNN, is also a member of the Advisory Council. The purpose of the Advisory Council is to monitor the progress of the ANZNN, discuss current issues and agree on new variables for inclusion in the minimum data set and to approve the use of the data for research – all as recommended by the Executive Committee.


The Executive Committee is an elected committee with regional representation from unit directors, a data manager group representative and neonatal nurse representatives from across the network, and a consumer representative. It oversees the general functioning of the network, finance and decision-making, as reported by the Chairman and Operations Manager.

The Data Collection and Operation Committee coordinates the operations of the ANZNN data collection, monitors the workload and progress of the annual report and reports through the Executive Committee to the Advisory Council.

The Operations Manager deals with day-to-day business of the ANZNN and reports to the Executive Committee and Data Collection and Operation Committee.

The unit data managers and audit officers are responsible for the collection and submission of data to the ANZNN. The ANZNN Operations Manager is the point of contact for the ANZNN and liaises with the ANZNN committees, NPESU, data managers and audit officers.

FIGURE 1: Structure of the ANZNN



*ANZNN Management Group – comprised of the Chairs of these committees and the ANZNN Operations Manager.

Note: NICU = neonatal intensive care unit.

Registration criteria

Babies who were admitted to a participating unit during the first 28 days of life and meet one or more of the following criteria are eligible for registration with the ANZNN clinical quality registry:

- born at less than 32 weeks gestation, or
- weighed less than 1,500 grams at birth, or
- received assisted ventilation (mechanical ventilation) including intermittent positive pressure ventilation (IPPV) or continuous positive airway pressure (CPAP) or high flow for four or more consecutive hours, or died while receiving mechanical ventilation prior to four hours of age, or
- received major surgery (surgery that involved opening a body cavity), or
- received therapeutic hypothermia.

The hospital of registration was the first level III NICU in which the baby, aged less than 28 days, stayed for four or more hours. Babies who received their entire care in a level II hospital or who were not transferred to a level III NICU during the first 28 days were registered to the first level II centre that they remained in for four or more hours. Data is collected until the baby's first discharge to home. Babies who were discharged home prior to admission to a participating unit were not eligible for registration in the ANZNN clinical quality registry.

Funding support

The ANZNN is primarily funded through the annual registration fees from level III units. The registration fee is determined annually by the Advisory Council. In return individual units receive a feedback report that enables them to benchmark their unit against the combined ANZNN data set.

Emerge Health (Australia) and Douglas Pharmaceuticals (New Zealand) make an annual contribution and the ANZNN thanks them for their generosity and support.

Data set variables

The variables used for the 2017 audit are listed in Appendix 5 and are also available on the website < **www.anznn.net** >.

2017

REPORT OF THE
**AUSTRALIAN AND
NEW ZEALAND
NEONATAL NETWORK**

Babies born in Australia

There were 8,736 babies registered to the ANZNN from the 23 level III NICUs in Australia, representing 2.8% of the 309,142 notified live births in 2017 (Australian Bureau of Statistics 2017). Of these registrants, 79.3% were born in a hospital with tertiary care facilities. There were 2,924 babies born before 32 weeks gestation representing 33.5% of Australian registrants.

Maternal ethnicity was provided for 91.4% of mothers: 71.4% of the mothers of these babies identified as Caucasian and 15.7% as Asian. Nearly one in thirteen mothers (7.6%) identified as Aboriginal or Torres Strait Islander, which was more than the proportion reported in all births in Australia in 2017 (4.6%) (Australian Bureau of Statistics 2017).

Among Australian NICU admissions registered to the ANZNN, 1,609 were from multiple births representing 18.4% of ANZNN admissions in Australia in 2017.

Male babies were over-represented among NICU admissions – 57.9% of the Australian ANZNN registrants, compared with 51.5% among live births in Australia (Australian Bureau of Statistics 2017).

Assisted ventilation was provided for 8,036 babies (2.6% of live births) and continuous positive airway pressure (CPAP) was the only form of respiratory assistance for 4,834 babies.

Babies born in New Zealand

There were 1,945 babies who met ANZNN registration criteria from the six level III NICUs in New Zealand representing 3.3% of the 59,610 live births registered in New Zealand in 2017 (Statistics New Zealand 2017). Of these registrants, 87.0% were born in a hospital with tertiary care facilities. There were 578 babies born before 32 weeks gestation representing 29.7% of New Zealand registrants.

Maternal ethnicity was reported for 99.3% of the New Zealand registrants. The percentage of Caucasian mothers was 48.2%. A higher proportion of mothers identified themselves as Maori (21.3%) compared to 11.9% of mothers identified as Pacific Islander and 15.1% as Asian.

Among New Zealand NICU admissions registered to the ANZNN, 223 were from multiple births representing 11.5% of ANZNN admissions in New Zealand in 2017.

Male babies were also over-represented among NICU admissions in New Zealand – 60.2% of the New Zealand registrants compared to 51.3% of total live births in New Zealand (Statistics New Zealand 2017).


Assisted ventilation was given to 1,836 babies representing 3.1% of all live births with 1,274 babies receiving CPAP as the only form of respiratory assistance (2.1% of all live births).

2. Babies registered to level III units

This section includes data on the ANZNN registrants from all 29 level III NICUs in Australia and New Zealand. Registrants also include babies born in other hospitals and transferred to a level III NICU within the first 28 days of life.

Of the babies born in 2017 and admitted to an NICU in Australia and New Zealand, 10,681 fulfilled the registration criteria for inclusion in the ANZNN clinical quality registry. The population represents 2.9% of the 368,752 live births in the two countries in 2017 (Australian Bureau of Statistics 2017; Statistics New Zealand 2017) (Figure 2) compared with 2.8% in 2016. The number of registrants in 2017 was 208 more than in 2016.

FIGURE 2: Proportion of liveborn babies in Australia and New Zealand who were ANZNN level III registrants, by year of birth, ANZNN 2008–2017



Note: Data on the ANZNN registrants from two level III NICUs were not available in 2010.

Of the 10,681 ANZNN registrants born in 2017, there were 3,502 (32.8%) babies born before 32 weeks gestation and 7,179 babies born at 32 weeks or more (67.2%). Of the registrants born before 32 weeks gestation 95.0% received assisted ventilation. The major indication for assisted ventilation in this age group was hyaline membrane disease.

The largest level III NICU in Australia and New Zealand registered just over 1,050 babies in 2017, the smallest just under 40 (Figure 3). The median number of babies registered to an ANZNN unit was 331.

The gestational age at birth and birthweight for babies qualifying for inclusion in the ANZNN 2017 level III audit is set out in Tables 1 and 2 respectively. The number of babies qualifying under each registration criteria is set out in Figure 4, and the 10-year trend (2008–2017) in gestational age at birth is presented in Figure 11 in Appendix 1.

FIGURE 3: Number of level III registrants born at each neonatal intensive care unit, ANZNN 2017




TABLE 1: Level III registrants born at each completed week of gestation, ANZNN 2017


Gestational age (weeks)	Number of babies	Percent	Cumulative percent
<24	101	0.9	0.9
24	176	1.6	2.6
25	220	2.1	4.7
26	311	2.9	7.6
27	343	3.2	10.8
28	445	4.2	14.9
29	474	4.4	19.4
30	636	6.0	25.3
31	796	7.5	32.8
All babies <32 weeks	3,502	32.8	
32	787	7.4	40.2
33	657	6.2	46.3
34	732	6.9	53.2
35	636	6.0	59.1
36	647	6.1	65.2
37	800	7.5	72.7
38	900	8.4	81.1
39	825	7.7	88.8
40	754	7.1	95.9
41	417	3.9	99.8
≥42	24	0.2	100.0
Total	10,681	100.0	

Note: Gestational ages ≥42 weeks have been combined to maintain confidentiality of small numbers.

TABLE 2: Level III registrants in each birthweight group, ANZNN 2017

Birthweight (grams)	Number of babies	Percent	Cumulative percent
<500	29	0.3	0.3
500–599	113	1.1	1.3
600–699	174	1.6	3.0
700–799	251	2.3	5.3
800–899	278	2.6	7.9
900–999	309	2.9	10.8
1,000–1,099	290	2.7	13.5
1,100–1,199	353	3.3	16.8
1,200–1,299	358	3.4	20.2
1,300–1,399	374	3.5	23.7
1,400–1,499	439	4.1	27.8
All babies <1,500g birthweight	2,968	27.8	
1,500–1,999	1,693	15.9	43.6
2,000–2,499	1,362	12.8	56.4
2,500–2,999	1,438	13.5	69.9
3,000–3,499	1,560	14.6	84.5
3,500–3,999	1,116	10.4	94.9
≥4,000	544	5.1	100.0
Total	10,681	100.0	

FIGURE 4: Level III registrants by registration criteria, ANZNN 2013–2017



Note: Babies are assigned to the first registration criteria that they meet in the following order: (i) gestational age <32 weeks, (ii) birthweight <1500g, (iii) received 4 or more hours of IPPV, CPAP or high flow, (iv) received major surgery, (v) received therapeutic hypothermia.

3. Mothers of level III registrants

Maternal age

While there are many determinants of perinatal outcome, an important one is maternal age. In 2017, the age of mothers of neonates registered as high-risk ranged from less than 15 years to over 55 years. The highest proportion of registrant mothers was aged 30–34 years (32.9%) followed by mothers aged 25–29 years (25.5%). Together they accounted for nearly three in five of the mothers (58.4%) of ANZNN registrants in 2017 (Table 3). In 2017, the proportion of babies born to teenage mothers decreased slightly (0.1%) from 2016, and those born to mothers in the 35–39 age group increased slightly, from 19.0% in 2016 to 19.5%.

Over two in five of the babies born to teenage mothers (41.2%) were born at less than 32 weeks completed gestation, while 31.3% of babies born to mothers 30–34 years were less than 32 weeks gestation at birth (Table 3).

TABLE 3: Age group of mothers of level III registrants by gestational age, ANZNN 2017

Maternal age (years)	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
	Number								
Less than 20	7	22	22	34	53	32	57	108	335
20–24	21	51	93	123	196	154	236	465	1,339
25–29	30	116	156	210	341	343	530	962	2,688
30–34	25	121	200	304	439	476	667	1,246	3,478
35–39	12	64	127	184	292	293	370	721	2,063
40 and over	6	18	50	55	99	135	125	169	657
Not stated	0	4	6	9	12	11	30	49	121
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
Less than 20	6.9	5.6	3.4	3.7	3.7	2.2	2.9	2.9	3.2
20–24	20.8	13.0	14.4	13.5	13.8	10.7	11.9	12.7	12.7
25–29	29.7	29.6	24.1	23.1	24.0	23.9	26.7	26.2	25.5
30–34	24.8	30.9	30.9	33.4	30.9	33.2	33.6	33.9	32.9
35–39	11.9	16.3	19.6	20.2	20.6	20.4	18.6	19.6	19.5
40 and over	5.9	4.6	7.7	6.0	7.0	9.4	6.3	4.6	6.2
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Note: Not stated data are excluded from per cent calculations.

Maternal data for babies of a multiple birth are presented for each registrant.

Previous antenatal history

A previous preterm delivery was reported by 1,146 (10.7%) mothers of babies registered to ANZNN while 357 mothers (3.3%) reported a previous perinatal loss.

Assisted conception

Assisted conception refers to any medically assisted infertility treatment used in the pregnancy. Types of infertility treatment include ovulation induction, in vitro fertilisation (IVF), intrauterine insemination and other infertility treatments not already mentioned.

There were 945 (8.8%) pregnancies resulting from assisted conception in the ANZNN 2017 cohort with most (86.1%) following IVF treatment. Of the pregnancies resulting from assisted conception, 51.7% of the mothers were more than 34 years of age at the time of giving birth, compared with 55.2% in 2016.

Presenting antenatal problem

Many mothers of ANZNN registrants were admitted to hospital with complications prior to the baby's birth. The presenting antenatal problem refers to the antenatal complication that led to the baby's birth and subsequent admission to an NICU. There may be other complications related to this pregnancy, but they are not reported here. Information about the presenting antenatal problem was available for 99.3% of 2017 ANZNN registrants. The mothers of one-fifth of registrants (19.7%) presented with preterm labour while fetal distress (16.1%) was the second highest presenting antenatal problem (Table 4).

The maternal antenatal complications for registrants born at 37–44 weeks, 32–36 weeks and less than 32 weeks gestational age are set out in Figure 5. For women who gave birth before 32 weeks gestation and women who gave birth at 34–36 weeks gestation, the most common presenting antenatal problem was preterm labour (33.1% and 26.5% respectively) followed by preterm pre-labour rupture of membranes (23.1% and 15.1% respectively).

Overall 86.8% of mothers of registrants had a pregnancy complication recorded. Among women who gave birth at term, just over one in three (35.5%) were recorded as having no maternal presenting antenatal problem.

TABLE 4: Mother's presenting antenatal problem for level III registrants by gestational age, ANZNN 2017

Presenting antenatal problem	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
	Number								
No antenatal problems	0	0	0	0	0	0	17	1,320	1,337
Preterm pre-labour rupture of membranes	19	121	164	199	307	263	303	54	1,430
Preterm labour	58	166	230	278	425	384	534	14 ^(a)	2,089
Hypertension in pregnancy	<5	19	81	128	200	n.p.	162	144	926
Antepartum haemorrhage	12	43	69	83	127	125	154	84	697
Intrauterine growth restriction	0	0	27	47	94	126	172	92	558
Fetal distress	5	30	60	121	187	176	282	847	1,708
Other problem	<5	17	n.p.	53	76	138	272	713	1,293
Congenital anomalies	0	0	<5	9	15	n.p.	117	384	568
Not stated	0	0	1	1	1	2	2	68	75
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
No antenatal problems	0.0	0.0	0.0	0.0	0.0	0.0	0.8	36.1	12.6
Preterm pre-labour rupture of membranes	18.8	30.6	25.1	21.7	21.5	18.2	15.1	1.5	13.5
Preterm labour	57.4	41.9	35.2	30.3	29.7	26.6	26.5	0.4	19.7
Hypertension in pregnancy	n.p.	4.8	12.4	13.9	14.0	n.p.	8.0	3.9	8.7
Antepartum haemorrhage	11.9	10.9	10.6	9.0	8.9	8.7	7.7	2.3	6.6
Intrauterine growth restriction	0.0	0.0	4.1	5.1	6.6	8.7	8.5	2.5	5.3
Fetal distress	5.0	7.6	9.2	13.2	13.1	12.2	14.0	23.2	16.1
Other problem	n.p.	4.3	n.p.	5.8	5.3	9.6	13.5	19.5	12.2
Congenital anomalies	0.0	0.0	n.p.	1.0	1.0	n.p.	5.8	10.5	5.4
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0


n.p. Data not published to maintain confidentiality of small numbers.

(a) These mothers presented with preterm labour, then went on to deliver at term.

Note: Not stated data are excluded from per cent calculations.

Maternal data for babies of a multiple birth are presented for each registrant.

FIGURE 5: Presenting antenatal problem for mothers of level III registrants by gestational age, ANZNN 2017



Note: Maternal data for babies of a multiple birth are presented for each registrant.

PPROM = preterm pre-labour rupture of membranes. APH = antepartum haemorrhage. IUGR = intrauterine growth restriction.

Antenatal corticosteroid use

Corticosteroids given to the mother during the antenatal period, via any route at a time likely to enhance fetal maturation, are recorded for ANZNN registrants.

Since 1997, consideration has been given to administering maternal antenatal corticosteroids before the 34th completed week of gestation with the aim of improving neonatal outcomes by enhancing newborns' maturation. The preferred regimen is more than one dose of antenatal corticosteroids, with the first dose given more than 24 hours and less than eight days before the baby's birth.

Table 5 presents antenatal corticosteroids use for mothers of ANZNN registrants in each gestational age group. In 2017, 88.8% of mothers of ANZNN registrants born before 34 weeks of gestation received one or more doses of antenatal corticosteroids leaving 11.2% of mothers of registrants in this group who did not report receiving any antenatal corticosteroids. Of the mothers who received antenatal corticosteroids, 14.0% received them more than seven days prior to giving birth.

For mothers of ANZNN registrants born before 32 weeks of gestation, 90.1% received one or more doses of antenatal corticosteroids and 9.9% mothers of registrants in this group did not report receiving any antenatal corticosteroids. Of the mothers who received antenatal corticosteroids, 12.9% received them more than seven days prior to giving birth (Table 5). The 10-year trend (2008–2017) for maternal corticosteroids is represented by Figure 12 in Appendix 1.

TABLE 5: Antenatal corticosteroid use for mothers of level III registrants by gestational age, ANZNN 2017

	Gestational age (weeks)								
Antenatal corticosteroids	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	Total
Number									
None	15	35	47	72	148	199	978	3,163	4,657
Incomplete course	31	109	173	218	330	360	254	15	1,490
Complete course within 7 days of birth	54	214	351	500	770	666	546	53	3,154
Given >7 days prior to birth	0	38	80	122	166	209	195	61	871
Not stated	1	0	3	7	18	10	42	428	509
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
None	15.0	8.8	7.2	7.9	10.5	13.9	49.6	96.1	45.8
Incomplete course	31.0	27.5	26.6	23.9	23.3	25.1	12.9	0.5	14.6
Complete course within 7 days of birth	54.0	54.0	53.9	54.8	54.5	46.4	27.7	1.6	31.0
Given >7 days prior to birth	0.0	9.6	12.3	13.4	11.7	14.6	9.9	1.9	8.6
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Note: Not stated data are excluded from per cent calculations.

Maternal data for babies of a multiple birth are presented for each registrant.

Magnesium sulphate

Babies born at less than 32 weeks gestation are at high risk of neurologic injury during labour and immediately after birth. Antenatal administration of magnesium sulphate (MgSO₄) to very preterm babies has been demonstrated to provide neuroprotection (Crowther et al 2003, Rouse 2009, Conde-Agudelo and Romero 2009).

For mothers of ANZNN registrants born at less than 32 weeks of gestation, 51.3% were given antenatal MgSO₄ (Table 6).

TABLE 6: Magnesium sulphate use for mothers of level III registrants by gestational age, ANZNN 2017

R222 of magnesium sulphate use for mothers of twins in registries by gestational age, 1980-2014										
	Gestational age (weeks)									
Magnesium sulphate	<24	24	25	26	27	28	29	30	31	Total
Number										
None	40	60	60	106	101	130	161	386	563	1,607
Complete course	33	57	56	89	96	117	135	98	78	759
Incomplete course	18	40	65	61	82	113	99	73	69	620
Given but details unknown	8	10	27	37	47	57	52	35	40	313
Not stated or clinical trial	2	9	12	18	17	28	27	44	46	203
Total	101	176	220	311	343	445	474	636	796	3,502
Per cent										
None	40.4	35.9	28.8	36.2	31.0	31.2	36.0	65.2	75.1	48.7
Complete course	33.3	34.1	26.9	30.4	29.4	28.1	30.2	16.6	10.4	23.0
Incomplete course	18.2	24.0	31.3	20.8	25.2	27.1	22.1	12.3	9.2	18.8
Given but details unknown	8.1	6.0	13.0	12.6	14.4	13.7	11.6	5.9	5.3	9.5
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Note: Not stated and clinical trial data are excluded from per cent calculations.

Maternal data for babies of a multiple birth are presented for each registrant.

Multiple gestation

Multiple gestation pregnancies are often associated with labour and delivery complications, an increased risk of premature birth, low birthweight infants as well as an increased risk of perinatal mortality and morbidity. In 2017, 17.2% of ANZNN registrants were reported as being from a multiple gestation pregnancy, and of these, the greatest percentage were twins (94.2%). Of the 2017 ANZNN registrants from multiple gestation pregnancies, 50.5% were born before 32 weeks gestation and 95.9% were born before 37 weeks gestation (Table 7). The 10-year trend (2008–2017) for multiple gestation pregnancies is represented by Figure 13 in Appendix 1.

TABLE 7: Plurality of level III registrants by gestational age, ANZNN 2017

Plurality	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
	Number								
Singletons	71	318	492	670	1,026	1,010	1,617	3,645	8,849
Twins	n.p.	78	150	229	377	402	389	n.p.	1,726
Triplets and higher orders	<5	0	12	20	29	32	9	<5	106
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
Singletons	70.3	80.3	75.2	72.9	71.6	69.9	80.2	98.0	82.8
Twins	n.p.	19.7	22.9	24.9	26.3	27.8	19.3	n.p.	16.2
Triplets and higher orders	n.p.	0.0	1.8	2.2	2.0	2.2	0.4	n.p.	1.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Method of birth

Data on method of birth are presented for each baby. Method of birth can be dependent upon gestational age, presenting part of the baby and maternal factors. For more than half of the 2017 registrants (58.9%) the method of birth was caesarean section with 62.9 of caesarean sections occurring before the onset of labour. One-third of registrants (33.5%) were non-instrumental vaginal births (Table 8). The rate of birth by caesarean section has gradually increased from 49.8%, since the first data collection in 1995, to 57.9% in 2016. The 2017 data shows an increase of 1.0% from 2016.

The most common method of birth for registrants born before 24 weeks gestation was non-instrumental vaginal birth (77.8%) (Table 8). The 10-year trend (2008–2017) for method of birth is represented by Figure 14 in Appendix 1.

TABLE 8: Method of birth for level III registrants by gestational age, ANZNN 2017

Method of birth	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
Number									
Vaginal birth	77	204	203	253	412	357	584	1,463	3,553
Vaginal instrumental birth	0	11	11	23	49	53	117	538	802
Caesarean section in labour	12	105	189	228	300	265	376	839	2,314
Caesarean section no labour	10	72	245	411	657	756	913	862	3,926
Not stated	2	4	6	4	14	13	25	18	86
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
Vaginal birth	77.8	52.0	31.3	27.7	29.1	24.9	29.3	39.5	33.5
Vaginal instrumental birth	0.0	2.8	1.7	2.5	3.5	3.7	5.9	14.5	7.6
Caesarean section in labour	12.1	26.8	29.2	24.9	21.2	18.5	18.9	22.7	21.8
Caesarean section no labour	10.1	18.4	37.8	44.9	46.3	52.8	45.9	23.3	37.1
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Note: Not stated data are excluded from per cent calculations.

Place of birth

In line with standard clinical practice guidelines, clinicians endeavour to have all births at less than 33 weeks gestation occur in a perinatal centre equipped with an NICU. In 2017, 80.7% of all babies and 88.1% of babies less than 32 weeks gestation at birth were born in a tertiary centre equipped with an NICU; 18.5% of all ANZNN registrants were born in a non-tertiary hospital; while 0.8% of registrants were not born in a hospital (Table 9).

TABLE 9: Level of hospital of birth for level III registrants by gestational age, ANZNN 2017

Level of birth hospital	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
Number									
Tertiary hospital	86	344	573	812	1,270	1,234	1,611	2,690	8,620
Non-tertiary hospital	n.p.	46	72	101	151	200	n.p.	1,000	1,978
Not born in a hospital ^(a)	<5	6	9	6	11	10	n.p.	28	81
Not stated	0	0	0	0	0	0	0	2	2
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
Tertiary hospital	85.1	86.9	87.6	88.4	88.7	85.5	80.0	72.4	80.7
Non-tertiary hospital	n.p.	11.6	11.0	11.0	10.5	13.9	n.p.	26.9	18.5
Not born in a hospital ^(a)	n.p.	1.5	1.4	0.7	0.8	0.7	n.p.	0.8	0.8
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) These babies were either born before arrival to hospital or born at home.

Note: Not stated data are excluded from per cent calculations.

Transport after birth to a level III NICU

Transport after birth to a level III NICU is required if there is insufficient time before birth to allow the mother to be transferred to a tertiary centre; if a cot is not available in the hospital of birth or if the hospital of birth is unable to manage the degree of immaturity and/or compromise of the newborn.

In 2017, 21.6% of ANZNN registrants were transferred to an NICU after birth. Of these the greatest percentage (80.3%) were transported by a specialist team with 15.5% transported by a non-specialist team (Table 10). The 10-year trend (2008–2017) for mode of transport to a level III NICU is represented by Figure 15 and Figure 16 in Appendix 1.

TABLE 10: Mode of transport to level III NICU after birth for level III registrants by gestational age, ANZNN 2017

Mode of Transport	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
	Number								
Not transported	87	336	572	809	1,261	1,207	1,566	2,520	8,358
Specialist retrieval team	9	48	63	83	133	196	374	941	1,847
Non-specialist team	<5	<5	8	11	20	26	60	225	355
Other	<5	n.p.	8	14	12	13	14	26	97
Not stated	1	1	3	2	6	2	1	8	24
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
	Per cent								
Not transported	87.0	85.1	87.9	88.2	88.4	83.7	77.8	67.9	78.4
Specialist retrieval team	9.0	12.2	9.7	9.1	9.3	13.6	18.6	25.4	17.3
Non-specialist team	n.p.	n.p.	1.2	1.2	1.4	1.8	3.0	6.1	3.3
Other	n.p.	n.p.	1.2	1.5	0.8	0.9	0.7	0.7	0.9
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

Breastfeeding at discharge

Data on breastfeeding at discharge were available for 99.4% of the babies born at less than 32 weeks gestation and/or less than 1,500 grams at birth who survived to discharge to home. Among registrants who provided data on breastfeeding, 76.0% were breastfed at discharge. The rate of breastfeeding at discharge of surviving extremely preterm babies (born at less than 28 weeks gestation) was 67.4% compared to 79.0% for surviving very preterm babies (born at least 28 weeks and less than 32 weeks gestation).

4. Characteristics of level III registrants

Baby gender

Male births exceeded female births in Australia and New Zealand and accounted for 51.5% of combined live births in both countries in 2017 (Australian Bureau of Statistics 2017; Statistics New Zealand 2017). The percentage was higher among ANZNN registrants with male births representing 58.3%. Gender was not available or indeterminate for two babies. For registrants born at less than 32 weeks gestation, 55.1% were male; of births at term, 61.9% were male.

Resuscitation in delivery suite

The type of resuscitation given to babies immediately after birth ranges from the least severe, suction to the most severe, external cardiac massage and ventilator support. For the purpose of this audit ANZNN only collected data on babies on whom endotracheal intubation was performed; in 2017, 16.0% of registrants were intubated in the delivery suite to establish independent respiration and heart rate. For babies born before 32 weeks the percentage was 31.6% and for babies born at term the percentage was 9.2%.

Apgar score at birth

The Apgar score gives a clinical indication of a baby's condition immediately after birth. It is a numerical score based on five characteristics: heart rate, respiratory condition, muscle tone, reflexes and colour with a maximum possible score of 10. A low score (less than 4) at one minute of age indicates a baby is considerably compromised and requires specialised resuscitation.

An Apgar score of less than 4 at one minute of age was recorded for 16.1% of ANZNN registrants, with 3.6% of registrants recording an Apgar score of less than 4 at five minutes of age. Among the babies who had low Apgar scores of less than 4 at one minute, 37.9% of babies were born at less than 32 weeks and 38.4% were born at term (Table 11).

TABLE 11: Apgar scores at birth for level III registrants by gestational age, ANZNN 2017

Apgar scores and median gestational age by gestational age, minutes									
	Gestational age (weeks)								
Apgar score	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	Total
Apgar score at 1 minute									
Median	4	5	5	6	7	7	7	7	7
IQR	2–5	3–6	3–7	4.5–8	5–8	5–9	5–9	5–9	5–9
Apgar score at 5 minutes									
Median	6	7	8	8	9	9	9	9	8
IQR	4–7	6–8	6–9	7–9	8–9	8–9	7–9	7–9	7–9

Note: IQR = Interquartile range

Admission temperature

The body temperature at admission to the NICU, or temperature nearest to admission to the registration unit, was reported for 94.4% of ANZNN registrants in 2017. The rectal temperature is preferred; however, if it is not available the axilla temperature is recorded.

For babies born before 32 weeks gestation the admission temperature together with the base excess, sex, gestation and birthweight is used to calculate the Clinical Risk Index for Babies (CRIB) II score. CRIB II score is a risk-adjustment instrument widely used in NICUs to measure initial illness severity and is a predictor of survival until discharge.

The median temperature at admission to the NICU was 36.6°C; the median temperature increased slightly with increasing gestational age at birth. The lowest median temperature recorded was 36.0°C by the youngest babies, i.e. those born at less than 24 weeks gestation (Table 12).

TABLE 12: Admission body temperature for level III registrants by gestational age, ANZNN 2017

Gestational age (weeks)	Number of babies	Temperature (°C)	
		Median	Interquartile range
<24	101	36.0	35.0–36.8
24–25	396	36.5	35.9–36.9
26–27	654	36.5	36.0–37.0
28–29	919	36.6	36.1–37.0
30–31	1,432	36.5	36.1–36.9
32–33	1,444	36.5	36.1–36.9
34–36	2,015	36.6	36.2–36.9
37–44	3,720	36.7	36.3–37.0
Total	10,681	36.6	36.2–36.9

Indication for respiratory support

In 2017, only 3.0% of all ANZNN registrants did not receive any form of respiratory support. For the remaining registrants, hyaline membrane disease (HMD) remained the most common indication for respiratory support at 42.5%. Non-specific respiratory distress accounted for 32.2% of babies, surgery for 4.2%, while congenital anomaly accounted for 3.4% (Table 13).

For babies born before 37 weeks gestation, HMD (60.8%) remained the most common indication for respiratory support. For babies born at term, non-specific respiratory distress (44.9%) was the most common indication followed by surgery (8.6%) and meconium aspiration syndrome (8.5%) (Table 13). The 10-year trend (2008–2017) for mode of assisted ventilation is represented by Figure 17 in Appendix 1.

TABLE 13: Indication for respiratory support for level III registrants by gestational age, ANZNN 2017

Indication for respiratory support	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
	Number								
No respiratory support	0	0	0	2	101	86	57	75	321
Non-specific respiratory distress	0	7	18	67	270	499	898	1,664	3,423
Hyaline membrane disease	n.p.	379	626	828	973	690	637	n.p.	4,522
Meconium aspiration syndrome	0	0	0	0	0	<5	5	n.p.	322
Pneumonia	0	<5	0	0	0	<5	10	100	113
Persistent pulmonary hypertension	<5	5	<5	5	<5	6	16	129	170
Apnoea	<5	0	<5	<5	19	30	48	46	149
Congenital anomaly	<5	0	0	<5	9	21	66	264	365
Other	0	2	1	8	43	71	125	282	532
Peri-surgery	0	0	0	<5	<5	24	103	318	449
Newborn encephalopathy	0	<5	0	<5	<5	7	42	217	270
Not stated	0	0	2	0	9	8	8	18	45
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
	Per cent								
No respiratory support	0.0	0.0	0.0	0.2	7.1	6.0	2.8	2.0	3.0
Non-specific respiratory distress	0.0	1.8	2.8	7.3	19.0	34.7	44.7	44.9	32.2
Hyaline membrane disease	n.p.	95.7	96.0	90.1	68.4	48.1	31.7	n.p.	42.5
Meconium aspiration syndrome	0.0	0.0	0.0	0.0	0.0	n.p.	0.2	n.p.	3.0
Pneumonia	0.0	n.p.	0.0	0.0	0.0	n.p.	0.5	2.7	1.1
Persistent pulmonary hypertension	n.p.	1.3	n.p.	0.5	n.p.	0.4	0.8	3.5	1.6
Apnoea	n.p.	0.0	n.p.	n.p.	1.3	2.1	2.4	1.2	1.4
Congenital anomaly	n.p.	0.0	0.0	n.p.	0.6	1.5	3.3	7.1	3.4
Other	0.0	0.5	0.2	0.9	3.0	4.9	6.2	7.6	5.0
Peri-surgery	0.0	0.0	0.0	n.p.	n.p.	1.7	5.1	8.6	4.2
Newborn encephalopathy	0.0	n.p.	0.0	n.p.	n.p.	0.5	2.1	5.9	2.5
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

Exogenous surfactant

Exogenous surfactant administered to babies with moderate to severe HMD has been shown to reduce the severity of the disease, the ventilation requirements and the risk of air leaks. Exogenous surfactant can be administered for both prevention and cure. For babies born at less than 31 weeks gestation most benefit is gained by early administration of exogenous surfactant (within two hours of birth). For babies born at 31 or more weeks gestation exogenous surfactant is usually only administered to those with a confirmed diagnosis of HMD.

In 2017, a quarter of ANZNN registrants (25.2%) were administered exogenous surfactant (Table 14). There were 2,172 babies who received intermittent positive pressure ventilation for HMD in 2017. Exogenous surfactant was given to 1,976 of these babies (91.0%). There were 196 babies diagnosed with HMD who were not given exogenous surfactant.

TABLE 14: Exogenous surfactant use for level III registrants by gestational age, ANZNN 2017

	Gestational age (weeks)								
Exogenous surfactant	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	Total
Number									
None	<5	23	137	418	1,034	1,192	1,731	n.p.	7,984
Surfactant given	n.p.	373	517	500	398	251	284	n.p.	2,692
▪ via endotracheal tube	85	340	467	426	336	213	234	239	2,340
▪ via catheter	6	16	22	32	22	12	7	6	123
▪ via other or unknown method	n.p.	17	28	42	40	26	43	n.p.	229
Not stated	0	0	0	1	0	1	0	3	5
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
None	n.p.	5.8	20.9	45.5	72.2	82.6	85.9	n.p.	74.8
Surfactant given	n.p.	94.2	79.1	54.5	27.8	17.4	14.1	n.p.	25.2
▪ via endotracheal tube	84.2	85.9	71.4	46.4	23.5	14.8	11.6	6.4	21.9
▪ via catheter	5.9	4.0	3.4	3.5	1.5	0.8	0.3	0.2	1.2
▪ via other or unknown method	n.p.	4.3	4.3	4.6	2.8	1.8	2.1	n.p.	2.1
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

Type of assisted ventilation

Assisted ventilation requires specialised nursing, medical and paramedical care and utilises a large component of the available resources. Of the babies registered to the ANZNN in 2017, 92.4% required assisted ventilation for four or more hours.

The two major forms of assisted ventilation used are intermittent positive pressure ventilation (IPPV), continuous positive airway pressure (CPAP). IPPV is assisted ventilation given via an endotracheal tube, while CPAP can be administered via an endotracheal tube or via nasopharyngeal prongs (nasal CPAP). For the purposes of this audit CPAP is recorded via any route. The 10-year trend (2008–2017) for assisted ventilation is represented in Figures 17 to 19 in Appendix 1.

In 2017, IPPV was given for a total of 526,715 hours to ANZNN registrants and CPAP was given for 1,736,870 hours. The total number of hours of ventilation equates to each baby receiving 8.8 days of assisted ventilation. The median number of hours of assisted ventilation is inversely related to the gestational age at birth in babies born preterm (Table 15).

The most common form of ventilation given to ANZNN registrants in 2017 remains CPAP with 57.2% of registrants receiving CPAP only, 9.8% receiving IPPV only and 25.4% receiving both CPAP and IPPV.

In addition to IPPV and CPAP babies may have received high frequency oscillatory ventilation (HFOV), nitric oxide or extracorporeal membrane oxygenation (ECMO). HFOV is administered via an endotracheal tube, and is usually given in conjunction with IPPV. In 2017, 20.7% of registrants who received IPPV also received HFOV. However, 24 babies received HFOV without at least four hours of IPPV. The use of HFOV among individual units varied between 0.9% and 14.8% with the highest percentage of babies receiving HFOV born at less than 24 weeks (43.3%) followed by babies born at 24–25 weeks gestation (34.2%) (Table 16). The 10-year trend (2008–2017) for HFOV is represented in Figure 20 in Appendix 1.

TABLE 15: Duration of assisted ventilation use for level III registrants by gestational age, ANZNN 2017

Duration of assisted ventilation	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
IPPV (hours)									
Median	422	233	71	24	24	27	46	48	46
IQR	137–762	71–564	17–218	11–71	11–57	12–72	19–91	21–104	17–134
CPAP (hours)									
Median	958.5	1106	904	244.5	64	29	22	15	36
IQR	720–1,264	767.5–1,368	518–1,186	110.5–624	24–139	14–65	10–50	7–37	13–128

Note: IQR = Interquartile range. IPPV = intermittent positive pressure ventilation. CPAP = continuous positive airway pressure.

In 2017, 32 registrants received ECMO of whom the majority were born at term. The percentage of ANZNN registrants who received nitric oxide was 5.1%. The use of nitric oxide continues to have a U-shaped distribution with the highest percentage of babies to receive nitric oxide born at term (18.0%) (Table 16). The 10-year trend (2008–2017) for nitric oxide is represented in Figure 21 in Appendix 1.

TABLE 16: Assisted ventilation for level III registrants by gestational age, ANZNN 2017

	Gestational age (weeks)								
Ventilation type	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	Total
Number									
Invasive ventilation	101	369	496	439	357	303	507	1,197	3,769
▪ HFOV given	77	191	148	76	51	29	51	162	785
▪ IPPV given	101	367	495	439	357	303	507	1,195	3,764
Nitric oxide given	23	75	50	37	37	25	51	244	542
CPAP given	62	336	635	880	1,239	1,232	1,658	2,780	8,822
Total in each age group	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
IPPV given	100.0	92.7	75.7	47.8	24.9	21.0	25.2	32.1	35.2
CPAP given	61.4	84.8	97.1	95.8	86.5	85.3	82.3	74.7	82.6
Per cent of babies given invasive ventilation									
HFOV given ^(a)	76.2	51.8	29.8	17.3	14.3	9.6	10.1	13.5	20.8
Nitric oxide given ^(a)	22.8	20.3	10.1	8.4	10.4	8.3	10.1	20.4	14.4

^(a) Denominator is babies given ventilation via endotracheal tube (IPPV and/or HFOV).

Note: Groups are not mutually exclusive.

HFOV = high frequency oscillatory ventilation. IPPV = intermittent positive pressure ventilation. CPAP = continuous positive airway pressure.

Ventilation in babies born at less than 32 weeks gestation

The major indication for assisted ventilation in babies born at less than 32 weeks gestation was hyaline membrane disease. Among the 3,502 babies born before 32 weeks gestation, 95.0% were given assisted ventilation in the form of IPPV or CPAP. For registrants in this age group CPAP was the only form of ventilation for 44.8% and IPPV was the only form of ventilation for 5.0% of registrants. Both IPPV and CPAP were given to 45.2% of registrants.

The total duration of IPPV for these very preterm babies was 338,017 hours, and the duration of CPAP was 1,479,706 hours.

Of the babies born before 32 weeks gestational age and given IPPV in 2017, 30.7% were given high frequency ventilation while 12.6% of these babies were given nitric oxide (Table 16).

Among 2017 ANZNN registrants born at less than 32 weeks gestation, 3,325 (94.9%) survived to day 28. Of these, 52.6% of registrants received respiratory support (airway support or supplemental oxygen therapy) at 28 days of age, with 18.8% of them discharged on home oxygen (Table 17).

Ventilation in babies born at 32 to 36 weeks gestation

Among the babies born at 32–36 weeks gestation, 91.3% received assisted ventilation. Non-specific respiratory distress was the main reason for ventilation. Total duration of CPAP use by registrants in this gestational age group was 139,669 hours and IPPV use was 70,891 hours.

Of the babies born at 32–36 weeks gestation and given IPPV in 2017, 9.9% were given HFOV while 9.4% of these babies were given nitric oxide (Table 16).

Ventilation in babies born at term

The main indication for respiratory support in term babies was non-specific respiratory distress (44.7%). This group required 117,807 hours of IPPV and 117,495 hours of CPAP.

Of the babies born at term and given IPPV in 2017, 13.4% were given high frequency ventilation while 20.4% of these babies were given nitric oxide (Table 16). There were 24 babies born at term who received ECMO.

Respiratory support

Respiratory support is critical for the survival of some babies especially those with respiratory problems and those born prematurely. Babies requiring treatment in a level III unit commonly require long-term respiratory support as part of their specialised care. The duration of respiratory support varies between babies, from as little as a few hours to several weeks or months. For the ANZNN audit, four consecutive hours in any single 24-hour period of CPAP, nasal high flow, IPPV, HFOV or supplemental oxygen therapy constitutes the use of respiratory support on that day. The continued use of respiratory support at 28 days of age is a predictor of postneonatal morbidity and the need for continued oxygen therapy after discharge.

Among the 2017 ANZNN registrants, 10,347 babies survived to day 28 and of these, 19.3% were reported as having received respiratory support on day 28 or later. Of the registrants who received respiratory support on day 28 and survived to discharge to home, 20.2% were discharged on home oxygen (Table 17).

TABLE 17: Respiratory support (airway support or supplemental oxygen therapy) for level III registrants who survived to day 28 by gestational age, ANZNN 2017

Respiratory support (airway support or oxygen)	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
	Number								
No respiratory support on day 28	<5	7	30	331	1,163	n.p.	1,890	3,494	8,257
Respiratory support on day 28	n.p.	317	592	567	252	n.p.	76	138	2,083
▪ survived to discharge home	54	295	579	561	247	79	68	122	2,005
▪ died before discharge	n.p.	22	13	6	5	<5	8	16	78
Not stated	0	2	2	0	0	0	0	3	7
Total in each age group	62	326	624	898	1,415	1,421	1,966	3,635	10,347
	Number								
Respiratory support on day 28 and given home oxygen	33	93	126	64	39	16	14	33	418
	Per cent								
No respiratory support on day 28	n.p.	2.2	4.8	36.9	82.2	n.p.	96.1	96.2	79.9
Respiratory support on day 28	n.p.	97.8	95.2	63.1	17.8	n.p.	3.9	3.8	20.1
▪ survived to discharge home	88.5	93.1	97.8	98.9	98.0	98.8	89.5	88.4	96.3
▪ died before discharge	n.p.	6.9	2.2	1.1	2.0	n.p.	10.5	11.6	3.7
	Per cent								
Respiratory support on day 28 and given home oxygen ^(a)	61.1	31.5	21.8	11.4	15.8	20.3	20.6	27.0	20.8

n.p. Data not published to maintain confidentiality of small numbers.

(a) Denominator is babies who received respiratory support on day 28 and survived to discharge to home.

Note: Not stated data are excluded from per cent calculations.

Nasal high flow therapy

Nasal high flow therapy as a form of non-invasive respiratory support for premature babies, is an emerging trend within neonatal units. Humidified blended air and oxygen mix is administered through a high flow device via high flow nasal cannula.

In 2017 nasal high flow therapy was reported for 3,528 babies (33.0%) of all level III registrants (Table 18), compared with 8.1% in 2009. Of the babies receiving nasal high flow therapy 65.4% were reported to have received a minimum rate of 2–4 litres per minute while 73.4% received a maximum of 6–8 litres per minute.

TABLE 18: Nasal high flow respiratory support for level III registrants by gestational age, ANZNN 2017

	Gestational age (weeks)								
Nasal high flow	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	Total
Number									
High flow	53	255	508	662	523	311	376	840	3,528
No high flow	48	141	146	257	909	1,133	1,639	2,880	7,153
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
High flow	52.5	64.4	77.7	72.0	36.5	21.5	18.7	22.6	33.0
No high flow	47.5	35.6	22.3	28.0	63.5	78.5	81.3	77.4	67.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Parenteral nutrition

Intravenous parenteral nutrition is common in very preterm babies because of the need for optimal nutrition from day one when enteral nutrition is difficult, whilst recovery from acute illness or from an intervention occurs, or due to poor weight gain. Of the 3,867 ANZNN registrants born at less than 32 weeks gestation and/or less than 1,500g at birth, 3,010 (77.8%) received parenteral nutrition during admission (Table 19). The median duration of parental nutrition reported was 233 hours.

Some babies are discharged home with a nasogastric tube in place to allow gavage or infusion feeding at home and this practice is increasing. Of those who received parenteral nutrition, 7.1% of babies were discharged home on gavage feeds.

TABLE 19: Parenteral nutrition for level III registrants by gestational age, ANZNN 2017

	Gestational age (weeks)										
Parenteral nutrition	<24	24	25	26	27	28	29	30	31	≥32 ^(a)	Total
Number											
Parenteral nutrition	95	164	n.p.	n.p.	n.p.	428	429	441	417	170	3,010
No parenteral nutrition	6	12	<5	<5	<5	17	45	195	379	195	857
Total	101	176	220	311	343	445	474	636	796	365	3,867
Number											
Home gavage feeding	8	19	n.p.	n.p.	n.p.	25	34	29	17	10	214
Per cent											
Parenteral nutrition	94.1	93.2	n.p.	n.p.	n.p.	96.2	90.5	69.3	52.4	46.6	77.8
No parenteral nutrition	5.9	6.8	n.p.	n.p.	n.p.	3.8	9.5	30.7	47.6	53.4	22.2
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Per cent											
Home gavage feeding ^(b)	8.4	11.6	6.9	9.7	7.9	5.8	7.9	6.6	4.1	5.9	7.1

n.p. Data not published to maintain confidentiality of small numbers.

(a) These babies were less than 1,500g at birth.

(b) Denominator is babies who received parenteral nutrition.

Chronic lung disease

Chronic lung disease (CLD) is currently defined by the ANZNN as a continued need for any form of respiratory support (supplemental oxygen and/or assisted ventilation) at 36 weeks post menstrual age (PMA) (post menstrual age is calculated by adding the baby's age in weeks to the gestational age at birth in weeks). For ANZNN registrants, 9.3% of babies in 2017 were reported to have had respiratory support at 36 weeks PMA, and of these, 19 (1.9%) died prior to discharge to home. CLD is a complication of premature lung development and the trauma of early respiratory support (supplemental oxygen and/or assisted ventilation). The prevalence of chronic lung disease continues to be highest in babies born less than 27 weeks gestation. The highest percentage was in those babies born at less than 24 weeks gestation (85.5%) who survived to 36 weeks PMA (Table 20). Not all babies survived to 36 weeks PMA and therefore CLD status could not be defined in these babies. The 10-year trend (2008–2017) for CLD is represented by Figure 22 in Appendix 1.

TABLE 20: Chronic lung disease at 36 weeks post menstrual age for level III registrants by gestational age, ANZNN 2017

Chronic lung disease (CLD)	Gestational age (weeks)									Total
	<24	24	25	26	27	28	29	30	31	
Number										
No CLD	8	20	44	100	171	296	363	545	727	2,274
CLD	47	100	144	189	153	134	98	76	47	988
Did not survive to 36 weeks PMA	46	54	32	21	17	13	10	9	10	212
Not stated	0	2	0	1	2	2	3	6	12	28
Total	101	176	220	311	343	445	474	636	796	3,502
Per cent										
No CLD	14.5	16.7	23.4	34.6	52.8	68.8	78.7	87.8	93.9	69.7
CLD	85.5	83.3	76.6	65.4	47.2	31.2	21.3	12.2	6.1	30.3
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Note: Not stated data and babies who did not survive to 36 weeks PMA are excluded from per cent calculations.
PMA = Post menstrual age

Of the ANZNN registrants born at less than 32 weeks, 281 (8.0%) babies were treated with systemic corticosteroids. Of these, 237 were reported to have had respiratory support at 36 weeks, while 40 (14.2%) reported no CLD.

Pulmonary air leak

A pulmonary air leak is a collection of air in the space around the lungs which can cause difficulty in breathing. There are several types of pulmonary air leak and while some produce only minor symptoms a number of them require treatment by the insertion of a drainage tube. For the purposes of this report the presence of any form of air leak that required drainage (either transient or continuous drainage) is reported for ANZNN registrants (Table 21).

TABLE 21: Pulmonary air leak for level III registrants by gestational age, ANZNN 2017

	Gestational age (weeks)								
Air leak	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	Total
Number									
Air leak	6	33	29	33	43	36	85	184	449
No air leak	95	363	625	886	1,389	1,408	1,930	3,536	10,232
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
Air leak	5.9	8.3	4.4	3.6	3.0	2.5	4.2	4.9	4.2
No air leak	94.1	91.7	95.6	96.4	97.0	97.5	95.8	95.1	95.8
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Neonatal sepsis

Each episode of sepsis is recorded as either early or late onset. Early onset sepsis is defined as the presence of at least one episode of systemic sepsis where the initial symptoms occurred within the first 48 hours after birth that is, in babies aged from 0 to 47 hours. Late onset sepsis is the presence of at least one episode of systemic sepsis with the initial symptoms occurring among babies aged 48 or more hours. Episodes of sepsis involving the same organism separated by at least 14 days are considered to be new episodes of infection. Symptomatic, blood culture positive septicaemia was reported in 4.7% of ANZNN registrants in 2017. Of these babies, 51.7% were born at less than 28 weeks gestation, 70.6% were born at less than 32 weeks gestation and 98.6%

of registrants survived up to 2 days of life (Table 22). Episodes of both early and late sepsis were reported in ten babies. The 5-year trends (2013–2017) for early and late sepsis are represented by Figure 25 and Figure 26 respectively in Appendix 1.

TABLE 22: Neonatal sepsis for level III registrants by gestational age, ANZNN 2017

Sepsis	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
	Number								
No sepsis	60	279	554	855	1,402	1,414	1,977	3,645	10,186
Sepsis at <48 hrs ^(a)	8	9	11	10	9	9	18	37	111
Sepsis at ≥48 hrs ^(a)	33	111	n.p.	55	21	n.p.	22	41	396
Babies alive on day 2	90	374	n.p.	911	1,427	n.p.	2,003	3,705	10,595
Babies who did not survive to day 2	11	22	<5	8	5	n.p.	12	15	86
Total in each age group	101	396	654	919	1,432	1,444	2,015	3,720	10,681
	Per cent								
No sepsis ^(b)	59.4	70.5	84.7	93.0	97.9	97.9	98.1	98.0	95.4
Sepsis at <48 hrs ^(b)	7.9	2.3	1.7	1.1	0.6	0.6	0.9	1.0	1.0
Sepsis at ≥48 hrs ^(c)	36.7	29.7	14.2	6.0	1.5	1.5	1.1	1.1	3.7

n.p. Data not published to maintain confidentiality of small numbers.

(a) Groups are not mutually exclusive.

(b) Denominator is all registrants.

(c) Denominator is registrants alive at 48 hours.

Viral infection for the purposes of this audit is defined as the presence of at least one episode of viral infection with initial symptoms occurring following 48 hours after birth. Symptomatic viral infection was reported in 271 (2.5%) of ANZNN registrants in 2017, as identified by isolation or identification of an organism by polymerase chain reaction (PCR) testing, immunofluorescence or similar technology from an appropriate body fluid.

Retinopathy of prematurity

The classification of retinopathy of prematurity (ROP) for ANZNN registrants are those recommended by the Committee for the Classification of Retinopathy of Prematurity (1984). The examination criteria for ROP vary between units within ANZNN. As in previous reports, the prevalence of ROP screening in 2017 was assessed among registrants with a gestational age of less than 31 weeks and/or a birthweight of less than 1,250 grams. Among the 2017 registrants, 27.0% were eligible for ROP examination and of these eligible registrants, 83.9% were examined and had the results of their eye examination recorded.

Of those ANZNN registrants who were eligible for an eye examination, 199 died before their ROP status could be determined. Of those examined, 7.4% had stage 3 or 4 eye disease (Table 23, Figure 6) and of these babies 40.8% received surgical treatment. The 10-year trend (2008–2017) for stages 3 and 4 ROP and treatment are represented by Figure 23 in Appendix 1.

TABLE 23: Retinopathy of prematurity for level III registrants by gestational age, ANZNN 2017


Retinopathy of prematurity (ROP)	Gestational age (weeks)									Total
	<24	24	25	26	27	28	29	30	≥31 ^(a)	
	Number									
No ROP	n.p.	n.p.	n.p.	118	n.p.	306	341	371	104	1,497
Stage 1	5	14	34	74	59	64	n.p.	n.p.	n.p.	388
Stage 2	18	44	57	68	67	44	31	16	10	355
Stage 3	27	54	39	29	12	9	<5	<5	<5	n.p.
Stage 4	<5	<5	<5	0	<5	0	0	0	0	<5
Not examined	44	53	31	21	21	22	34	191	44	461
Not stated	0	0	0	1	0	0	0	1	1	3
Total	101	176	220	311	343	445	474	636	177	2,883
Per cent										
No ROP	n.p.	n.p.	n.p.	40.8	n.p.	72.3	77.5	83.6	78.8	61.9
Stage 1	8.8	11.4	18.0	25.6	18.3	15.1	n.p.	n.p.	n.p.	16.0
Stage 2	31.6	35.8	30.2	23.5	20.8	10.4	7.0	3.6	7.6	14.7
Stage 3	47.4	43.9	20.6	10.0	3.7	2.1	n.p.	n.p.	n.p.	n.p.
Stage 4	n.p.	n.p.	n.p.	0.0	n.p.	0.0	0.0	0.0	0.0	n.p.
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) These babies were less than 1,250g at birth.

Note: Not stated and not examined data are excluded from per cent calculations.

FIGURE 6: Retinopathy of prematurity for level III registrants by gestational age, ANZNN 2017



Intraventricular haemorrhage

An initial cerebral ultrasound is generally performed during the first week of life to detect signs of intraventricular haemorrhage (IVH) which is graded according to an internationally recognised method in which severity increases with higher grade (Papile et al. 1978).

There were 3,502 babies born at less than 32 weeks gestation eligible for a cerebral ultrasound, 3,439 survived to day 3 and 93.2% had an examination recorded. A normal report was recorded for 80.7% of these 2017 ANZNN registrants.

There were 148 babies reported to have grade 3 or 4 IVH representing 4.3% of the babies born before 32 weeks gestation. Of the babies who had a grade 3 IVH, 12.1% were unilateral, while 74.3% of grade 4 IVH cases were unilateral. The incidence of IVH, particularly of severe grades, is clearly shown to be inversely related to gestation. The highest percentage of babies who had severe IVH (grade 4) were born before 26 weeks gestational age, with the majority (66.7%) of these babies born before 25 weeks gestation (Table 24, Figure 7). The 10-year trend (2008–2017) for registrants with grades 3 and 4 IVH who survived to day 3 is represented in Figure 24 in Appendix 1.


TABLE 24: Intraventricular haemorrhage for level III registrants born before 32 weeks and survived to day 3, by gestational age, ANZNN 2017

Intraventricular haemorrhage	Gestational age (weeks)									Total
	<24	24	25	26	27	28	29	30	31	
Number										
None	30	79	134	221	277	380	392	508	566	2,587
Grade 1	20	15	30	34	27	n.p.	45	43	n.p.	302
Grade 2	15	27	23	n.p.	n.p.	12	9	12	13	167
Grade 3	7	8	7	<5	<5	<5	6	n.p.	0	43
Grade 4	16	24	20	12	16	6	5	<5	<5	105
Not examined	0	0	0	1	1	5	13	60	155	235
Total	88	153	214	308	342	439	470	632	793	3,439
Per cent										
None	34.1	51.6	62.6	72.0	81.2	87.6	85.8	88.8	88.7	80.7
Grade 1	22.7	9.8	14.0	11.1	7.9	n.p.	9.8	7.5	n.p.	9.4
Grade 2	17.0	17.6	10.7	n.p.	n.p.	2.8	2.0	2.1	2.0	5.2
Grade 3	8.0	5.2	3.3	n.p.	n.p.	n.p.	1.3	n.p.	0.0	1.3
Grade 4	18.2	15.7	9.3	3.9	4.7	1.4	1.1	n.p.	n.p.	3.3
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not examined data are excluded from per cent calculations.

FIGURE 7: Intraventricular haemorrhage in level III registrants born at less than 32 weeks gestation and survived to day 3, by gestational age, ANZNN 2017



Late cerebral ultrasound

Late cerebral ultrasound data are based on changes seen in brain tissue at the cerebral ultrasound scan nearest to six weeks of age. As noted above there were 3,502 babies born at less than 32 weeks gestation eligible for a cerebral ultrasound, 3,439 survived until day 3 and late ultrasound results were available for 2,274 (66.1%) of these babies. A normal report of no cysts was recorded for 97.4% of these registrants, 1.1% reported porencephalic cysts and 1.5% reported periventricular leukomalacia (PVL) (Table 25). Of the 33 babies who were reported with PVL, seven had extensive leukomalacia involving two or more of the anterior frontal, posterior frontal, parietal, temporal or occipital regions.

TABLE 25: Late cerebral ultrasound results for level III registrants born before 32 weeks by gestational age, ANZNN 2017

	Gestational age (weeks)									
Cerebral ultrasound results	<24	24	25	26	27	28	29	30	31	Total
Number										
No cysts	n.p.	111	n.p.	n.p.	n.p.	n.p.	338	350	299	2,150
Porencephalic cysts	0	<5	<5	7	<5	<5	<5	<5	<5	24
Periventricular leukomalacia	<5	<5	6	<5	6	7	<5	<5	<5	33
Not stated	48	60	54	66	83	79	132	282	491	1,295
Total	101	176	220	311	343	445	474	636	796	3,502
Per cent										
No cysts	n.p.	95.7	n.p.	n.p.	n.p.	n.p.	98.8	98.9	98.0	97.4
Porencephalic cysts	0.0	n.p.	n.p.	2.9	n.p.	n.p.	n.p.	n.p.	n.p.	1.1
Periventricular leukomalacia	n.p.	n.p.	3.6	n.p.	2.3	1.9	n.p.	n.p.	n.p.	1.5
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

Therapeutic hypothermia

Therapeutic hypothermia is the intentional cooling of an infant to a core temperature of less than 35°C (generally 33–34°C). The evidence in support for controlled hypothermia, initiated before 6 hours of age, as a means of limiting the reperfusion injury that follows perinatal asphyxia in term infants has been evolving over the last 10 years.

Hypothermia begins at the onset of cooling and ends at the onset of warming. Cooling is normally for 72 hours with a period of up to 6 hours of rewarming. In 2017, 307 (6.1%) of the ANZNN registrants born at more than 34 weeks gestation received therapeutic hypothermia, and of these, 76.2% were cooled for at least 72 hours. Of those babies who did not receive cooling for a full 72 hours, information on the principal reason for non-completion of the full 72 hours of therapeutic hypothermia was available for 90.1% of babies.

Necrotising enterocolitis

Necrotising enterocolitis (NEC) is a gastrointestinal disease affecting premature infants that can be life threatening and is a leading cause of mortality and morbidity among infants in NICUs. There is no definitive cause identified for NEC although infection, empirical use of antibiotics for more than five days and enteral artificial formula feeding are thought to be involved. With an early diagnosis, NEC can be treated medically through cessation of feeds, use of parenteral nutrition and antibiotic treatment. If medical treatment is unsuccessful surgery may be required to remove the affected bowel.

For ANZNN registrants in 2017 the percentage of babies with confirmed NEC was 1.5%. Of these babies, 66.9% were born before 28 weeks gestation with 48.6% of them undergoing surgery, and 15.9% were born between 28–31 weeks gestation; surgery was required for 40.0% of them. In total 33 registrants died from NEC. The number of registrants with confirmed NEC is similar to that in 2016 (Table 26).

TABLE 26: Necrotising enterocolitis in level III registrants by year of birth, ANZNN 2008–2017

Necrotising enterocolitis	Year of birth									
	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017
Number										
Babies born at <28 weeks										
▪ NEC	114	94	112	78	87	75	64	81	91	105
▪ No NEC	1,039	1,032	964	1,025	980	1,015	1,039	978	1,126	1,046
▪ Not stated	9	2	4	5	2	0	3	4	2	0
Babies born at 28-31 weeks										
▪ NEC	49	34	41	36	35	27	21	40	37	25
▪ No NEC	2,396	2,384	2,182	2,401	2,417	2,384	2,484	2,384	2,353	2,325
▪ Not stated	15	0	4	0	2	0	2	6	1	1
Babies born at ≥32 weeks										
▪ NEC	23	19	21	14	14	19	26	27	30	27
▪ No NEC	4,906	5,410	4,903	5,626	5,778	6,200	6,515	6,267	6,832	7,151
▪ Not stated	10	2	4	1	3	1	4	9	1	1
Total in each birth year	8,561	8,977	8,235	9,186	9,318	9,721	10,158	9,796	10,473	10,681
Per cent										
NEC <28 weeks ^(a)	9.9	8.3	10.4	7.1	8.2	6.9	5.8	7.6	7.5	9.1
NEC 28-31 weeks ^(b)	2.0	1.4	1.8	1.5	1.4	1.1	0.8	1.7	1.5	1.1
NEC ≥32 weeks ^(c)	0.5	0.3	0.4	0.2	0.2	0.3	0.4	0.4	0.4	0.4

(a) Denominator is babies born at <28 weeks.

(b) Denominator is babies born at 28-31 weeks.

(c) Denominator is babies born at ≥32 weeks.

Note: Not stated data are excluded from per cent calculations.

Spontaneous intestinal perforation

Spontaneous intestinal perforation is distinct from NEC and usually involves a single perforation of the intestine. In 2017, 64 (0.6%) of ANZNN registrants had a confirmed diagnosis of spontaneous intestinal perforation. Of these, one baby was also reported to have a confirmed NEC diagnosis. Of babies born before 28 weeks gestation, 37 (3.2%) had a confirmed diagnosis of spontaneous intestinal perforation.

Neonatal surgery

The information given in this report includes the registrant's first admission to an NICU before their first discharge home after birth. Babies who were discharged home and re-admitted for surgery during the neonatal period are not included in this audit.

In 2017, there were 958 ANZNN registrants who had major surgery, of whom over half (54.1%) were born at term. Of registrants born in a hospital, 77.3% were born in a hospital with tertiary care facilities. Of registrants who had major surgery, 73.5% also had a congenital anomaly present with 63.4% of these diagnosed during the antenatal period. 7.8% had surgery for proven NEC. The median length of stay for survivors was 33 days (Table 27).

TABLE 27: Characteristics of level III registrants who underwent surgery by gestational age, ANZNN 2017

Characteristics	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
	Number								
Male	11	31	31	16	25	32	88	315	549
Female	9	31	23	11	12	32	88	203	409
Congenital anomaly present	<5	n.p.	12	9	20	44	153	455	704
Congenital anomaly diagnosed antenatally	0	0	<5	<5	9	23	115	294	446
Proven NEC	6	27	18	6	<5	<5	6	6	75
Hospital of birth:									
▪ Tertiary	n.p.	56	46	n.p.	n.p.	45	138	372	733
▪ Non-tertiary	<5	6	8	<5	<5	18	36	140	215
Median length of stay for survivors (days)	132	131	111	89	78	53	36	21	33
Died before discharge home	<5	12	8	0	<5	<5	7	5	38
Total in each age group	20	62	54	27	37	64	176	518	958
	Per cent								
Male	55.0	50.0	57.4	59.3	67.6	50.0	50.0	60.8	57.3
Female	45.0	50.0	42.6	40.7	32.4	50.0	50.0	39.2	42.7
Congenital anomaly present	n.p.	n.p.	22.2	33.3	54.1	68.8	86.9	87.8	73.5
Congenital anomaly diagnosed antenatally	0.0	0.0	n.p.	n.p.	24.3	35.9	65.3	56.8	46.6
Proven NEC	30.0	43.5	33.3	22.2	n.p.	n.p.	3.4	1.2	7.8
Hospital of birth:									
▪ Tertiary	n.p.	90.3	85.2	n.p.	n.p.	70.3	78.4	71.8	76.5
▪ Non-tertiary	n.p.	9.7	14.8	n.p.	n.p.	28.1	20.5	27.0	22.4
Died before discharge home	n.p.	19.4	14.8	0.0	n.p.	n.p.	4.0	1.0	4.0

n.p. Data not published to maintain confidentiality of small numbers.

The median age of mothers of neonates who received major surgery was 30 years. Within the 2017 surgical cohort, 7.6% of pregnancies resulted from assisted conception, compared with 8.8% in the whole cohort. Of the 2017 ANZNN registrants who received major surgery, gastrointestinal procedures were the most commonly performed (57.3%) followed by cardiac procedures (28.2%).

There were 92 (0.9%) babies born in 2017 who received surgery to repair a gastroschisis before discharge to home. Approximately half of these babies were male (52.2%) and two-thirds were born at more than 35 weeks gestation (67.4%). In 2017, 48 babies received surgery to repair a congenital diaphragmatic hernia, of which 58.3% were male and 72.9% were born at more than 37 weeks gestation.

Congenital anomalies

In 2017, 1,318 ANZNN registrants (12.3%) had one or more major congenital anomalies. For registrants who had a major congenital anomaly, 14.6% were born before 32 weeks gestation, 28.9% were born between 32 and 36 weeks gestation and more than half of registrants (56.5%) were born at term.

Of the ANZNN registrants with major congenital anomalies, over half (52.7%) were diagnosed during the antenatal period with 7.9% of babies recorded as having a fatal congenital anomaly. A higher proportion of babies with congenital anomalies were male (58.0%).

Transfer from level III NICUs to other units

Once intensive care is no longer required babies are often 'down' transferred to a level II unit, sometimes referred to as a 'special care baby unit', either within the same hospital or to another hospital for convalescence before discharge home. In 2017, more than one third of ANZNN registrants (34.2%) were transferred from a level III NICU to a level II unit in another hospital before discharge home. The ability to down transfer for any level III unit will depend on the availability of receiving level II hospitals and this is a limiting factor in some regions (e.g. South Australia). Almost half of the registrants (47.1%) transferred from level III to level II or level I units were born at less than 32 weeks gestation compared to 14.3% born at term.

Some level III registrants required transfer to a specialist children's hospital and in 2017 these accounted for 4.8% of registrants. Overall 58.0% of level III registrants were not transferred after registration (Table 28).

TABLE 28: Transfer after registration of level III registrants by level of destination hospital and gestational age, ANZNN 2017

Transfer status	Gestational age (weeks)								Total
	<24	24–25	26–27	28–29	30–31	32–33	34–36	37–44	
	Number								
Not transferred	72	227	277	364	532	606	1,252	2,858	6,188
Level III hospital	<5	25	38	45	46	n.p.	38	85	322
Level II or I hospital	n.p.	112	295	482	818	n.p.	646	521	3,653
Children's hospital	12	32	44	26	35	31	78	256	514
Not stated	0	0	0	2	1	0	1	0	4
Total	101	396	654	919	1,432	1,444	2,015	3,720	10,681
Per cent									
Not transferred	71.3	57.3	42.4	39.7	37.2	42.0	62.2	76.8	58.0
Level III hospital	n.p.	28.3	45.1	52.6	57.2	n.p.	32.1	14.0	3.0
Level II or I hospital	n.p.	6.3	5.8	4.9	3.2	n.p.	1.9	2.3	34.2
Children's hospital	11.9	8.1	6.7	2.8	2.4	2.1	3.9	6.9	4.8
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

Length of stay until discharge home

Factors that influence a baby's length of stay in hospital include gestational age, birthweight and plurality. Preterm and low birthweight babies require more intensive care, lengthening their hospital stay. Extremely preterm babies are usually discharged home by the time they reach 40 weeks corrected age.

In the ANZNN the length of stay includes all the time the baby spends in hospital from the first day of their first admission up until and including the day of their discharge home. The length of stay has added together the time spent in all hospitals, which includes level III and subsequent level II or I hospitals or children's hospitals. It does not include the time spent in hospital in any subsequent admissions from home, nor does it include periods spent in 'Hospital in the Home' programs. Discharge information was available for 96.5% of ANZNN registrants in 2017 who survived to discharge to home. The median length of stay was 24 days with an interquartile range of 8–50 days (Table 29). Length of stay is inversely related to gestational age with the very preterm and extremely preterm babies having a longer stay in hospital than those babies born at or near term.

Babies born at less than 32 weeks gestation spent 221,510 days in hospital, babies born between 32 and 36 weeks spent 83,777 days and babies born at term spent 47,679 days in hospital.

TABLE 29: Length of stay for level III registrants who survived until discharge home by gestational age, ANZNN 2017

Gestational age (weeks)	Number of babies	Median length of stay (days)	Interquartile range (days)
<24	55	128	119–142
24	120	125	111–138
25	182	108	97–120
26	284	96	85–110
27	322	82	73–93
28	431	71	62–82
29	460	60	53–70
30	627	50	43–60
31	781	40	35–47
32	774	34	28–42
33	646	25	21–32
34	712	20	15–27
35	625	14	10–19
36	621	9	6–18
37	778	8	5–17
38	873	7	4–16
39	800	6	4–14
40	732	5	4–12
41	407	5	3–10
≥42	24	5	3–12
Total	10,254	24	8–50

Note: Survival status was not provided for eight babies.

Gestational ages ≥42 weeks have been combined to maintain confidentiality of small numbers.

Survival

In 2017, 96.0% of ANZNN registrants survived to go home. These data include babies who were transferred to level II or level I units, those transferred to another level III unit and those babies transferred to a children's hospital. The survival rate to discharge home as shown in Table 30 does not encompass the following: fetal deaths; neonatal deaths that occurred on a labour ward; babies born in level II hospitals; and babies not transferred to an NICU or children's hospital.

During 2017, there were 419 neonatal deaths, of which 215 occurred in the early neonatal period that is within seven days of birth (Table 30). Mortality was highest among babies born before 29 weeks gestation with a survival rate at discharge increasing week on week from 54.5% for babies born before 24 weeks to 96.9% for babies born at 28 weeks (Table 30, Figure 8). A similar pattern of increasing survival with increasing birthweight is seen in Figure 9.

Lethal congenital anomaly was the cause of death for 1.0% of registrants, with most occurring in babies born between 36–39 weeks gestation (Table 30).

TABLE 30: Survival to discharge home for level III registrants by gestational age, ANZNN 2017

Gestational age (weeks)	Number of babies	Lethal congenital anomalies	Babies alive on day 7	Babies alive on day 28	Survived to discharge to home	Per cent survival at discharge to home
<24	101	<5	75	62	55	54.5
24	176	0	145	132	120	68.2
25	220	<5	208	194	182	82.7
26	311	<5	304	295	284	91.3
27	343	0	339	329	322	93.9
28	445	<5	439	433	431	96.9
29	474	<5	466	465	460	97.0
30	636	<5	630	629	627	98.6
31	796	6	789	786	781	98.1
32	787	9	778	775	774	98.3
33	657	<5	650	646	646	98.3
34	732	8	724	714	712	97.3
35	636	6	631	627	625	98.3
36	647	15	632	625	621	96.0
37	800	13	790	786	778	97.3
38	900	16	885	878	873	97.0
39	825	9	810	805	800	97.0
40	754	5	737	734	732	97.1
41	417	<5	410	408	407	97.6
≥42	24	0	24	24	24	100.0
Total	10,681	104	10,466	10,347	10,254	96.0

Note: Survival status was not provided for eight babies.

Gestational ages ≥42 weeks have been combined to maintain confidentiality of small numbers

FIGURE 8: Survival of level III registrants to discharge home (with 95% CI) by gestational age, ANZNN 2017





FIGURE 9: Survival of level III registrants to discharge home (with 95% CI) by birthweight group, ANZNN 2017



5. Babies registered to level II units

Overview

Neonatal units with facilities to manage mild or moderately ill babies are known as ‘level II units’ or ‘special care baby units’. The classification of the level for care for perinatal hospitals is changing and the new classifications for ‘level II’ are now often ‘level IV and V’. For the purpose of this report at this time, the term “level II” has been retained. Individual units may have varying levels of resources for giving special care. The ANZNN registration criteria for level II and level III units are the same. Babies born in a level II unit and transferred to a level III unit within 28 days of birth are registered to that level III unit. Babies are registered to a level II unit if their hospital stay was entirely within non-tertiary centre units, or if they were transferred to a level III NICU after 28 days, or they were transferred to a level II neonatal unit from a children’s hospital without first having been admitted to a level III unit.

There are 16 level II units in New Zealand and 18 in Australia that are members of the ANZNN. Altogether, 32 level II units contributed data for this 2017 report.

In 2017, 1,677 babies fulfilled the ANZNN criteria for registration to a level II unit. Of those babies, 6.0% were born at less than 32 weeks gestation and 4.3% weighed less than 1,500 grams at birth (Table 31 and Table 32). The highest number of babies registered to a level II unit in 2017 was over 120.

TABLE 31: Level II registrants by gestational age, ANZNN 2017

Gestational age (weeks)	Number of babies	Per cent	Cumulative per cent
<30	16	1.0	1.0
30–31	85	5.1	6.0
All babies <32 weeks gestation	101	6.0	
32–33	262	15.6	21.7
34–36	482	28.8	50.4
37–44	831	49.6	100.0
Total	1,676	100.0	

Note: Gestational ages below 30 weeks have been combined to maintain confidentiality of small numbers. Gestational age was not provided for one baby.

TABLE 32: Level II registrants by birthweight, ANZNN 2017

Birthweight (grams)	Number of babies	Per cent	Cumulative per cent
<1,000	6	0.4	0.4
1,000–1,099	6	0.4	0.7
1,100–1,199	6	0.4	1.1
1,200–1,299	9	0.5	1.6
1,300–1,399	11	0.7	2.3
1,400–1,499	34	2.0	4.3
All babies <1,500g birthweight	72	4.3	
1,500–1,999	215	12.8	17.1
2,000–2,499	328	19.6	36.7
2,500–2,999	302	18.0	54.7
3,000–3,499	338	20.2	74.8
3,500–3,999	277	16.5	91.4
≥4,000	145	8.6	100.0
Total	1,677	100.0	

Note: Birthweight groups below 1,000g have been combined to maintain confidentiality of small numbers.

Three in five of the level II registrants, 980 babies (58.4%), were born to Caucasian mothers, 48.6% of whom were born preterm. The number of registrants born to Maori mothers was 185 (11.0%), and 98 (53.0%) were born preterm. There were 46 babies (2.7%) born to Pacific Islander mothers.

There were 1,024 male (61.1%) and 649 female (38.7%) registrants in the audit. Gender was not recorded for four registrants. Non-specific respiratory distress was the major reason for assisted ventilation for level II registrants.

Maternal, pregnancy and birth characteristics

Of the mothers of level II registrants, 26.5% did not present with any maternal complications. Among babies born before 37 weeks, 36.6% of mothers had presented with preterm labour (Table 33).

TABLE 33: Mothers of level II registrants presenting antenatal problem by gestational age, ANZNN 2017

Presenting antenatal problem	Gestational age (weeks)					Total
	<30	30–31	32–33	34–36	37–44	
	Number					
No antenatal problems	0	0	0	<5	n.p.	440
Preterm pre-labour rupture of membranes	<5	21	64	n.p	13	205
Preterm labour	n.p	39	94	166	<5 ^(a)	309
Hypertension in pregnancy	<5	n.p	27	55	26	114
Antepartum haemorrhage	6	8	34	31	14	93
Intrauterine growth restriction	0	<5	n.p	31	28	74
Fetal distress	<5	8	n.p	41	132	200
Other problem	0	2	11	45	166	224
Congenital anomalies	0	0	0	<5	n.p.	7
Not stated	0	1	0	2	7	10
Total	16	85	262	482	831	1,676
	Per cent					
No antenatal problems	0.0	0.0	0.0	n.p	n.p	26.4
Preterm pre-labour rupture of membranes	n.p	25.0	24.4	n.p	1.6	12.3
Preterm labour	n.p	46.4	35.9	34.6	n.p	18.5
Hypertension in pregnancy	n.p	n.p	10.3	11.5	3.2	6.8
Antepartum haemorrhage	37.5	9.5	13.0	6.5	1.7	5.6
Intrauterine growth restriction	0.0	n.p	n.p	6.5	3.4	4.4
Fetal distress	n.p	9.5	n.p	8.5	16.0	12.0
Other problem	0.0	2.4	4.2	9.4	20.1	13.4
Congenital anomalies	0.0	0.0	0.0	n.p	n.p	0.4
Total	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) These mothers presented with preterm labour, then went on to deliver at term.

Note: Not stated data are excluded from per cent calculations.

Maternal data for babies of a multiple birth are presented for each registrant.

Gestational age was not provided for one baby.

Previous preterm births were reported by 170 (10.1%) of the mothers of level II registrants and 56 mothers (3.3%) had had a previous perinatal death(s).

Most mothers (88.6%) of level II registrants had booked into a level II hospital for delivery. Of the level II registrants born before 34 weeks gestation, 68.0% of the mothers were given antenatal corticosteroids within seven days of the birth (Table 34).

TABLE 34: Antenatal corticosteroid use by mothers of level II registrants by gestational age, ANZNN 2017

	Gestational age (weeks)					
Antenatal corticosteroids	<30	30–31	32–33	34–36	37–44	Total
Number						
None	<5	12	54	n.p.	807	1122
Incomplete course	11	33	81	n.p.	<5	215
Complete course within 7 days of birth	<5	28	91	110	n.p.	241
Given >7 days prior to birth	0	9	26	24	5	64
Not stated	1	3	10	14	6	34
Total	16	85	262	482	831	1,676
Per cent						
None	n.p.	14.6	21.4	n.p.	97.8	68.3
Incomplete course	73.3	40.2	32.1	n.p.	n.p.	13.1
Complete course within 7 days of birth	n.p.	34.1	36.1	23.5	n.p.	14.7
Given >7 days prior to birth	0.0	11.0	10.3	5.1	0.6	3.9
Total	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

Maternal data for babies of a multiple birth are presented for each registrant.

Gestational age was not provided for one baby.

Vaginal and instrumental vaginal delivery was the most common method of birth for 51.1% of level II registrants (Table 35). Of those who were delivered by caesarean section, over half (56.2%) occurred before the onset of labour.

TABLE 35: Method of delivery for level II registrants by gestational age, ANZNN 2017

Method of delivery	Gestational age (weeks)					Total
	<30	30–31	32–33	34–36	37–44	
Number						
Vaginal birth ^(a)	6	42	91	210	497	846
Caesarean section ^(b)	10	43	166	270	320	809
Not stated	0	0	5	2	14	21
Total	16	85	262	482	831	1,676
Per cent						
Vaginal birth	37.5	49.4	35.4	43.8	60.8	51.1
Caesarean section	62.5	50.6	64.6	56.3	39.2	48.9
Total	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

^(a) Vaginal and instrumental vaginal births have been combined to maintain confidentiality of small numbers.

^(b) Caesarean section deliveries in labour and no labour have been combined to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

Gestational age was not provided for one baby.

Characteristics of level II babies

Among the 1,677 babies registered to level II units, 163 were from multiple gestation pregnancies (9.7%). There were 1,024 (61.1%) male births and four babies whose gender was not recorded.

A low Apgar score of less than 4 at one minute of age was recorded for 18.0% of babies and 8.7% of them required endotracheal intubation in the labour ward to assist in their adaptation to extrauterine life.

Non-specific respiratory distress (72.5%) was the major reason for assisted ventilation for level II registrants, followed by hyaline membrane disease (13.8%) (Table 36).

For level II registrants, the median duration of assisted ventilation by intermittent positive pressure ventilation (IPPV) was 7.5 hours and 16 hours by continuous positive airway pressure (CPAP) (Table 37).

TABLE 36: Indication for respiratory support for level II registrants by gestational age, ANZNN 2017

Indication for respiratory support	Gestational age (weeks)					Total
	<30	30–31	32–33	34–36	37–44	
Number						
No respiratory support	0	10	7	11	6	34
Non-specific respiratory distress	8	44	177	340	641	1,210
Hyaline membrane disease	n.p.	31	67	101	n.p.	231
Meconium aspiration syndrome	0	0	<5	<5	63	68
Pneumonia	0	0	0	<5	40	n.p.
Persistent pulmonary hypertension	0	0	0	<5	15	18
Apnoea	0	0	<5	<5	7	11
Congenital anomaly	<5	0	<5	<5	<5	6
Other	1	0	6	12	24	43
Peri-surgery	0	0	0	0	0	0
Newborn encephalopathy	0	0	0	0	<5	<5
Not stated	0	0	1	3	3	7
Total	16	85	262	482	831	1,676
Per cent						
No respiratory support	0.0	11.8	2.7	2.3	0.7	2.0
Non-specific respiratory distress	50.0	51.8	67.8	71.0	77.4	72.5
Hyaline membrane disease	n.p.	36.5	25.7	21.1	n.p.	13.8
Meconium aspiration syndrome	0.0	0.0	n.p.	n.p.	7.6	4.1
Pneumonia	0.0	0.0	0.0	n.p.	4.8	n.p.
Persistent pulmonary hypertension	0.0	0.0	0.0	n.p.	1.8	1.1
Apnoea	0.0	0.0	n.p.	n.p.	0.8	0.7
Congenital anomaly	n.p.	0.0	n.p.	n.p.	n.p.	0.4
Other	6.3	0.0	2.3	2.5	2.9	2.6
Peri-surgery	0.0	0.0	0.0	0.0	0.0	0.0
Newborn encephalopathy	0.0	0.0	0.0	0.0	n.p.	n.p.
Total	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

Gestational age was not provided for one baby.

TABLE 37: Duration of assisted ventilation use for level II registrants by gestational age, ANZNN 2017

Duration of assisted ventilation	Gestational age (weeks)					Total
	<30	30–31	32–33	34–36	37–44	
IPPV (hours)						
Median	4	20.5	7	10.5	20	7.5
IQR	2.5–6.5	13.5–26	5–8	6–15	6–44	5–25
CPAP (hours)						
Median	77	45	23	18	12	16
IQR	54–104	24–72	12–46	10–35	7–22	9–32

Note: IQR = Interquartile range. IPPV = intermittent positive pressure ventilation. CPAP = continuous positive airway pressure.

Eye examination

Screening for retinopathy of prematurity (ROP) was reported for only 24 of the 47 eligible babies born at less than 31 weeks gestational age and/or weighing less than 1,250 grams at birth (51.1% compared to 83.9% of eligible level III registrants). All were reported as normal except for one baby who had stage 1 ROP.

Cerebral ultrasound

Of the 101 babies born at less than 32 weeks, 73 (72.3%) had a cerebral ultrasound in the first week after birth. 69 of them were reported as normal, that is no intraventricular haemorrhage (IVH), two reported a grade 1 IVH, one reported a grade 2 IVH, and one reported a grade 4 IVH. Most babies who did not have an early cerebral ultrasound reported at this time were born at 31 weeks gestation. A late cerebral ultrasound nearest to six weeks of age was reported for 33 babies, all of whom had normal reports excepting one baby with reported porencephalic cysts and one baby with periventricular leukomalacia.

Other morbidities

Septicaemia was proven in 14 babies, including 13 before day two, that is less than 48 hours. There was one case of necrotising enterocolitis. Major congenital anomalies were reported for 47 babies, of which one required major surgery.

Level II transfers

In total 139 level II registrants were transferred to other units, 102 were transferred to a level I or another level II unit, 30 were transferred to a level III unit and the remaining seven to a children's hospital.

Survival

There were 1,665 level II registrants who survived to discharge home (99.3%). Eleven babies died within the first seven days of birth (Table 38). Two babies were reported to have had a lethal congenital anomaly.

TABLE 38: Survival to discharge home for level II registrants by gestational age, ANZNN 2017

Gestational age (weeks)	All babies	Babies alive on day 7	Babies alive on day 28	Survived to discharge to home	Per cent survival at discharge to home
<30	16	11	11	11	68.8
30–31	85	85	85	85	100.0
32–33	262	260	260	259	98.9
34–36	482	481	481	481	99.8
37–44	831	828	828	828	99.6
All babies	1,676	1,665	1,665	1,664	99.3

***Note:** Gestational age was not provided for one baby.
Survival status was not provided for four babies.*

6. Extremely preterm follow-up, 2011–2014 births

Introduction

Neurological and developmental problems are common among surviving extremely preterm and/or extremely low birthweight babies (Doyle et al. 2010, Doyle et al. 2011). Impairments can include cerebral palsy, blindness, deafness and developmental delay.

This chapter includes 2–3 year outcome data on extremely preterm and/or extremely low birthweight ANZNN registrants for 2011 to 2014 births. All infants born from 2011 to 2014 at less than 28 weeks gestation or less than 1,000 grams at birth and admitted to one of the 29 level III NICUs in Australia and New Zealand, who survived to discharge to home were eligible for inclusion in the ANZNN 2–3 year follow-up data collection. There were 4,625 infants who fulfilled the criteria for 2–3 year follow-up.

Care should be taken with interpretation of these data as post-discharge data were not retrieved from the NICU for 223 (4.8%) of the eligible ANZNN registrants born from 2011 to 2014.

Follow-up rate

From 2011 to 2014, 5,464 extremely preterm and/or extremely low birthweight babies were registered to the ANZNN, with 4,625 (84.6%) surviving to discharge to home. For the babies who survived to discharge, not all NICUs were able to submit post-discharge data. It should be noted that one NICU was unable to submit post-discharge data for 2012, 2013 and 2014 births and one NICU was unable to submit post-discharge data for 2013 and 2014 births before the publication of this report. The 201 eligible survivors registered to these NICUs were excluded from further outcome analysis.

Of the 4,424 eligible survivors registered to NICUs that were able to submit data, 3,471 (78.5%) had outcome data available. There were 25 infants who died after discharge and 3,446 who had a follow-up assessment. Outcome data were not available for 953 (21.5%) infants, with 931 (21.0%) recorded by the NICU as lost to follow-up and the remainder with no post-discharge data being retrieved from the NICU (Figure 10). Overall, the rate of follow-up among eligible survivors registered to NICUs that were able to submit data was 78.3% (3,446 of 4,399), excluding deaths after discharge. The follow-up rate was highest for infants born at less than 25 weeks gestation or less than 500g birthweight (Table 39 & Table 40).

Of the 3,446 infants who were followed-up, 3,049 (88.5%) had a formal developmental assessment. For the remaining 397 (11.5%) infants, some follow-up information was obtained but a formal developmental assessment was not completed.

FIGURE 10: ANZNN 2–3 year follow-up cohort of extremely preterm infants, 2011–2014 births




TABLE 39: Births, survival and 2–3 year follow-up of extremely preterm and/or extremely low birthweight infants by gestational age, ANZNN 2011–2014 births

	Gestational age (weeks)						Total
	<24	24	25	26	27	≥28 ^(a)	
Number							
Registrants	230	719	960	1,179	1,285	1,091	5,464
Survived to discharge	112	484	778	1,041	1,192	1,018	4,625
Per cent							
Survived to discharge ^(b)	48.7	67.3	81.0	88.3	92.8	93.3	84.6
Number							
NICU not included	9	37	33	37	42	43	201
Follow-up cohort ^(c)	103	447	745	1,004	1,150	975	4,424
▪ Died post-discharge	0	<5	<5	<5	11	5	25
▪ Follow-up assessment ^(d)	85	365	589	813	880	714	3,446
▪ No outcome data	18	n.p.	n.p.	n.p.	259	256	953
Per cent							
Follow-up rate ^(e)	82.5	82.2	79.5	81.1	77.3	73.6	78.3

n.p. Data not published to maintain confidentiality of small numbers.

(a) These infants were <1,000 grams at birth.

(b) Denominator is all registrants.

(c) Registrants who survived to discharge from NICUs able to submit data.

(d) Includes 84 infants assessed at <18 months corrected age and 27 infants with unknown age at assessment.

(e) Denominator is registrants who survived to discharge from NICUs able to submit data minus registrants who died post-discharge.

TABLE 40: Births, survival and 2–3 year follow-up of extremely preterm and/or extremely low birthweight infants by birthweight, ANZNN 2011–2014 births

	Birthweight (grams)							Total
	<500	500-599	600-699	700-799	800-899	900-999	≥1000 ^(a)	
Number								
Registrants	127	375	764	934	1,064	1,216	984	5,464
Survived to discharge	64	249	556	761	955	1,135	905	4,625
Per cent								
Survived to discharge ^(b)	50.4	66.4	72.8	81.5	89.8	93.3	92.0	84.6
Number								
NICU not included	2	14	25	38	41	48	33	201
Follow-up cohort ^(c)	62	235	531	723	914	1,087	872	4,424
▪ Died post-discharge	<5	0	<5	5	<5	6	8	25
▪ Follow-up assessment ^(d)	55	198	419	582	713	810	669	3,446
▪ No outcome data	n.p.	37	n.p.	136	n.p.	271	195	953
Per cent								
Follow-up rate ^(e)	90.2	84.3	79.4	81.1	78.2	74.9	77.4	78.3

n.p. Data not published to maintain confidentiality of small numbers.

(a) These infants were <28 weeks at birth.

(b) Denominator is all registrants.

(c) Registrants who survived to discharge from NICUs able to submit data.

(d) Includes 84 infants assessed at <18 months corrected age and 27 infants with unknown age at assessment.

(e) Denominator is registrants who survived to discharge from NICUs able to submit data minus registrants who died post-discharge.

Assessment and tools

Children were assessed by the developmental assessment team at the level III hospital in which they received their neonatal care or the closest level III hospital to their current place of residence. If the parents were unable to travel to a level III hospital, a local paediatrician or general practitioner may have examined the child.

A formal developmental assessment comprised of neurological examination by a developmental paediatrician or physiotherapist, vision by an ophthalmologist or optometrist, hearing by an audiologist, and a developmental test using the Bayley Scales of Infant Development-III, Griffiths Mental Developmental Scales or another developmental test performed by a psychologist, developmental paediatrician, physiotherapist, or other qualified person.

Assessment of growth and development was based on the age of the infant corrected for prematurity, that is, the age the infant would have been on the date of assessment if they had been born on their due date. The median age of assessment was 25.0 months with an interquartile range of 24.0–28.5 months, corrected for prematurity.

Neurological outcome

Cerebral palsy is characterised by abnormal muscle tone and impaired motor function and control. It is a well-recognised neurological outcome among extremely preterm and/or extremely low birthweight babies (Oskoui et al. 2013). Cerebral palsy outcomes were only included for infants assessed at 18 months corrected age or older as mild cerebral palsy may be difficult to diagnose prior to this age.

Cerebral palsy was graded using the Gross Motor Function Classification System (GMFCS). For the purposes of this report, mild was defined by GMFCS level 1, moderate by GMFCS level 2 or level 3, and severe by GMFCS level 4 or level 5. It should be noted that the definition of mild, moderate and severe cerebral palsy used in this report may be at variance with other reporting definitions.

Of the 3,335 infants with a follow-up assessment at 18 months corrected age or older, information about cerebral palsy was available for 3,254 (97.6%), and of these, 190 (5.8%) had a diagnosis of cerebral palsy. The movement ability of 179 (94.2%) infants with cerebral palsy was graded by the GMFCS, from level 1 for minimal impairment to level 5 for severe impairment. Of the infants with a GMFCS classification, 95 (53.1%) infants were graded as level 1, 32 (17.9%) as level 2, 22 (12.3%) as level 3, 13 (7.3%) as level 4 and 17 (9.5%) as level 5 (Table 41).

Of the 111 infants who were assessed at less than 18 months corrected age or whose corrected age at assessment was unknown, there was one case of mild cerebral palsy, three cases of moderate cerebral palsy, two cases of severe cerebral palsy and two cases of cerebral palsy where the severity was unknown.

TABLE 41: Cerebral palsy at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births

Cerebral Palsy (CP)	Gestational age (weeks)						Total
	<24	24	25	26	27	≥28	
	Number						
No CP	64	305	512	723	813	647	3,064
CP	10	42	47	36	31	24	190
▪ Mild Level 1	5	20	24	18	15	13	95
▪ Moderate Level 2–3	<5	12	n.p.	8	11	5	54
▪ Severe Level 4–5	0	5	7	10	<5	<5	30
▪ Level unknown	<5	5	<5	0	<5	<5	11
Not stated	2	7	15	25	14	18	81
Total^(a)	76	354	574	784	858	689	3,335
	Per cent						
No CP	86.5	87.9	91.6	95.3	96.3	96.4	94.2
CP	13.5	12.1	8.4	4.7	3.7	3.6	5.8
▪ Mild Level 1	6.8	5.8	4.3	2.4	1.8	1.9	2.9
▪ Moderate Level 2–3	n.p.	3.5	n.p.	1.1	1.3	0.7	1.7
▪ Severe Level 4–5	0.0	1.4	1.3	1.3	n.p.	n.p.	0.9
▪ Level unknown	n.p.	1.4	n.p.	0.0	n.p.	n.p.	0.3

n.p. Data not published to maintain confidentiality of small numbers.

(a) Excludes 84 infants assessed at <18 months corrected age and 27 infants with unknown age at assessment.

Note: Not stated data are excluded from per cent calculations.

Vision and hearing

Extremely preterm and/or extremely low birthweight babies are at significant risk of retinopathy of prematurity (ROP) which has, in some cases, substantial long term retinal morbidity plus a risk of amblyopia and strabismus. Of the 3,446 infants with a follow-up assessment, 3,355 (97.4%) had data on blindness available, and of these, only 11 (0.3%) were recorded as being blind (<6/60 in the better eye). Five (45.5%) of the infants with blindness were born at 24 weeks gestational age or younger.

Permanent congenital, delayed-onset, or progressive hearing loss is a significant adverse outcome of extreme prematurity. Risk factors include prolonged oxygen supplementation and hyperbilirubinemia (Robertson et al. 2009). Data on the use of devices for hearing amplification were only included for the 3,416 infants assessed at nine months corrected age or older as hearing devices would only likely be fitted from this age.

Information about the use of hearing devices was available for 3,338 (97.7%) of infants with a follow-up assessment at nine months corrected age or older. Of these, nine (0.3%) infants were fitted with a unilateral hearing aid, 34 (1.0%) infants with bilateral hearing aids, seven (0.2%) infants with a cochlear implant and seven (0.2%) infants with a cochlear implant and hearing aids. The proportion of infants with hearing devices was greatest among those 24 weeks gestational age or younger (3.7%) compared with any other gestational age group (1.0–2.1%).

Congenital anomalies

Information on congenital anomalies reported for infants with a follow-up assessment was reviewed by the ANZNN Follow-up Subcommittee to identify central nervous system malformations and chromosomal anomalies known to directly cause central nervous system dysfunction and hence delayed cognitive, language and motor development. Congenital anomalies or conditions that were identified by the ANZNN Follow-up Subcommittee as being common side-effects of prematurity were not excluded from cognitive, language and motor delay analyses and functional impairment analyses.

Of the 3,335 infants assessed at 18 months corrected age or older there were 25 infants who were identified as having a congenital anomaly that could cause developmental delay. These infants were excluded from cognitive, language and motor delay analyses and functional impairment analyses (Table 42 to Table 46). Of those excluded, there were six infants with congenital central nervous system malformations, including encephalomalacia, hydrocephalus, meningomyelocele, microcephaly, septo-optic dysplasia, and other reduction anomalies of brain. Also excluded were 17 infants with genetic disorders or chromosomal anomalies, including chromosome deletion, chromosome duplication, Crouzon syndrome, Klinefelter syndrome, Menkes syndrome, Mowat-Wilson syndrome, Prader-Willi syndrome, Russell-Silver syndrome, Trisomy 21, and tuberous sclerosis. The remaining two infants were excluded due to other congenital malformations affecting development.

Developmental testing

Cognitive and language delay is the most prevalent impairment in extremely preterm and/or extremely low birthweight babies (Doyle et al. 2010, Doyle et al. 2011). As mild delays are unlikely to be reliably diagnosed prior to 18 months corrected age or without formal developmental assessment, cognitive, language and motor delay was graded only for those infants formally assessed at 18 months corrected age or older. Results were included for 2,874 infants assessed by the Bayley Scales of Development-III, 31 infants assessed by the Griffiths Mental Developmental Scales, 32 infants assessed by the Wechsler Preschool and Primary Scale of Intelligence (WPPSI) and 15 infants assessed by the Stanford-Binet Intelligence Scales. It should be noted that motor and language subscale scores were not available for the infants who were assessed by WPPSI or Stanford-Binet alone.

Results were not included for infants assessed using other developmental assessments including screening assessments such as the Bayley Screening Test, Ages and Stages Questionnaires, or based on clinical assessments by healthcare professionals.

For the purposes of this report, cognitive, language and motor delay were graded as mild, moderate or severe. Severe delay was defined as scores <-3 standard deviations (SD), moderate delay as scores -3 SD to <-2 SD, and mild delay as scores -2 SD to <-1 SD relative to the mean. For a typical scale with a mean of 100 (SD 15), these cut-points were defined as follows: severe <55 , moderate 55–69, and mild 70–84. Because 55 is the lowest composite score that can be assigned on the Bayley cognitive scale, cut-points for severe and moderate cognitive delay were adjusted to ≤ 55 and 56–69 respectively for infants assessed on this scale. It should be noted that the definition of mild, moderate and severe delay used in this report may be at variance with other reporting definitions.

Additionally, there were 23 infants who were reported as unable to be assessed due to severe developmental delay and were therefore included in the severe category for cognitive, language and motor delay. While an additional nine infants without formal developmental assessment had a severe impairment recorded (one with severe cerebral palsy and blindness, one with blindness and seven with severe cerebral palsy), severe cognitive, language or motor delay could not be reliably assigned to these infants.

Overall, there were 441 (14.9%) infants with mild to severe cognitive delay, 779 (28.4%) with mild to severe language delay and 508 (18.3%) with mild to severe motor delay (Table 42 to Table 44). It should be noted that language delays are difficult to assess in infants at two years of age, especially for infants who speak a language other than English. Furthermore, mild language delays detected in this age group may not reflect a problem or disability at later ages.

TABLE 42: Cognitive delay at 2–3 year follow-up by gestational age for Bayley, Griffiths, WPPSI and Stanford-Binet assessments, ANZNN 2011–2014 births

	Gestational age (weeks)						
Cognitive delay	<24	24	25	26	27	≥28	Total
Number							
None	45	251	434	593	667	533	2,523
Mild	12	37	47	67	65	65	293
Moderate	<5	14	15	19	11	n.p.	74
Severe	<5	15	15	16	12	n.p.	74
Not stated ^(a)	1	3	2	1	1	3	11
Total^(b)	63	320	513	696	756	627	2,975
Per cent							
None	72.6	79.2	84.9	85.3	88.3	85.4	85.1
Mild	19.4	11.7	9.2	9.6	8.6	10.4	9.9
Moderate	n.p.	4.4	2.9	2.7	1.5	n.p.	2.5
Severe	n.p.	4.7	2.9	2.3	1.6	n.p.	2.5
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Infants assessed by Bayley, Griffiths, WPPSI or Stanford-Binet but with no Bayley cognitive subscale composite score, Griffiths performance subscale quotient or WPPSI/Stanford-Binet full scale intelligence quotient recorded.

(b) Infants assessed by Bayley, Griffiths, WPPSI or Stanford-Binet at ≥18 months corrected age or older or unable to be assessed due to severe delay. Excludes 25 infants with a congenital anomaly known to impair development.

Note: Assessments with no cognitive subscale score are excluded from per cent calculations.

TABLE 43: Language delay at 2–3 year follow-up by gestational age for Bayley and Griffiths assessments, ANZNN 2011–2014 births

	Gestational age (weeks)						
Language delay	<24	24	25	26	27	≥28	Total
Number							
None	36	187	320	476	539	410	1,968
Mild	12	59	94	101	115	101	482
Moderate	n.p.	39	35	45	28	n.p.	204
Severe	<5	15	19	24	18	n.p.	93
Not stated ^(a)	5	16	39	38	44	39	181
Total^(b)	63	316	507	684	744	614	2,928
Per cent							
None	62.1	62.3	68.4	73.7	77.0	71.3	71.6
Mild	20.7	19.7	20.1	15.6	16.4	17.6	17.5
Moderate	n.p.	13.0	7.5	7.0	4.0	n.p.	7.4
Severe	n.p.	5.0	4.1	3.7	2.6	n.p.	3.4
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Infants assessed by Bayley or Griffiths but with no Bayley language subscale composite score or Griffiths language subscale quotient recorded.

(b) Infants assessed by Bayley or Griffiths at ≥18 months corrected age or older or unable to be assessed due to severe delay. Excludes 25 infants with a congenital anomaly known to impair development.

Note: Assessments with no language subscale score are excluded from per cent calculations.

TABLE 44: Motor delay at 2–3 year follow-up by gestational age for Bayley and Griffiths assessments, ANZNN 2011–2014 births

	Gestational age (weeks)						
Motor delay	<24	24	25	26	27	≥28	Total
Number							
None	41	222	381	541	604	482	2,271
Mild	13	49	68	71	73	68	342
Moderate	<5	18	24	24	16	n.p.	110
Severe	<5	12	9	14	8	n.p.	56
Not stated ^(a)	4	15	25	34	43	28	149
Total^(b)	63	316	507	684	744	614	2,928
Per cent							
None	69.5	73.8	79.0	83.2	86.2	82.3	81.7
Mild	22.0	16.3	14.1	10.9	10.4	11.6	12.3
Moderate	n.p.	6.0	5.0	3.7	2.3	n.p.	4.0
Severe	n.p.	4.0	1.9	2.2	1.1	n.p.	2.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Infants assessed by Bayley or Griffiths but with no Bayley motor subscale composite score or Griffiths locomotor subscale quotient recorded.

(b) Infants assessed by Bayley or Griffiths at ≥18 months corrected age or older or unable to be assessed due to severe delay. Excludes 25 infants with a congenital anomaly known to impair development.

Note: Assessments with no motor subscale score are excluded from per cent calculations.

Functional impairment

Functional impairment was analysed for 2,542 infants assessed at 18 months corrected age or older, with cognitive, language and motor subscale scores from Bayley or Griffiths assessments, and with data on blindness, hearing device use, and cerebral palsy. Functional impairment was graded as mild (GMFCS level 1 cerebral palsy, mild language, cognitive or motor delay), moderate (GMFCS level 2 to 3 cerebral palsy, deafness requiring amplification, moderate language, cognitive or motor delay) or severe (GMFCS level 4 to 5 cerebral palsy, blindness or severe language, cognitive or motor delay). It should be noted that the definition of mild, moderate and severe delay used in this report may be at variance with other reporting definitions.

Additionally, 21 infants who met at least one of the criteria for severe impairment, but had missing data for one or more outcomes, and 23 infants who were unable to be assessed due to severe developmental delay were included in the severe category for functional impairment. Of these infants, three were less than 24 weeks, nine were 24 weeks, eleven were 25 weeks, nine were 26 weeks, nine were 27 weeks and three were 28 weeks gestational age or older.

Of the 2,586 infants where functional impairment could be graded, there were 929 (35.9%) infants with any degree of functional impairment, including 560 (21.7%) with a mild impairment, 240 (9.3%) with a moderate impairment and 129 (5.0%) with a severe impairment. Functional impairment was most prevalent and most severe among infants who were born at younger gestational ages (Table 45). Of the 929 infants with any degree of functional impairment, 291 (31.3%) were classified based on language delays alone.

TABLE 45: Severity of functional impairment at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births

	Gestational age (weeks)						
Functional impairment	<24	24	25	26	27	≥28	Total
Number							
None	26	148	278	410	443	352	1,657
Mild	15	65	102	118	147	113	560
Moderate	n.p.	46	45	50	41	n.p.	240
Severe	<5	22	27	34	21	n.p.	129
Incomplete formal test ^(a)	10	36	59	75	93	79	352
Other formal test	1	3	8	23	21	14	70
No formal test	10	32	52	69	87	52	302
Total^(b)	75	352	571	779	853	680	3,310
Per cent							
None	48.1	52.7	61.5	67.0	67.9	65.8	64.1
Mild	27.8	23.1	22.6	19.3	22.5	21.1	21.7
Moderate	n.p.	16.4	10.0	8.2	6.3	n.p.	9.3
Severe	n.p.	7.8	6.0	5.6	3.2	n.p.	5.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Infants with Bayley or Griffiths assessments but with missing data for one or more outcomes.

(b) Excludes 84 infants assessed at <18 months corrected age and 27 infants with unknown age at assessment. Excludes 25 infants with a congenital anomaly known to impair development.

Note: Infants with incomplete, other or no formal developmental assessment are excluded from per cent calculations. This table includes 291 infants with a mild, moderate or severe functional impairment classification based on language delay alone.

Moderate to severe functional impairment

In addition to the above infants where functional impairment could be graded, infants assessed by Bayley or Griffiths but with missing data for one or more outcomes, infants assessed by other formal developmental assessments, and infants without formal developmental assessments, were reviewed by the ANZNN Follow-up Subcommittee to determine if there was sufficient information to be classified as with or without moderate to severe functional impairment. In some cases, further information was requested from the NICU for clarification of outcomes.

A classification of ‘with moderate to severe impairment’ was assigned to infants who were assessed at 18 months corrected age or older who had any recorded formal assessment of moderate or severe impairment or developmental delay, or any clinical assessment of severe developmental delay.

A classification of ‘without moderate to severe impairment’ was assigned to infants where moderate to severe impairment could be reasonably excluded based on the following criteria:

- Infants who did not have moderate or severe functional impairment based on formal developmental assessment conducted at 18 months corrected age or older.
- Infants who did not have moderate or severe functional impairment based on assessment by a health care professional at 18 months corrected age or older. Of these, infants with missing or unknown results for cerebral palsy, hearing or vision were presumed likely to be without moderate or severe impairment. Where infants had a partially completed formal assessment, and a clinical assessment of normal development or only mild developmental delay was not specifically recorded by the NICU, infants were also presumed likely to be without moderate or severe impairment.

Any remaining infants who had a recorded clinical assessment of moderate developmental delay or delays of uncertain severity in at least one domain were reviewed and classified on a case by case basis.

Functional impairment was classified as ‘not stated’ for infants with no moderate or severe impairment reported who did not meet the above criteria. Moderate or severe impairment may be present among these

infants, but for the purposes of this report they are excluded from the calculation of moderate to severe impairment, on the basis of lack of sufficient information.

Upon review, 548 infants with incomplete or other formal developmental assessments, or without formal developmental assessments had sufficient information to be classified as with or without moderate to severe functional impairment. Of these 548 infants, together with the 2,586 infants graded in Table 45, there were 467 (14.9%) infants with moderate to severe functional impairment. Moderate to severe functional impairment decreased with increasing gestational age (Table 46). Of these 467 infants with moderate to severe functional impairment, there were 155 (33.2%) infants classified with moderate to severe functional impairment based on language delay alone.

TABLE 46: Infants with or without moderate to severe functional impairment at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births

	Gestational age (weeks)						
Functional impairment	<24	24	25	26	27	≥28	Total
Number							
Without moderate-severe impairment	51	251	453	635	721	556	2,667
Moderate-severe impairment	17	85	91	102	85	87	467
Not stated ^(a)	7	16	27	42	47	37	176
Total^(b)	75	352	571	779	853	680	3,310
Per cent							
Without moderate-severe impairment	75.0	74.7	83.3	86.2	89.5	86.5	85.1
Moderate-severe impairment	25.0	25.3	16.7	13.8	10.5	13.5	14.9
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

(a) Infants where moderate to severe functional impairment could not be excluded based on the available data.

(b) Excludes 84 infants assessed at <18 months corrected age and 27 infants with unknown age at assessment. Excludes 25 infants with a congenital anomaly known to impair development.

Note: Not stated data are excluded from per cent calculations. This table includes 155 infants with a moderate-severe functional impairment classification based on language delay alone.

Growth – weight, height and head circumference

Growth standards published by the World Health Organization, 2006, were used to determine weight, height and head circumference for age percentiles, and weight for length/height percentiles.

Growth measurements were only included for the 3,335 infants assessed at 18 months corrected age or older. Of these infants with computable percentiles, 9.7% fell below the 3rd percentile for weight for age, 16.8% for length/height for age, 7.1% for head circumference for age and 5.6% for weight for length/height at 2–3 year follow-up. For weight and length/height for age and weight for length/height, the proportion of infants below the 3rd percentile was highest among those 28 weeks gestational age or older who weighed less than 1,000 grams at birth (Table 47 to Table 50). These infants were highly likely to have been intrauterine growth restricted (IUGR) and may continue to show a pattern of slower growth (Hediger et al. 1998).

TABLE 47: Weight for age at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births

	Gestational age (weeks)						
Weight for age centile ^(a)	<24	24	25	26	27	≥28	Total
Number							
<3	<5	16	57	47	36	n.p.	285
3–9	11	38	63	68	65	109	354
10–90	n.p.	244	342	492	561	n.p.	2,059
>90	5	19	43	73	94	19	253
Not stated	4	37	69	104	102	68	384
Total^(b)	76	354	574	784	858	689	3,335
Per cent							
<3	n.p.	5.0	11.3	6.9	4.8	n.p.	9.7
3–9	15.3	12.0	12.5	10.0	8.6	17.6	12.0
10–90	n.p.	77.0	67.7	72.4	74.2	n.p.	69.8
>90	6.9	6.0	8.5	10.7	12.4	3.1	8.6
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Centiles derived from WHO child growth standards, World Health Organization, 2006.

(b) Excludes 84 infants assessed at <18 months corrected age and 27 infants with unknown corrected age at assessment.

Note: Not stated data are excluded from per cent calculations.

TABLE 48: Length/height for age at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births

	Gestational age (weeks)						
Height for age centile ^(a)	<24	24	25	26	27	≥28	Total
Number							
<3	11	39	93	90	79	166	478
3–9	9	44	60	79	79	93	364
10–90	n.p.	211	304	434	504	n.p.	1,815
>90	<5	12	27	52	61	n.p.	180
Not stated	8	48	90	129	135	88	498
Total^(b)	76	354	574	784	858	689	3,335
Per cent							
<3	16.2	12.7	19.2	13.7	10.9	27.6	16.8
3–9	13.2	14.4	12.4	12.1	10.9	15.5	12.8
10–90	n.p.	69.0	62.8	66.3	69.7	n.p.	64.0
>90	n.p.	3.9	5.6	7.9	8.4	n.p.	6.3
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Centiles derived from WHO child growth standards, World Health Organization, 2006.

(b) Excludes 84 infants assessed at <18 months corrected age and 27 infants with unknown corrected age at assessment.

Note: Not stated data are excluded from per cent calculations.

TABLE 49: Head circumference for age at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births

Head circumference for age centile ^(a)	Gestational age (weeks)						Total
	<24	24	25	26	27	≥28	
Number							
<3	11	20	35	32	22	60	180
3–9	8	26	36	45	22	58	195
10–90	n.p.	191	317	413	479	n.p.	1,812
>90	<5	24	57	102	107	n.p.	339
Not stated	10	93	129	192	228	157	809
Total^(b)	76	354	574	784	858	689	3,335
Per cent							
<3	16.7	7.7	7.9	5.4	3.5	11.3	7.1
3–9	12.1	10.0	8.1	7.6	3.5	10.9	7.7
10–90	n.p.	73.2	71.2	69.8	76.0	n.p.	71.7
>90	n.p.	9.2	12.8	17.2	17.0	n.p.	13.4
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Centiles derived from WHO child growth standards, World Health Organization, 2006.

(b) Excludes 84 infants assessed at <18 months corrected age and 27 infants with unknown corrected age at assessment.

Note: Not stated data are excluded from per cent calculations.

TABLE 50: Weight for length/height at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births

	Gestational age (weeks)						
Weight for height centile ^(a)	<24	24	25	26	27	≥28	Total
Number							
<3	6	12	30	28	20	63	159
3–9	<5	18	39	51	53	n.p.	244
10–90	n.p.	252	354	474	534	n.p.	2,087
>90	6	24	59	100	115	37	341
Not stated	8	48	92	131	136	89	504
Total^(b)	76	354	574	784	858	689	3,335
Per cent							
<3	8.8	3.9	6.2	4.3	2.8	10.5	5.6
3–9	n.p.	5.9	8.1	7.8	7.3	n.p.	8.6
10–90	n.p.	82.4	73.4	72.6	74.0	n.p.	73.7
>90	8.8	7.8	12.2	15.3	15.9	6.2	12.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Centiles derived from WHO child growth standards, World Health Organization, 2006.

(b) Excludes 84 infants assessed at <18 months corrected age and 27 infants with unknown corrected age at assessment.

Note: Not stated data are excluded from per cent calculations.

Respiratory and gastrointestinal tract


Respiratory and gastrointestinal tract complications such as respiratory distress syndrome and necrotising enterocolitis commonly affect extremely premature babies and can lead to ongoing disease. Of the 3,153 infants with data available on the use of respiratory support, four (0.1%) were supported by tracheostomy and 17 (0.5%) were supported by supplemental oxygen at the time of 2–3 year follow-up. Over one-third (38.1%) of infants receiving respiratory support were less than 25 weeks gestational age.

Of the 3,150 infants with nutritional support data, two infants were reported as receiving parenteral nutrition, and intragastric tube feeding via a percutaneous endoscopic gastronomy tube or nasogastric tube was reported for 71 (2.3%) infants at the time of 2–3 year follow-up. It should be noted that seven of the 73 infants receiving nutritional support at follow-up were assessed at younger than 18 months corrected age and therefore support may have ceased by two years corrected age. Nutritional support was most prevalent among infants younger than 24 weeks gestational age (6.4%) compared with any other gestational age group (1.3–2.8%).

APPENDICES


Appendix 1: Trends

FIGURE 11: Trends in gestational age at birth of level III registrants, ANZNN 2008–2017



Note: Data on the ANZNN registrants from two level III NICUs were not available in 2010. Please refer to www.anznn.net for colour version.

FIGURE 12: Trends in the use of corticosteroids for mothers of babies less than 32 weeks gestation, ANZNN 2008–2017



Note: Corticosteroid treatment to enhance fetal lung maturation is considered 'complete' when two doses are given, the first dose more than 24 hours and less than 8 days before the baby's birth. 'Any steroids within 7 days' includes babies who received a 'complete course' as well as babies who received their first dose of corticosteroids at less than 24 hours prior to birth.

FIGURE 13: Trends in multiple births of level III registrants by gestational age, ANZNN 2008–2017




FIGURE 14: Trends in method of birth for level III registrants by year of birth, ANZNN 2008–2017




FIGURE 15: Trends in referral source to level III NICU by year of birth, ANZNN 2008–2017




FIGURE 16: Trends in mode of transport to level III NICU, ANZNN 2008–2017






FIGURE 17: Trends in mode of assisted ventilation for level III registrants, ANZNN 2008–2017



Note: CPAP = continuous positive airway pressure. IPPV = intermittent positive pressure ventilation.

FIGURE 18: Trends in provision of intermittent positive pressure ventilation and continuous positive airway pressure by year of birth for level III registrants ventilated, ANZNN 2008–2017



Note: CPAP = continuous positive airway pressure. IPPV = intermittent positive pressure ventilation.

FIGURE 19: Trends in the use of continuous positive airway pressure as the only form of ventilation by gestational age for level III registrants, ANZNN 2008, 2011, 2014–2017






FIGURE 20: Trends in provision of high frequency oscillatory ventilation (with 95% CI) for level III registrants born before 28 weeks and at 28 or more weeks gestation, ANZNN 2008–2017



Note: Results are given as the percentage of babies given intermittent positive pressure ventilation.

FIGURE 21: Trends in nitric oxide (with 95% CI) provision for level III registrants born before 28 weeks and 28-31 weeks gestation, ANZNN 2008–2017



Note: Results are given as the percentage of babies given intermittent positive pressure ventilation.

FIGURE 22: Trends in chronic lung disease (with 95% CI) for level III registrants who survived to 36 weeks post menstrual age, ANZNN 2008–2017




FIGURE 23: Trends in stage 3 or 4 retinopathy of prematurity and treated retinopathy among babies born before 31 weeks gestation and/or birthweight of less than 1,250 grams who survived to 36 weeks post menstrual age for level III registrants, ANZNN 2008–2017




FIGURE 24: Trends in grade 3 or 4 intraventricular haemorrhage (with 95% CI) in babies born at less than 32 weeks gestation who survived to day 3 for level III registrants, ANZNN 2008–2017




FIGURE 25: Trends in incidence of early sepsis for level III registrants by gestational age, ANZNN 2013–2017





FIGURE 26: Trends in incidence of late sepsis for level III registrants by gestational age, ANZNN 2013–2017



Appendix 2: Data tables by birthweight

TABLE 51: Antenatal corticosteroid use for level III registrants by birthweight, ANZNN 2017

Antenatal corticosteroids	Birthweight (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
	Number											
None	<5	35	46	70	101	270	528	941	1,280	n.p.	457	4,657
Incomplete course	<5	92	172	190	197	406	262	129	21	n.p.	11	1,490
Complete course within 7 days of birth	21	234	404	462	550	788	401	186	66	26	16	3,154
Given >7 days prior to birth	<5	38	97	94	135	205	148	92	33	n.p.	8	871
Not stated	0	1	6	3	12	24	23	90	160	138	52	509
Total	29	400	725	819	995	1,693	1,362	1,438	1,560	1,116	544	10,681
	Per cent											
None	n.p.	8.8	6.4	8.6	10.3	16.2	39.4	69.8	91.4	n.p.	92.9	45.8
Incomplete course	n.p.	23.1	23.9	23.3	20.0	24.3	19.6	9.6	1.5	n.p.	2.2	14.6
Complete course within 7 days of birth	72.4	58.6	56.2	56.6	56.0	47.2	29.9	13.8	4.7	2.7	3.3	31.0
Given >7 days prior to birth	n.p.	9.5	13.5	11.5	13.7	12.3	11.1	6.8	2.4	n.p.	1.6	8.6
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

TABLE 52: Plurality of level III registrants by birthweight, ANZNN 2017

Plurality	Birthweight (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
Number												
Singleton	n.p.	n.p.	553	601	675	1,183	1,048	1,289	1,531	n.p.	544	8,849
Twins	7	106	157	201	296	478	301	149	n.p.	<5	0	1,726
Triplets and higher orders	<5	<5	15	17	24	32	13	0	<5	0	0	106
Total	29	400	725	819	995	1,693	1,362	1,438	1,560	1,116	544	10,681
Per cent												
Singleton	n.p.	n.p.	76.3	73.4	67.8	69.9	76.9	89.6	98.1	n.p.	100.0	82.8
Twins	24.1	26.5	21.7	24.5	29.7	28.2	22.1	10.4	n.p.	n.p.	0.0	16.2
Triplets and higher orders	n.p.	n.p.	2.1	2.1	2.4	1.9	1.0	0.0	n.p.	0.0	0.0	1.0
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

TABLE 53: Method of birth for level III registrants by birthweight, ANZNN 2017

Method of birth	Birthweight (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
	Number											
Vaginal birth	9	181	213	191	244	531	454	510	590	436	194	3,553
Vaginal instrumental birth	0	6	11	15	23	72	84	154	212	152	73	802
Caesarean section in labour	<5	63	174	192	225	347	n.p.	300	344	277	117	2,314
Caesarean section no labour	n.p.	147	318	417	493	730	n.p.	460	405	242	156	3,926
Not stated	1	3	9	4	10	13	10	14	9	9	4	86
Total	29	400	725	819	995	1,693	1,362	1,438	1,560	1,116	544	10,681
Per cent												
Vaginal birth	32.1	45.6	29.7	23.4	24.8	31.6	33.6	35.8	38.0	39.4	35.9	33.5
Vaginal instrumental birth	0.0	1.5	1.5	1.8	2.3	4.3	6.2	10.8	13.7	13.7	13.5	7.6
Caesarean section in labour	n.p.	15.9	24.3	23.6	22.8	20.7	n.p.	21.1	22.2	25.0	21.7	21.8
Caesarean section no labour	n.p.	37.0	44.4	51.2	50.1	43.5	n.p.	32.3	26.1	21.9	28.9	37.1
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

TABLE 54: Level of hospital of birth for level III registrants by birthweight, ANZNN 2017

Level of birth hospital	Birthweight (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
Number												
Tertiary	n.p.	358	644	735	890	1,457	1,081	1,119	n.p.	804	388	8,620
Non-tertiary	<5	36	76	73	99	224	273	309	n.p.	304	148	1,978
Not born in a hospital ^(a)	0	6	5	11	6	12	8	9	8	8	8	81
Not stated	0	0	0	0	0	0	0	1	1	0	0	2
Total	29	400	725	819	995	1,693	1,362	1,438	1,560	1,116	544	10,681
Per cent												
Tertiary	n.p.	89.5	88.8	89.7	89.4	86.1	79.4	77.9	n.p.	72.0	71.3	80.7
Non-tertiary	n.p.	9.0	10.5	8.9	9.9	13.2	20.0	21.5	n.p.	27.2	27.2	18.5
Not born in a hospital ^(a)	0.0	1.5	0.7	1.3	0.6	0.7	0.6	0.6	0.5	0.7	1.5	0.8
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

^(a) These babies were either born before arrival to hospital or born at home.

Note: Not stated data are excluded from per cent calculations.

TABLE 55: Mode of transport for level III registrants to level III unit after birth by birthweight, ANZNN 2017

Mode of transport	Birthweight (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
	Number											
Not transported	n.p.	n.p.	643	728	885	1,428	1,044	1,045	1,055	768	380	8,358
Specialist retrieval team	0	36	61	69	81	217	261	303	405	279	135	1,847
Non-specialist team	<5	<5	11	8	15	24	43	81	87	59	24	355
Other	0	7	6	11	12	20	14	7	9	7	4	97
Not stated	0	1	4	3	2	4	0	2	4	3	1	24
Total	29	400	725	819	995	1,693	1,362	1,438	1,560	1,116	544	10,681
Per cent												
Not transported	n.p.	n.p.	89.2	89.2	89.1	84.5	76.7	72.8	67.8	69.0	70.0	78.4
Specialist retrieval team	0.0	9.0	8.5	8.5	8.2	12.8	19.2	21.1	26.0	25.1	24.9	17.3
Non-specialist team	n.p.	n.p.	1.5	1.0	1.5	1.4	3.2	5.6	5.6	5.3	4.4	3.3
Other	0.0	1.8	0.8	1.3	1.2	1.2	1.0	0.5	0.6	0.6	0.7	0.9
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

TABLE 56: Exogenous surfactant use for level III registrants by birthweight, ANZNN 2017

Exogenous surfactant	Birthweight (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
Number												
None	<5	40	191	398	708	1,307	1,141	1,242	1,420	1,032	n.p.	7,984
Surfactant given	n.p.	360	533	420	287	386	221	195	139	83	n.p.	2,692
▪ via endotracheal tube	20	325	483	363	247	327	177	171	121	73	33	2,340
▪ via catheter	<5	22	19	24	16	18	13	<5	<5	<5	<5	123
▪ via other or unknown method	5	13	31	33	24	41	31	n.p.	n.p.	n.p.	6	229
Not stated	0	0	1	1	0	0	0	1	1	1	0	5
Total	29	400	725	819	995	1,693	1,362	1,438	1,560	1,116	544	10,681
Per cent												
None	n.p.	10.0	26.4	48.7	71.2	77.2	83.8	86.4	91.1	92.6	n.p.	74.8
Surfactant given	n.p.	90.0	73.6	51.3	28.8	22.8	16.2	13.6	8.9	7.4	n.p.	25.2
▪ via endotracheal tube	69.0	81.3	66.7	44.4	24.8	19.3	13.0	11.9	7.8	6.5	6.1	21.9
▪ via catheter	n.p.	5.5	2.6	2.9	1.6	1.1	1.0	n.p.	n.p.	n.p.	n.p.	1.2
▪ via other or unknown method	17.2	3.3	4.3	4.0	2.4	2.4	2.3	n.p.	n.p.	n.p.	1.1	2.1
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

TABLE 57: Assisted ventilation for level III registrants by birthweight, ANZNN 2017

Ventilation type	Birthweight (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
Number												
Invasive ventilation	27	362	512	372	269	426	377	453	489	344	138	3,769
▪ HFOV given	22	215	157	79	41	48	28	55	71	50	19	785
▪ IPPV given	27	361	510	372	269	426	377	453	487	344	138	3,764
Nitric oxide given	7	63	71	30	27	39	30	66	92	79	38	542
CPAP given	21	329	672	749	809	1,481	1,161	1,147	1,189	846	418	8,822
Total in each birthweight group	29	400	725	819	995	1,693	1,362	1,438	1,560	1,116	544	10,681
Per cent												
IPPV given	93.1	90.3	70.3	45.4	27.0	25.2	27.7	31.5	31.2	30.8	25.4	35.2
CPAP given	72.4	82.3	92.7	91.5	81.3	87.5	85.2	79.8	76.2	75.8	76.8	82.6
Per cent of babies given invasive ventilation												
HFOV given	81.5	59.4	30.7	21.2	15.2	11.3	7.4	12.1	14.5	14.5	13.8	20.8
Nitric oxide given	25.9	17.4	13.9	8.1	10.0	9.2	8.0	14.6	18.8	23.0	27.5	14.4

(a) Denominator is babies given ventilation via endotracheal tube (IPPV and/or HFOV).

Note: Groups are not mutually exclusive.

HFOV = high frequency oscillatory ventilation. IPPV = intermittent positive pressure ventilation. CPAP = continuous positive airway pressure.

TABLE 58: Duration of assisted ventilation use for level III registrants by birthweight, ANZNN 2017

Duration of assisted ventilation	Birthweight group (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
IPPV (hours)												
Median	462	271	87	28	20	27	44	44	50	44	45	46
IQR	29–689	94–628	22–263	11–102.5	10–47	12–76	17–88	20–91	22.5–97.5	18–99	19–102	17–134
CPAP (hours)												
Median	1,079	1,045	840	270	86	37	26	18	16	16	17	36
IQR	681–1,296	706–1,330	408–1,195	88–727	28–227	17–90	12–59	8–45	8–40	8–37	9–38	13–128

Note: IQR = Interquartile range. IPPV = intermittent positive pressure ventilation. CPAP = continuous positive airway pressure.

TABLE 59: Chronic lung disease at 36 weeks post menstrual age for level III registrants by birthweight, ANZNN 2017

Chronic lung disease (CLD)	Birthweight (grams)							Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	≥2000	
Number								
No CLD	n.p.	49	289	514	603	753	n.p.	2,274
CLD	n.p.	253	370	198	95	50	n.p.	988
Not stated	0	1	5	4	9	8	1	28
Ineligible ^(a)	12	97	61	103	288	882	5,948	7,391
Total	29	400	725	819	995	1,693	6,020	10,681
Per cent								
No CLD	n.p.	16.2	43.9	72.2	86.4	93.8	n.p.	69.7
CLD	n.p.	83.8	56.1	27.8	13.6	6.2	n.p.	30.3
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Includes babies who did not survive to 36 weeks post menstrual age and babies born at 32 or more weeks gestational age.

Note: Not stated and ineligible data are excluded from per cent calculations.

TABLE 60: Respiratory support (airway support or supplemental oxygen therapy) for level III registrants who survived to day 28 by birthweight, ANZNN 2017

Respiratory support (airway support or oxygen)	Birthweight (grams)											Total
	<500	500- 749	750- 999	1000- 1249	1250- 1499	1500- 1999	2000- 2499	2500- 2999	3000- 3499	3500- 3999	≥4000	
Number												
No respiratory support on day 28	0	7	65	305	739	1,483	1,262	1,339	1,481	1,063	513	8,257
Respiratory support on day 28	17	314	613	491	243	183	69	59	41	31	22	2,083
▪ survived to discharge home	n.p.	289	596	486	n.p.	177	60	52	n.p.	n.p.	n.p.	2,005
▪ died before discharge	<5	25	17	5	<5	6	9	7	<5	<5	<5	78
Not stated	0	2	2	0	0	0	1	0	2	0	0	7
Total in each birthweight group	17	323	680	796	982	1,666	1,332	1,398	1,524	1,094	535	10,347
Number												
Respiratory support on day 28 and given home oxygen	11	114	120	61	34	28	12	9	9	13	7	418
Per cent												
No respiratory support on day 28	0.0	2.2	9.6	38.3	75.3	89.0	94.8	95.8	97.3	97.2	95.9	79.9
Respiratory support on day 28	100.0	97.8	90.4	61.7	24.7	11.0	5.2	4.2	2.7	2.8	4.1	20.1
▪ survived to discharge home	n.p.	92.0	97.2	99.0	n.p.	96.7	87.0	88.1	n.p.	n.p.	n.p.	96.3
▪ died before discharge	n.p.	8.0	2.8	1.0	n.p.	3.3	13.0	11.9	n.p.	n.p.	n.p.	3.7
Per cent												
Respiratory support on day 28 and given home oxygen ^(a)	68.8	39.4	20.1	12.6	14.0	15.8	20.0	17.3	24.3	43.3	35.0	20.8

n.p. Data not published to maintain confidentiality of small numbers.

(a) Denominator is babies who received respiratory support on day 28 and survived to discharge to home.

Note: Not stated data are excluded from per cent calculations.

TABLE 61: Transfer after registration of level III registrants by level of destination hospital by birthweight, ANZNN 2017

Transfer status	Birthweight (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
Number												
Not transferred	18	229	335	332	383	698	718	1,012	1,195	854	414	6,188
Level III hospital	<5	23	39	38	40	56	31	30	22	29	n.p.	322
Level II or I hospital	6	107	309	417	551	888	559	319	249	162	86	3,653
Children's hospital	<5	41	42	30	20	50	54	77	94	71	n.p.	514
Not stated	0	0	0	2	1	1	0	0	0	0	0	4
Total	29	400	725	819	995	1,693	1,362	1,438	1,560	1,116	544	10,681
Per cent												
Not transferred	62.1	57.3	46.2	40.6	38.5	41.3	52.7	70.4	76.6	76.5	76.1	58.0
Level III hospital	n.p.	5.8	5.4	4.7	4.0	3.3	2.3	2.1	1.4	2.6	n.p.	3.0
Level II or I hospital	20.7	26.8	42.6	51.0	55.4	52.5	41.0	22.2	16.0	14.5	15.8	34.2
Children's hospital	n.p.	10.3	5.8	3.7	2.0	3.0	4.0	5.4	6.0	6.4	n.p.	4.8
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Not stated data are excluded from per cent calculations.

TABLE 62: Retinopathy of prematurity for level III registrants by birthweight, ANZNN 2017

Table 2.21 Retinopathy of prematurity for level III registrants by birthweight, 1980-1994							
Retinopathy of prematurity (ROP)	Birthweight (grams)						Total
	<500	500-749	750-999	1000-1249	1250-1499	≥1500	
	Number						
No ROP	5	68	321	523	512	463	1,892
Stage 1 ROP	<5	n.p.	n.p.	110	67	33	403
Stage 2 ROP	<5	90	141	85	n.p.	13	359
Stage 3 ROP	6	94	61	10	<5	<5	177
Stage 4 ROP	0	<5	<5	0	0	<5	5
Not examined	12	95	60	90	376	6,625	7,258
Not stated	0	0	1	1	10	575	587
Total	29	400	725	819	995	7,713	10,681
Per cent							
No ROP	29.4	22.3	48.3	71.8	84.1	90.3	66.7
Stage 1 ROP	n.p.	n.p.	n.p.	15.1	11.0	6.4	14.2
Stage 2 ROP	n.p.	29.5	21.2	11.7	n.p.	2.5	12.7
Stage 3 ROP	35.3	30.8	9.2	1.4	n.p.	n.p.	6.2
Stage 4 ROP	0.0	n.p.	n.p.	0.0	0.0	n.p.	0.2
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

Note: Weight criterion less than 1,250 grams for ANZNN but 1,500 grams for some individual units.

Not stated and not examined data are excluded from per cent calculations.

TABLE 63: Intraventricular haemorrhage for level III registrants who survived to day 3 by birthweight, ANZNN 2017^(a)

Intraventricular haemorrhage	Birthweight (grams)						Total
	<500	500-749	750-999	1000-1249	1250-1499	≥1500	
	Number						
None	21	224	542	658	749	1,727	3,921
Grade 1	<5	41	69	56	70	n.p.	359
Grade 2	<5	46	56	32	16	n.p.	184
Grade 3	<5	16	8	7	n.p.	8	46
Grade 4	<5	39	32	22	n.p.	22	122
Not examined	0	1	4	35	145	5,744	5,929
Total	27	367	711	810	992	7,654	10,561
Per cent							
None	77.8	61.2	76.7	84.9	88.4	90.4	84.7
Grade 1	n.p.	11.2	9.8	7.2	8.3	n.p.	7.8
Grade 2	n.p.	12.6	7.9	4.1	1.9	n.p.	4.0
Grade 3	n.p.	4.4	1.1	0.9	n.p.	0.4	1.0
Grade 4	n.p.	10.7	4.5	2.8	n.p.	1.2	2.6
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0

n.p. Data not published to maintain confidentiality of small numbers.

(a) Weight criterion for IVH is a birthweight of less than 1,500 grams.

Note: Not examined data are excluded from per cent calculations.

TABLE 64: Neonatal sepsis for level III registrants by birthweight, ANZNN 2017

Sepsis	Birthweight (grams)											Total
	<500	500-749	750-999	1000-1249	1250-1499	1500-1999	2000-2499	2500-2999	3000-3499	3500-3999	≥4000	
Number												
No sepsis	22	278	597	760	970	1,656	1,332	1,412	1,537	1,093	529	10,186
Sepsis at <48 hrs ^(a)	<5	12	11	12	6	10	14	12	16	9	n.p.	111
Sepsis at ≥48 hrs ^(a)	n.p.	112	122	46	20	27	16	15	10	n.p.	n.p.	396
Babies alive on day 2	n.p.	375	714	813	n.p.	1,686	1,354	1,425	1,555	n.p.	n.p.	10,595
Babies who did not survive to day 2	<5	25	11	6	<5	7	8	13	5	<5	<5	86
Total in each birthweight group	29	400	725	819	995	1,693	1,362	1,438	1,560	1,116	544	10,681
Per cent												
No sepsis ^(b)	75.9	69.5	82.3	92.8	97.5	97.8	97.8	98.2	98.5	97.9	97.2	95.4
Sepsis at <48 hrs ^(b)	n.p.	3.0	1.5	1.5	0.6	0.6	1.0	0.8	1.0	0.8	n.p.	1.0
Sepsis at ≥48 hrs ^(c)	22.2	29.9	17.1	5.7	2.0	1.6	1.2	1.1	0.6	1.3	1.3	3.7

n.p. Data not published to maintain confidentiality of small numbers.

(a) Groups are not mutually exclusive.

(b) Denominator is all registrants.

(c) Denominator is registrants alive at 48 hours.

TABLE 65: Length of stay for level III registrants who survived until discharge home by birthweight, ANZNN 2017

Birthweight (grams)	Number of babies	Median length of stay (days)	Interquartile range (days)
<500	16	125	109–163
500-749	296	116	102–133
750-999	658	89	75–107
1,000-1,249	791	66	53–80
1,250-1,499	979	48	38–60
1,500-1,999	1,659	36	28–46
2,000-2,499	1,322	20	14–28
2,500-2,999	1,391	11	6–19
3,000-3,499	1,516	7	4–14
3,500-3,999	1,093	6	4–13
≥4,000	533	6	4–13
Total	10,254	24	8–50

Note: Survival status was not provided for eight babies.

TABLE 66: Survival to discharge home for level III registrants by birthweight, ANZNN 2017

Birthweight (grams)	Number of babies	Lethal congenital anomalies	Babies alive on day 7	Babies alive on day 28	Survived to discharge to home	Percent survival at discharge home
<500	29	0	23	17	16	55.2
500-749	400	<5	349	323	296	74.0
750-999	725	<5	700	680	658	90.8
1,000-1,249	819	<5	807	796	791	96.6
1,250-1,499	995	9	988	982	979	98.4
1,500-1,999	1,693	15	1,676	1,666	1,659	98.0
2,000-2,499	1,362	21	1,344	1,332	1,322	97.1
2,500-2,999	1,438	25	1,408	1,398	1,391	96.7
3,000-3,499	1,560	19	1,534	1,524	1,516	97.2
3,500-3,999	1,116	7	1,100	1,094	1,093	97.9
≥4,000	544	<5	537	535	533	98.0
Total	10,681	104	10,466	10,347	10,254	96.0

Note: Survival status was not provided for eight babies.

Appendix 3: Methods used in this report

The ANZNN data collection was moved to the then-named Perinatal & Reproductive Epidemiology Research Unit, School of Women's & Children's Health, University of New South Wales in June 2008.

The historical ANZNN data were received as a Microsoft Access database and archived as a Microsoft SQL Server database. Updated data for the ANZNN audit of babies born in 2017 who qualified as high-risk neonates were requested from each participating unit in June 2018 with a deadline of August 2018. The data was submitted to the ANZNN by each participating unit through an online Data Capture System (DCS), which uses a series of queries to ensure quality, consistency and completeness of data. Units are unable to submit data if mandatory data items are missing or contain non-compliant data values. For all other data items, outliers flagged by the program may only be submitted by designated supervisors at each unit.

An extract from the database was made in March 2019. Apart from grouping, the data presented in the report reflect the database at that time with one exception: a series of derived data items were generated. These are listed below.

Derived data items:

Survival to day n	The number of days between the date of birth and the date of death was calculated and records flagged if this was less than n days.
Survival to 36 weeks post menstrual age	This item is for babies born at less than 36 weeks gestation only. The day the baby reaches 36 weeks post menstrual age is considered to be the infant's gestational age (completed weeks) plus chronological age in days. For example, a baby born at '28 weeks and four days' gestation on 1 January is 36 weeks post menstrual age on 26 February.
Chronic lung disease (CLD)	This item is for babies born at less than 32 weeks gestation only. The baby received any respiratory support (supplemental oxygen or intermittent positive pressure ventilation (IPPV) or continuous positive airway pressure (CPAP) for a chronic pulmonary disorder on the day the baby reached 36 weeks post menstrual age. Date of final added respiratory support must be: > Date of birth or $\{[(\text{Hours of IPPV} + \text{Hours of CPAP})/168] + \text{Gestational age}\} > 35.9$ weeks
Length of stay	The total number of days a baby spent in hospital during their first admission from birth. The total may include stays in more than one hospital.

All data manipulations and analysis for the 2017 report were carried out using Microsoft SQL Server software, and tabulations and figures were produced using Microsoft Excel.

Appendix 4: Confidentiality guidelines

Confidentiality guidelines provide an unambiguous framework for the handling of data that met the strict criteria of governing bodies. Confidentiality guidelines for the collection, processing and analysis of data from the minimum data collection of ANZNN were devised and agreed to by the Advisory Committee at the ANZNN Advisory Committee Meeting, Auckland, New Zealand on 2 April 1995. The summary below incorporates modifications agreed in the Memorandum of Understanding (MOU) between ANZNN and the National Perinatal Epidemiology and Statistics Unit, School of Women's and Children's Health, the University of New South Wales.

The purpose of these guidelines is to set out the principles under which the National Minimum Data Collection (NMDC) for neonatal intensive care units (NICUs) is formulated and the conditions that apply to the use of these data and release to parties internal and external to the ANZNN.

The essential purpose of the NMDC is to provide national unit record tabulations on babies meeting specified criteria who have been admitted to NICUs or affiliated nurseries in Australia and New Zealand. In general, this will be achieved through distribution of an annual report containing summary tables without identifying characteristics, either of a personal, institutional or state, territory or national nature. In certain other instances, data may be provided internally in the following manner:

- as de-identified summary tables not provided in the annual report, but available upon request
- as de-identified unit record data for analytical purposes as approved by the ANZNN
- as NICU identifiable summary and/or unit record data for clinical audit purposes by the respective NICU providing the data. These guidelines will cover the collection and provision of data retrospectively from 1 January 1994.

Principles of ownership and maintenance of data

- The National Perinatal Epidemiology and Statistics Unit (NPESU) agrees to house and maintain the ANZNN Data Collection through electronic data submission from neonatal intensive care units and special care nurseries during the period 1 January 2008 to 31 December 2018. A renewed agreement extends this period to 1 February 2024.
- The ANZNN Data Collection will be housed at NPESU. It will be managed according to existing data security procedures as for other data collections at NPESU. The Data Custodian is the Director of NPESU.

The ANZNN Data Collection Operation Committee ("ANZNN DCOC") was established in June 2008 to make decisions concerning the management, operation, data provision and reporting of the ANZNN Data Collection. The ANZNN DCOC is comprised of: three members appointed by the ANZNN Executive Committee and the ANZNN Advisory Council; two members appointed by the NPESU; and the Chairperson appointed by the ANZNN Executive Committee. The operations and progress of ANZNN Data Collection will be reported quarterly by ANZNN DCOC to the ANZNN Executive Committee.

NPESU will ensure that the data structure of the ANZNN Data Collection will remain the same as the existing data collection. Any modification to the data structure will be a joint decision between ANZNN Executive Committee and NPESU. Issues such as data entry, collation, retrieval and analysis will be considered.

The ANZNN will be responsible for collection and maintenance of the data set and decision-making with respect to its use.

All queries related to the NMDC should be referred to the Data Custodian at NPESU who will address them personally or refer them to the appropriate source person.

Conditions for data collection

It is expected that all participating NICUs will collect the agreed-upon minimum set of data in a standardised format for eligible babies registered to the ANZNN audit in their unit. Data will be transferred securely to the ANZNN coordinator.

Conditions for data security

The electronic version of these data is maintained in a secure partition at the University of New South Wales. Access to the server is limited to authorised named staff and further protected by the use of a high-level password. Attempted security breaches are monitored and investigated. Any hard copy potentially identifiable data are kept in secured and locked safe cabinets. Master lists of code material and source record identifiers are kept away from the database in a separate locked area. All rooms and offices used by the ANZNN are locked when not in use.

Computerised data on the server are protected by high-level passwords known only to each person who has access to computerised data. Potentially identifiable data will not leave the site of the ANZNN. Security disposal of data is available through use of designated bags or a shredding machine and must be witnessed by at least two staff members. A destruction certificate stating the name of the data and the date on which they are destroyed is to be issued and retained in the records.

Small numbers

Cell values of less than five in tables have not been published, in accordance with ethical guidelines for protecting the privacy of individuals. Exceptions to this are small numbers in 'Other' and 'Not stated' categories. The cell with small numbers and at least one other cell in the same row and column are suppressed to prevent back calculation. Where n.p. (not published) has been used to protect confidentiality, the suppressed numbers are included in the totals.

Appendix 5: Minimum Data Set variables

Neonatal Minimum Data Set

Registration hospital

Definition: The hospital of registration is the first level III NICU that the baby remained in for four or more hours during the first 28 days of life. Babies who received their entire care in a level II hospital, or who were not transferred to a level III NICU during the first 28 days are registered to the first level II centre that they remain in for four or more hours.

Coding: Numeric code representing registration hospital

Guide for use: If a baby dies within four hours, they are registered to the unit where they died.

Maternal age

Definition: Age in completed years of the woman giving birth on the date of the baby's birth.

Coding: 2-digit number representing maternal age in completed years

Previous preterm birth

Definition: This mother has had a previous birth that was at less than 37 weeks gestation and more than 20 completed weeks, regardless of outcome.

Coding:

- 99: unknown.
- 0: no previous preterm birth.
- 1: yes, there was a previous preterm birth.

Previous perinatal death

Definition: Mother has had a previous perinatal loss.

Coding:

- 99: unknown.
- 0: no previous perinatal death.
- 1: yes, has had a previous perinatal death.

Guide for use: A perinatal loss is when a baby with a birthweight of more than 400 grams or a gestational age of more than 20 completed weeks died during the first 28 days of life.

Assisted conception in this pregnancy

Definition: The type of infertility treatment used during conception or used to conceive this pregnancy.

Coding:

- 0: unknown.
- 1: none – no infertility treatment used for this pregnancy.
- 2: hyperovulation – any hormone therapy used to stimulate ovulation.
- 3: IVF / GIFT etc. – any method of in vitro fertilisation. Including in vitro fertilisation, gamete intra-fallopian transfer, zygote intra-fallopian transfer and IC sperm injection.
- 4: other – infertility treatment used that is not mentioned above, including artificial insemination.

Guide for use: Disregard any treatment for any previous pregnancies.

Ethnicity of mother

Definition: Ethnic origin of the mother of baby, as identified by the mother.

Coding:

- 0: Unknown.
- 1: Aboriginal or Torres Strait Islander – is a person of Aboriginal or Torres Strait Islander descent who identifies as an Aboriginal or Torres Strait Islander and is accepted as such by the community with which she is associated.
- 2: Asian – all whose ethnic background originates from countries of Asia, South East Asia and Indian subcontinent (e.g. Fijian Indian).
- 3: Caucasian – all Caucasoid heritage, including, European, Russian, Middle Eastern and Arabic.
- 4: Other – includes Indigenous Africans, Inuit, African Americans, Native Americans, Melanesian.

- 5: Pacific Islander – all from Pacific Islander background, including Samoan, Cook Islands Maori, Niuean, Tokelauan, and other Pacific Islands groups (e.g. Hawaiian, Tahitian). Excludes Maori.
- 6: Maori – a person of New Zealand Maori descent who identifies as Maori.

Source of referral

Definition: Source of referral to registration unit.

Coding:

- 0: unknown.
- 1: booked at tertiary obstetric hospital – mother booked into a hospital with an NICU and was not transferred during the most recent admission.
- 2: in utero transfer from obstetric hospital – mother transferred during most recent admission, baby in utero.
- 3: ex utero retrieval – baby transferred from any hospital by a specialist retrieval team.
- 4: ex utero transfer – baby transferred from any hospital by non-specialist team, includes transport by ambulance.
- 5: other – born in transit or not booked.
- 6: booked at this level II unit – mother booked into this hospital, no NICU.
- 7: in utero transfer to this level II unit – mother transferred, baby in utero.
- 8: ex utero retrieval to this level II unit – baby ‘retrieved’ from any other hospital.
- 9: ex utero transfer to this level II unit.

Guide for use: Use most recent referral.

Presenting antenatal problem

Definition: The antenatal complication that the mother presented with in this pregnancy.

Coding:

- 0: unknown.
- 1: preterm pre-labour rupture of membranes – confirmed spontaneous rupture of membranes occurring prior to the onset of labour and before 37 weeks gestation.
- 2: preterm labour.
- 3: hypertension in pregnancy.
- 4: antepartum haemorrhage.
- 5: suspected intrauterine growth restriction.
- 6: fetal distress.

- 7: other.
- 8: none – no presenting problem. Born at term.
- 9: antenatal diagnosis of fetal malformation.

Other antenatal complications

Definition: Any other antenatal complication.

Coding:

- 99: unknown.
- 0: no other antenatal complication present.
- 1: yes, other antenatal complication present.

Preterm labour

Definition: Regular painful contractions, leading to progressive effacement and dilatation of the cervix, eventually leading to the birth of the baby, and commencing before 37 weeks gestation.

Coding:

- 99: unknown.
- 0: no, labour did not commence before term.
- 1: yes, labour commenced in preterm period.

Hypertension in pregnancy

Definition: A systolic blood pressure (BP) ≥ 140 mmHg and/or diastolic BP ≥ 90 mmHg, or a rise in systolic BP ≥ 25 mmHg and/or a rise in diastolic BP ≥ 15 mmHg from a reading before conception or in 1st trimester; confirmed by two readings 6 hours apart.

Coding:

- 99: unknown.
- 0: no hypertension in pregnancy detected.
- 1: yes, hypertension in pregnancy diagnosed.

Antepartum haemorrhage

Definition: Significant haemorrhage in the time from 20 weeks gestation to the end of second stage of labour (excludes a ‘show’).

Coding:

- 99: unknown.
- 0: no antepartum haemorrhage noted.
- 1: yes, antepartum haemorrhage.

Suspected intrauterine growth restriction

Definition: A condition of the fetus in which it fails to reach its genetically predetermined full growth potential due to intrinsic or extrinsic factors based on more than one obstetric ultrasound.

Coding:

- 99: unknown.
- 0: no intrauterine growth restriction.
- 1: yes, intrauterine growth restriction suspected.

Fetal compromise

Definition: Any 'distress' of this fetus leading to intervention by the obstetric team.

Coding:

- 99: unknown.
- 0: no intervention necessary.
- 1: yes, obstetric intervention required.

Antenatal diagnosis of fetal malformation

Definition: A fetal malformation is diagnosed prior to the baby's birth, by any method.

Coding:

- 99: unknown.
- 0: no.
- 1: yes, malformation detected prior to birth.

Guide for use: The diagnosis of the malformation may or may not be confirmed after birth.

Other antenatal complication

Definition: Other significant antenatal complication noted for this baby, not specified.

Coding:

- 99: unknown.
- 0: no other significant antenatal complication.
- 1: yes, other significant antenatal complication.

Sex

Definition: The sex of the patient.

Coding:

- 0: unknown.
- 1: male.
- 2: female.
- 3: ambiguous or indeterminate.

Infant weight

Definition: The first weight of the baby after birth.

Coding: A 4-digit number representing birthweight in grams.

Guide for use: The weight is usually measured to the nearest five grams and is obtained within one hour of birth, or shortly after the infant has been admitted.

Gestational age

Definition: The estimated gestational age of the baby in completed weeks.

Coding: A 2-digit number representing the number of completed weeks of gestation.

Guide for use: Derived from a clinical assessment of the baby when accurate information is not stated.

Place of birth

Definition: Place of baby's birth.

Coding:

- 0: unknown.
- 1: non-tertiary hospital – born in a hospital with no level III NICU.
- 2: tertiary hospital – born in a hospital with a level III NICU.
- 3: homebirth – planned.
- 4: born before arrival – unplanned birth at home, or in an ambulance, a car etc.

Presentation at birth

Definition: Presenting part of the fetus (at lower segment of the uterus) at birth.

Coding:

- 0: unknown.
- 1: cephalic – including face and brow.
- 2: breech – legs or feet were facing the cervix.
- 3: other – includes transverse.

Mode of birth

Definition: The method of complete expulsion or extraction from its mother of a product of conception.

Coding:

- 0: unknown.
- 1: vaginal – vaginal birth, includes breech.
- 2: instrument – vaginal birth using an instrument – forceps, rotations, vacuum extraction.
- 3: Caesarean section in labour – caesarean performed after the commencement of labour.
- 4: Caesarean section, no labour – caesarean section performed prior to labour commencing.

Antenatal corticosteroids

Definition: Corticosteroids given during the antenatal period via any route to the mother at a time likely to enhance fetal lung maturation.

Coding:

- 0: unknown.
- 1: none – steroids not given.
- 2: less than 24 hours – first dose given less than 24 hours prior to this baby's birth.
- 3: complete – more than 1 dose of steroids given, and 1st dose at more than 24 hours and less than 8 days before birth.
- 4: given at more than 7 days before baby's birth.

Guide for use: If two courses given, and one fulfils the 'complete' criteria, use 'complete'. If the time of doses given is not available, but two doses are known to have been given appropriately, also use 'complete'.

Magnesium sulphate

Definition: Magnesium sulphate (MgSO_4) provided to the mother during the 24 hours immediately before birth, either because of maternal preeclampsia or specifically for fetal neuro-protection.

Coding:

- 0: unknown – information not available.
- 1: MgSO_4 not given at all.
- 2: MgSO_4 course stopped > 24 hours before birth.

- 3: MgSO_4 commenced > 24 hours before birth and stopped < 24 hours before birth.
- 4: MgSO_4 commenced between 4 to 24 hours before birth.
- 5: MgSO_4 commenced within 4 hours of birth.
- 6: MgSO_4 given but details not known.
- 7: MgSO_4 /placebo given for randomised trial.

Guide for use: In the case of planned birth, MgSO_4 is recommended to be commenced as close to four hours before birth as possible, however if birth is planned or expected to occur sooner than four hours, administration is recommended, as there is still advantage likely from administration within this time.

Plurality

Definition: The total number of births resulting from this pregnancy.

Coding:

- 0: singleton – only one baby born.
- 1: twins – two babies.
- 2: triplets – three babies.
- 3: quads – four babies.
- 4: more – quintuplets, sextuplets etc.

Guide for use: Determined by the number of live births or by the number of fetuses that remain in utero at 20 weeks gestation. If gestational age is unknown, only live births of any birthweight or gestation, or fetuses weighing ≥ 400 grams are taken into account. Fetuses aborted at < 20 weeks or fetuses compressed in the placenta at or more than 20 weeks are excluded.

Birth order

Definition: Order of each baby of a multiple birth.

Coding: Single-digit number representing birth order.

- 0: singleton.
- 1: first of a multiple birth.
- 2: second of a multiple birth.
- 3: third of a multiple birth etc.
- 4: other.

Date of birth

Definition: Date of birth of the patient.

Coding: DD / MM / YYYY

Admission date

Definition: The date on which an inpatient or same-day patient commences an episode of care.

Coding: DD / MM / YYYY

Apgar score (1 minute)

Definition: Numerical score to evaluate the baby's condition at one minute after birth.

Coding: 2-digit number representing Apgar score.

Guide for use: The score is based on the five characteristics of heart rate, respiratory condition, muscle tone, reflexes and colour.

Apgar score (5 minute)

Definition: Numerical score to evaluate the baby's condition at five minutes after birth.

Coding: 2-digit number.

Guide for use: As for Apgar score (1 minute).

Intubated at resuscitation

Definition: An active measure taken shortly after birth to establish independent respiration and heart rate, or to treat depressed respiratory effort by endotracheal intubation.

Coding:

- 99: unknown.
- 0: no, intubation was not necessary in labour ward.
- 1: yes, intubation necessary in labour ward.

Guide for use: Does not include intubation for tracheal aspiration or intubation in the NICU after resuscitation is complete.

Congenital anomalies

Definition: Structural abnormalities (including deformations) present at birth and diagnosed prior to separation from care (discharge home).

Coding:

- 99: unknown.
- 0: no major congenital malformations noted.
- 1: yes, major congenital malformation noted.

Specified congenital anomalies

Definition: Detail of the major congenital malformation.

Coding: Free text field representing congenital malformation coded by ICD-10-AM.

Temperature on admission

Definition: Temperature on admission to the NICU or closest to admission to registration unit. Use rectal temperature or, if not available, per axilla.

Coding: A 4-digit number representing temperature measured in degrees Celsius to 1 decimal place.

Guide for use: If the baby is transported by a specialist neonatal retrieval team, admission is considered to commence when the team arrive at the baby's bedside. If the baby is more than 12 hours of age when NICU care started, or if an admission temperature is not recorded, use '0' to denote missing.

Worst base excess

Definition: Worst base deficit recorded between admission to NICU and 12 hours after birth.

Coding: 3 digit numbered field representing base excess measured in mmol per litre. May be negative.

Guide for use: Use '99' to denote missing.

Main respiratory diagnosis

Definition: Main indication for respiratory support.

Coding:

- 0: unknown.
- 1: normal – no respiratory support.
- 2: non-specific – any non-specific respiratory distress in an infant requiring respiratory support (combines previous items transient tachypnoea of newborn and immature lung).
- 3: hyaline membrane disease – increasing respiratory distress or oxygen (O₂) requirements, or the need for ventilator support from the first six hours of life with a chest x-ray showing generalised reticulogranular pattern, plus or minus air bronchogram.
- 4: meconium aspiration – respiratory distress presenting from immediately after birth to 12 hours of age. Hypoxia, tachypnoea and gasping respirations are often signs of underlying asphyxia. Chest x-ray shows over-expansion of lungs with wide spread coarse, fluffy infiltrates.
- 5: pneumonia – respiratory distress with proven or suspected infection (toxic blood

count), and chest x-ray showing persisting opacities.

- 6: persistent pulmonary hypertension – echocardiatic (shunting) or clinical evidence – O₂ need unexplained by chest x-ray or loud P2, or differential pre /post ductal TCPO₂.
- 8: apnoea – recurrent pauses in breathing for more than 20 seconds, or for less than 20 seconds associated with bradycardia or any desaturation requiring intervention.
- 9: congenital malformation – malformation is the primary reason for respiratory distress, e.g. diaphragmatic hernia (list malformation in appropriate field).
- 10: other – unspecified other respiratory distress.
- 11: peri surgical – no respiratory distress, support given for surgical intervention.
- 12: newborn encephalopathy – a syndrome of disturbed neurological function in an infant with difficulties initiating or maintaining respiration, depression of tone reflexes or consciousness and often with seizures.

Guide for use: For a diagnosis other than ‘normal’ the baby must receive respiratory support. If more than one diagnosis is possible, use the most serious condition.

Exogenous surfactant

Definition: A dose of any type of exogenous surfactant was used to treat this baby.

Coding:

- 99: unknown.
- 0: no exogenous surfactant given to this baby.
- 1: yes, exogenous surfactant given to this baby.

Guide for use: Includes incomplete administration.

Method of administration of first dose of surfactant

Definition: Method used to administer the first dose of surfactant.

Coding:

- 0: unknown.
- 1: endotracheal tube.
- 2: catheter (eg. MIST).
- 3: Other – eg. laryngeal mask, aerosolisation.

Air leak requiring drainage

Definition: Any form of pulmonary air leak requiring drainage (transient or continuous).

Coding:

- 99: unknown.
- 0: no air leak requiring drainage present.
- 1: yes, air leak requiring drainage.

Hours of intermittent positive pressure ventilation (IPPV)

Definition: Total number of hours of IPPV given via an endotracheal tube, at any rate.

Coding: 4-digit number – IPPV hours.

Guide for use: The hours of all forms of assisted ventilation via an endotracheal tube are summed. The usual rounding up applies.

Hours of continuous positive airway pressure (CPAP)

Definition: Total number of hours of CPAP via any route, and nasopharyngeal ventilation.

Coding: 4-digit number – CPAP hours

Guide for use: As for hours of IPPV.

High frequency oscillatory ventilation (HFOV)

Definition: Mechanical ventilation presented at high frequencies (small tidal volumes with frequencies > 4Hz) initiated for this baby.

Coding:

- 99: unknown.
- 0: no high frequency oscillatory ventilation initiated.
- 1: yes, high frequency oscillatory ventilation was initiated.

Nitric oxide

Definition: Nitric oxide was used in any form or dose for respiratory support of the baby.

Coding:

- 99: unknown.
- 0: no, nitric oxide therapy never used.
- 1: yes, nitric oxide therapy used.

Extracorporeal membrane oxygenation

Definition: An extracorporeal circuit was established to divert baby's blood to a membrane lung for oxygenation, was initiated for this baby.

Coding:

- 99: unknown.
- 0: no ECMO initiated.
- 1: yes, ECMO initiated.

Date of final added respiratory support

Definition: Date supplemental oxygen (O₂), high flow, CPAP or mechanical ventilation ceased appropriately.

Coding: DD / MM / YYYY

Guide for use: Four consecutive hours in any 24-hour period constitutes a 'day'.

Nasal high flow therapy

Definition: Blended air and oxygen mix with a delivery flow of greater than 1 litre per minute through any high flow device with humidification.

Coding:

- 99: unknown.
- 0: nasal high flow was never initiated.
- 1: yes, nasal high flow was used for more than four hours.

Minimum nasal high flow

Definition: Minimum flow rate (greater than 1L/min) with air and oxygen mix delivered through a high flow device during the entire treatment period.

Coding: Number correct to one decimal place.

Guide for use: Device specifically designed to deliver high intranasal flow which has been shown to be associated with some air pressure.

Maximum nasal high flow

Definition: Maximum flow rate (in L/min) with air and oxygen mix delivered through a high flow device during the entire treatment period.

Coding: Number correct to one decimal place.

Guide for use: Device specifically designed to deliver high intranasal flow which has been shown to be associated with some air pressure.

Respiratory support at 36 weeks post menstrual age

Definition: Status of respiratory support at 36 weeks and 0 days / post menstrual age 252 days.

Coding:

- 0: unknown.
- 1: no respiratory support.
- 2: low flow air +/- oxygen with feeds (≤ 1 L/min).
- 3: low flow oxygen (≤ 1 L/min).
- 4: oxygen via head box or incubator.
- 5: high flow > 1 L/min.
- 6: nasal CPAP.
- 7: nasal ventilation (includes nasal high frequency).
- 8: endotracheal CPAP or ventilation (includes high frequency).
- 9: endotracheal tube alone.
- 10: tracheostomy CPAP or ventilation (includes high frequency).
- 11: tracheostomy alone.

Guide for use: Supersedes "Chronic lung disease".

Post-natal steroids for chronic lung disease

Definition: The infant was treated with systemic corticosteroids by any route for chronic lung disease.

Coding:

- 99: unknown.
- 0: no systemic post-natal steroids for chronic lung disease.
- 1: yes, the baby did have post-natal steroids for chronic lung disease.

Guide for use: Record if corticosteroids used with the objective of treating evolving CLD at any stage or to prevent development of CLD. It must not include corticosteroid use for the treatment of conditions such as post-extubation subglottic oedema or in the use for hypotension or any forms of corticosteroid deficiency.

Home oxygen therapy

Definition: Supplemental oxygen therapy was used at home after discharge from hospital.

Coding:

- 99: unknown.
0: no supplemental oxygen used at home.
-1: yes, home oxygen therapy given.

Guide for use: Must have required supplemental oxygen in hospital.

Neonatal surgery

Definition: This baby had surgery which involved opening a body cavity during this admission.

Coding:

- 99: unknown.
0: no major neonatal surgery.
-1: yes, major surgery took place during this admission.

Parenteral nutrition

Definition: Intravenous infusion of a nutritia solution consisting of a minimum of dextrose and protein but generally providing a complete nutrient infusion including electrolytes, calcium, phosphorus, zinc, trace elements, vitamins and fat.

Coding:

- 99: unknown.
0: parenteral nutrition never initiated.
-1: yes, parenteral nutrition initiated.

Home gavage feeding

Definition: The baby was discharged home with a nasogastric tube in place to allow gavage / infusion feeding at home.

Coding:

- 99: unknown.
0: no, not discharged with gavage tube.
-1: yes, discharged to home with a gavage tube.

Guide for use: Must have required gavage feeding in hospital.

Proven necrotising enterocolitis

Definition: Diagnosis of proven necrotising enterocolitis (NEC) is definite.

Coding:

- 99: unknown.
0: no necrotising enterocolitis proven.
-1: yes, necrotising enterocolitis proven.

Guide for use: Has at least one of the following symptoms:

1. Diagnosis at surgery or post mortem.
2. Radiological diagnosis, a clinical history plus:
 - pneumatosis intestinalis, or
 - portal vein gas, or
 - a persistent dilated loop on serial X-rays.
3. Clinical diagnosis, a clinical history plus abdominal wall cellulitis and palpable abdominal mass.

Spontaneous intestinal perforation

Definition: Intestinal perforation not associated with NEC nor with any bowel obstruction/atresia, nor with any mechanical trauma.

Coding:

- 99: unknown.
0: no, the baby did not have spontaneous intestinal perforation.
-1: yes, the baby did have spontaneous intestinal perforation.

Guide for use: Record if SIP has occurred, without any radiological signs of NEC and/or without surgical diagnosis of NEC.

Therapeutic hypothermia

Definition: Intentional cooling of an infant of any gestational age to a core temperature <35.0°C (generally 33–34°C).

Coding:

- 99: unknown.
0: no.
-1: yes.

Guide for use: Record if therapeutic hypothermia has occurred.

Principal reason for non-completion of full 72 hours of hypothermia

Definition: The principal reason why therapeutic hypothermia was terminated early / before 72 hours of treatment had been completed.

Coding:

- 0: not ceased before 72 hours
- 1: palliation.
- 2: recognised as not fulfilling standard criteria for cooling.
- 3: fulfilled standard criteria for cooling but clinical improvement suggests no need.
- 4: qualification equivocal with change of clinical decision making.
- 5: severe coagulopathy not responding to blood products.
- 6: hypotension not responding to inotrope.
- 7: severe PPHN refractory to iNO.
- 8: arrhythmia.
- 9: reason for early cessation not known.

Guide for use: Hypothermia begins at the onset of cooling and ends at the onset of warming.

Bacterial, fungal or viral infection present

Definition: The presence of proven systemic bacterial or fungal sepsis or late onset nosocomial viral infection for this baby.

Coding:

- 99: unknown.
- 0: no, the baby did not have a proven bacterial, fungal or viral infection noted.
- 1: yes, the baby did have a proven bacterial, fungal or viral infection noted.

Guide for use: Systemic sepsis is defined as a clinical picture consistent with sepsis, and either a positive bacterial or fungal culture of blood and/or cerebrospinal fluid (CSF). For each episode of sepsis, the following conditions must apply:

- Isolation of an organism from at least one blood or CSF culture or identification via polymerase chain reaction in CSF and,
- After consideration of clinical and laboratory evidence, a decision is made to give the patient antibiotics with therapeutic intent against this organism.

For each episode of infection, the following conditions must not apply:

- Mixed coagulase negative staphylococcus or other skin flora contaminant episode.

Viral infection should only be considered if initial symptoms occurred after 48 hours of birth.

- Clinical features consistent with viral infection
- Isolation or identification of an organism by PCR, immunofluorescence or similar technology from an appropriate body fluid eg mouth swab/saliva, rectal swab/faeces, nasopharyngeal aspirate, endotracheal aspirate, CSF, or other relevant tissues eg skin lesion
- Asymptomatic colonisation with rotavirus should be excluded.

Type of infection

Definition: The type of the proven systemic bacterial or fungal infection or nosocomial viral infection present.

Coding:

- 1: early infection (bacterial or fungal infection) – the presence of systemic bacterial or fungal sepsis with initial symptoms occurring prior to 48 hours after birth.
- 0: late infection (bacterial or fungal infection) – the presence of blood or CSF infection with initial symptoms occurring from 48 hours after birth.
- 2: viral infection – the presence of at least one episode of viral infection with initial symptoms occurring following 48 hours after birth.

Guide for use: As for Bacterial, fungal or viral infection present. The same organism isolated from blood or CSF during previous 14 days-repeat isolate should not be included.

Date of collection of positive blood or CSF culture for systemic sepsis or date of onset of nosocomial viral infection occurring after 48 hours of birth

Definition: The date of the collection of blood or CSF culture for each episode of systemic sepsis, or the date of the onset of clinical illness caused by each episode of viral infection, with initial symptoms occurring after 48 hours of birth.

Coding: DD / MM / YYYY

Guide for use: Must be coded as “yes” for ‘Bacterial, fungal or viral infection present’. The same organism isolated from blood or CSF during previous 14 days-repeat isolate should not be included. Leave blank when corresponding ‘Type of infection’ is coded as “Early infection”.

Maximum grade of left sided periventricular haemorrhage

Definition: Worst level of periventricular haemorrhage seen on the left side of the head by imaging or post mortem examination during the first 14 days of life.

Coding:

- 0: none – ultrasound / post mortem shows no haemorrhage.
- 1: grade 1 – subependymal germinal matrix haemorrhage.
- 2: grade 2 – intraventricular haemorrhage.
- 3: grade 3 – intraventricular haemorrhage with ventricle distended with blood.
- 4: grade 4 – localised intraparenchymal haemorrhage.
- 5: grade 4 – extensive intraparenchymal haemorrhage.
- 9: not examined – by ultrasound or by post mortem examination.

Guide for use: Early ventricular dilatation may occur with or without haemorrhages. Mild ventricular dilatation without intraventricular blood distension is excluded (not grade 3). Localised intraparenchymal haemorrhage/haemorrhagic infarction is defined as being solitary and mainly confined to one of the following territories: anterior frontal, posterior frontal, parietal, occipital, temporal, thalamus. Extensive intraparenchymal haemorrhage/haemorrhagic infarction is defined as involving two or more of the territories. Note: exclude echodensity which resolves within 10 days.

Maximum grade of right sided periventricular haemorrhage

Definition: Worst level of periventricular haemorrhage seen on the right side of the head by imaging or post mortem examination during the first 14 days of life.

Coding:

- 0: none – ultrasound / post mortem shows no haemorrhage.
- 1: grade 1 – subependymal germinal matrix haemorrhage.
- 2: grade 2 – intraventricular haemorrhage.
- 3: grade 3 – intraventricular haemorrhage with ventricle distended with blood.
- 4: grade 4 – localised intraparenchymal haemorrhage.
- 5: grade 4 – extensive intraparenchymal haemorrhage.
- 9: not examined– by ultrasound or by post mortem examination.

Guide for use: As for Maximum grade of left sided periventricular haemorrhage.

Cerebellar haemorrhage

Definition: Most extensive cerebellar haemorrhage noted by imaging or post mortem examination during the first 14 days of life.

Coding:

- 0: no cerebellar haemorrhage – mastoid ultrasound views undertaken and no cerebellar haemorrhage / post mortem shows no cerebellar haemorrhage.
- 1: left hemisphere haemorrhage only.
- 2: right hemisphere haemorrhage only.
- 3: haemorrhage in vermis only.
- 4: bilateral hemisphere haemorrhage.
- 5: haemorrhage in either or both hemispheres AND vermis.
- 9: not examined– by ultrasound or by post mortem examination.

Guide for use: Mastoid view is required for this detection.

Date of late head ultrasound

Definition: Date of the cerebral ultrasound scan nearest to six weeks of age.

Coding: DD / MM / YYYY

Guide for use: Data is confined to ultrasounds performed between four and eight weeks of age. Accept finding if transferred to Level II units between three and four weeks of age.

Ventricle size

Definition: Ventricular size measured by the ultrasound scan closest to six weeks (four to eight weeks) of age, as the largest measurement from either ventricle.

Coding: 4-digit number correct to one decimal place.

Guide for use: Record if the measurement for the largest ventricle. The lateral ventricle measurement is taken at the mid body in the coronal view at the foramen of Munroe.

Cerebral cysts (left)

Definition: Cystic change in left cerebral hemisphere measured by the ultrasound scan closest to six weeks of age. Record worst cystic periventricular leukomalacia severity (extensive or localised) if more cystic changes seen in four to eight week scans.

Coding:

- 0: no cysts – no cystic lesions seen on ultrasound.
- 1: porencephalic cyst(s).
- 2: periventricular leukomalacia primarily confined to one of the regions: anterior frontal, posterior frontal, parietal, temporal or occipital region (same as defined for periventricular haemorrhage).
- 3: extensive leukomalacia involving two or more of the above regions.
- 4: unknown – information not available, includes not scanned.

Guide for use: Ependymal cysts, cysts of the choroid plexus and conatal cysts are considered normal variants and are excluded. If any of these are present score as no cysts.

Cerebral cysts (right)

Definition: Cystic change in right cerebral hemisphere measured by the ultrasound scan closest to six weeks of age. Record worst cystic periventricular leukomalacia severity (extensive or localised) if more cystic changes seen in four to eight week scans.

Coding:

- 0: no cysts – no cystic lesions seen on ultrasound.
- 1: porencephalic cyst(s).
- 2: periventricular leukomalacia primarily confined to one of the regions: anterior frontal, posterior frontal, parietal, temporal or occipital region (same as defined for periventricular haemorrhage).
- 3: extensive leukomalacia involving two or more of the above regions.
- 4: unknown – information not available, includes not scanned.

Guide for use: As for Cerebral cysts (left)

Baby meets local criteria for ROP exam

Definition: The baby meets the criteria for eye examination for ROP.

Coding:

- 99: unknown.
- 0: no.
- 1: yes, did meet local criteria.

Retinopathy of prematurity (ROP)

Definition: Worst stage of ROP in either eye prior to going home.

Coding:

- 0: none seen – no changes seen.
- 1: stage I – demarcation line.
- 2: stage II – ridge.
- 3: stage III – ridge with extraretinal fibrovascular proliferation.
- 4: stage IV – retinal detachment.
- 5: not examined – no eye examination.

Surgical therapy for retinopathy of prematurity

Definition: Any surgical therapy used to treat retinopathy of prematurity (ROP), i.e. laser or cryotherapy.

Coding:

- 99: unknown.
- 0: no surgical therapy for ROP received.
- 1: yes, surgical therapy given for ROP.

Died

Definition: The death of this baby occurred prior to discharge from hospital.

Coding:

- 99: unknown.
- 0: no, survived to discharge to home.
- 1: yes, died.

Date of death

Definition: Date of death of the baby.

Coding: DD / MM / YYYY

Guide for use: If baby is known to have died after discharge, record date here and 'no' to died.

Post mortem

Definition: Post mortem examination performed.

Coding:

- 99: unknown.
- 0: no post mortem performed.
- 1: yes, a post mortem was performed.

Immediate cause of death

Definition: The cause of death as stated on the death certificate.

Coding: unspecified free text field

Guide for use: To be described in morbid anatomical terms.

Death due to congenital anomaly

Definition: The death of the infant directly attributed to the congenital anomaly.

Coding:

- 99: unknown.
- 0: no.
- 1: yes.

Guide for use: Must be coded as 'yes' for major congenital anomaly and 'yes' for died.

Transferred to another hospital

Definition: The baby was transferred to another hospital nursery before going home.

Coding:

- 99: unknown.
- 0: no, never transferred.
- 1: yes, transferred.

Date of transfer

Definition: Date on which a baby completes an episode of care after birth in the hospital of registration.

Coding: DD / MM / YYYY

Guide for use: Use the most significant date.

Discharge date

Definition: Date on which a patient completes an episode of care.

Coding: DD / MM / YYYY

Comment: All data collection ceases on this date.

Extremely Preterm Follow-up Minimum Data Set

Date assessed

Definition: Date on which the two to three year follow-up developmental assessment was performed.

Coding: DD / MM / YYYY

Corrected age in months

Definition: Age in months corrected for prematurity based on the age the child would be if the pregnancy had gone to term (40 weeks).

Coding: Number representing the number of months to one decimal place

Guide for use: The age when performance is no longer influenced by prematurity and the need to use corrected age is controversial. However objective evidence supports the need to make this allowance up to approximately 8 years of age. To calculate corrected age in months, use the formula: (Date Assessed – Estimated Date of Confinement) / (365.25 / 12)

Outcome for children at two to three years

Definition: Survival of the child at two to three years corrected age.

Coding:

- 99: unknown.
- 0: no, child died after discharge from hospital to home and prior to the two to three year follow-up.
- 1: yes, survived to the two to three year follow-up.

Outcome for follow-up at two to three years

Definition: Outcome of the child for follow-up at two to three years of age.

Coding:

- 1: formal developmental assessment (e.g. Bayley III or Griffiths).
- 2: information obtained but formal assessment not done.
- 3: child is unable to be assessed due to severe developmental delay.
- 4: child is unable to be assessed due to behavioural disorder.

- 5: child is unable to be assessed due to non-compliance.

- 6: lost- the child is lost to follow-up.

Guide for use: If the child attended assessment but was uncooperative, child is recorded as “Child is unable to be assessed due to non-compliance (5)”. If no contact with the child’s parent(s)/guardian(s) could be made or if the child’s parent(s)/guardian(s) were unwilling or unable to bring the child in for assessment, child is recorded as “Lost- the child has been lost to follow-up (6)”.

Reason for lost to follow-up

Definition: Main reason child was lost to follow-up at two to three years corrected age.

Coding:

- 0: unknown.
- 1: could not be contacted.
- 2: refused/did not attend appointment.
- 3: moved from area – referral to another hospital for follow-up assessment unknown.
- 4: referred to another hospital for follow-up assessment – the registration hospital could not obtain follow-up outcomes from the referral hospital.
- 5: did not meet local criteria for follow-up assessment.
- 6: other.

Guide for use: Only one outcome to be used. If child is referred to another hospital for follow-up assessment, the registration hospital should request any two to three year follow-up outcomes from the referral hospital. If the referral hospital fails to provide any follow-up outcomes, record as “Referred to another hospital for follow-up assessment – the registration hospital could not obtain follow-up outcomes from the referral hospital (4)”.

Place of follow-up assessment

Definition: Place of two to three year follow-up assessment.

Coding:

- 0: unknown.
- 1: follow-up clinic at registration hospital.
- 2: follow-up clinic at another hospital.
- 3: paediatrician.
- 4: general practitioner.
- 5: outreach clinic.
- 6: other.

Guide for use: Only one outcome to be used.

Weight

Definition: The weight (body mass) of a child measured in kilograms.

Coding: A 2-4 digit number representing weight in kilograms.

Guide for use: If the weight of the child was measured either side of one month of the date of assessment then an extrapolated value should be provided as determined by the z-score.

Type of stature measurement

Definition: The type of stature measurement used at the two to three year follow-up assessment.

Coding:

- 99: unknown.
- 1: standing height.
- 2: recumbent length.

Stature

Definition: The stature of a child measured in centimetres.

Coding: A 2-4 digit number representing stature in centimetres.

Guide for use: If the stature of the child was measured either side of one month of the date of assessment then an extrapolated value should be provided as determined by the z-score.

Head circumference

Definition: The head circumference of a child aged between two and three years measured in centimetres.

Coding: A 2-4 digit number representing head circumference in centimetres.

Guide for use: If the head circumference of the child was measured either side of one month of the date of assessment then an extrapolated value should be provided as determined by the z-score.

Hearing aid

Definition: Hearing aid has been prescribed or not. Information as provided by parent or carer at the two to three year follow-up assessment.

Coding:

- 99: unknown.
- 0: no hearing aid prescribed.
- 1: unilateral hearing aid prescribed.
- 2: bilateral hearing aid prescribed.

Cochlear implant

Definition: Cochlear Implant has been inserted or not. Information as provided by parent or carer at the two to three year follow-up assessment.

Coding:

- 99: unknown.
- 0: no cochlear implant.
- 1: yes, cochlear implant.

Blind

Definition: Ophthalmologist assessment has demonstrated that the child has blindness (<6/60 in better eye). This information may be provided by the parent or carer at the two to three year follow-up assessment.

Coding:

- 99: unknown.
- 0: no blindness.
- 1: yes, blindness (<6/60 in better eye).

Respiratory support

Definition: At the time of the two to three year follow-up assessment, the type of therapy the child is receiving for respiratory disease.

Coding:

- 99: unknown.
- 0: no respiratory support.
- 1: continued ventilator support.
- 2: oxygen.
- 3: tracheostomy.

Gastrointestinal feeding

Definition: At the time of the two to three year follow-up assessment, the therapy the child requires for gastrointestinal disease, represented by a code.

Coding:

- 99: unknown.
- 0: no therapy.
- 1: nasogastric tube.
- 2: parenteral nutrition.
- 3: percutaneous endoscopic gastrostomy (PEG) feeding.

Cerebral palsy

Definition: Cerebral palsy diagnosed.

Coding:

- 99: unknown.
- 0: no cerebral palsy.
- 1: yes, cerebral palsy.

Gross motor function classification system for cerebral palsy (GMFCS) (2-4 years)

Definition: The Gross Motor Function Classification System (GMFCS) classifies the movement ability of children with cerebral palsy. The Gross Motor Function Classification System (GMFCS) for cerebral palsy is based on self-initiated movement, with emphasis on sitting, transfers, and mobility, as represented by a code.

Coding:

- 1: Level I – Children floor sit with both hands free to manipulate objects. Movements in and out of floor sitting and standing are performed without adult assistance. Children walk as the preferred method of mobility without the need for any assistive mobility device.
- 2: Level II – Children floor sit but may have difficulty with balance when both hands are free to manipulate objects. Movements in and out of sitting are performed without adult assistance. Children pull to stand on a stable surface. Children crawl on hands and knees with a reciprocal pattern, cruise holding onto furniture and walk using an assistive mobility device as preferred methods of mobility.
- 3: Level III – Children maintain floor sitting often by "W-sitting" (sitting between flexed and internally rotated hips and

knees) and may require adult assistance to assume sitting. Children creep on their stomach or crawl on hands and knees (often without reciprocal leg movements) as their primary methods of self-mobility. Children may pull to stand on a stable surface and cruise short distances. Children may walk short distances indoors using a hand-held mobility device (walker) and adult assistance for steering and turning.

- 4: Level IV – Children floor sit when placed, but are unable to maintain alignment and balance without use of their hands for support. Children frequently require adaptive equipment for sitting and standing. Self-mobility for short distances (within a room) is achieved through rolling, creeping on stomach, or crawling on hands and knees without reciprocal leg movement.
- 5: Level V – Physical impairments restrict voluntary control of movement and the ability to maintain antigravity head and trunk postures. All areas of motor function are limited. Functional limitations in sitting and standing are not fully compensated for through the use of adaptive equipment and assistive technology. At Level V, children have no means of independent movement and are transported. Some children achieve self-mobility using a powered wheelchair with extensive adaptations.

Bayley scales of infant and toddler development – third edition

Definition: The Bayley-III assesses infant and toddler development across five domains: Cognitive, Language, Motor, Social-Emotional, and Adaptive.

Coding:

- 99: unknown.
- 0: no Bayley-III assessment performed.
- 1: yes, Bayley-III assessment performed.

Cognitive composite score

Definition: The cognitive scale of the Bayley-III assesses the sensory motor development, exploration and manipulation, object relatedness, concept formation, memory and other aspects of cognitive processing.

Coding: A 2-3 digit number representing the composite score from the cognitive scale.

Receptive communication scaled score

Definition: The receptive communication scale of the Bayley-III includes items that assess preverbal behaviours, vocabulary development, such as being able to identify objects and pictures that are referenced; vocabulary related to morphological development, such as pronouns and prepositions; and understanding of morphological markers, such as plural -s, tense markings (-ing, -ed) and the possessive -'s.

Coding: A 1-2 digit number representing the scaled score from the receptive communication scale.

Expressive communication scaled score

Definition: The expressive communication scale of the Bayley-III includes items that assess preverbal communication, such as babbling, gesturing, joint referencing, and turn taking, vocabulary development such as naming objects, pictures and attributes (e.g. colour and size); and morpho-syntactic development, such as using two-word utterances, plurals and verb tense.

Coding: A 1-2 digit number representing the scaled score from the expressive communication scale.

Language composite score

Definition: The language scale of the Bayley-III is the sum of the receptive communication score and the expressive communication score. This sum is then used to calculate the composite score for the language scale.

Coding: A 2-3 digit number representing the composite score from the language scale.

Fine motor scaled score

Definition: The fine motor scale of the Bayley-III includes skills associated with prehension, perceptual-motor integration, motor planning, and motor speed. Items measure young children's skills related to visual tracking, reaching, object manipulation and grasping. Children's functional hand skills and responses to tactile information are also measured.

Coding: A 1-2 digit number representing the scaled score from the fine motor scale.

Gross motor scaled score

Definition: The gross motor scale of the Bayley-III primarily measures the movement of the limbs and torso. Items assess static positioning (e.g., sitting, standing); dynamic movement, including locomotion and coordination; balance; and motor planning.

Coding: A 1-2 digit number representing the scaled score from the gross motor scale.

Motor composite score

Definition: The motor scale of the Bayley-III is the sum of the fine motor score and the gross motor score. This sum is then used to calculate the composite score for the motor scale.

Coding: A 2-3 digit number representing the composite score from the motor scale.

Griffiths Mental Development Scales (GMDS)

Definition: The GMDS assesses the mental development of young children. The GMDS consists of six subscales – Locomotor, Personal-Social, Language, Eye and Hand Co-ordination, Performance and Practical Reasoning.

Coding:

99: unknown.

0: no GMDS assessment performed.

-1: yes, GMDS assessment performed.

Locomotor subscale quotient

Definition: The locomotor subscale of the GMDS examines the child's gross motor skills including the child's ability to balance, and to co-ordinate and control movements. Test items include age appropriate activities such as walking up and down stairs, kicking a ball, riding a bike, jumping and skipping.

Coding: A 2-3 digit number representing the quotient from locomotor subscale.

Personal/social subscale quotient

Definition: The personal/social subscale of the GMDS examines the child's proficiency in the activities of daily living, level of independence and ability to interact with other children. Test items include age appropriate activities such as dressing and undressing, competency using cutlery and knowledge of information such as date of birth or address.

Coding: A 2-3 digit number representing the quotient from personal/social subscale.

Language subscale quotient

Definition: The language subscale of the GMDS examines the child's receptive and expressive language. The test includes age appropriate items such as naming objects and colours, repeating sentences, describing a picture and answering a series of questions about comprehension/similarities/ differences.

Coding: A 2-3 digit number representing the quotient from language subscale.

Eye and hand co-ordination subscale quotient

Definition: The eye and hand co-ordination subscale of the GMDS examines the child's fine motor skills, manual dexterity and visual perception skills. The test items include age appropriate items such as threading beads, cutting with scissors, copying shapes and writing letters and numbers.

Coding: A 2-3 digit number representing the quotient from eye and hand co-ordination subscale.

Performance subscale quotient

Definition: The performance subscale of the GMDS examines the child's manipulation skills including their speed of working and precision. The test items include age appropriate activities such as building bridges or stairs, completion of foam boards and pattern making.

Coding: A 2-3 digit number representing the quotient from performance subscale.

Practical reasoning subscale quotient

Definition: The practical reasoning subscale of the GMDS examines the child's ability to solve practical problems and understand basic mathematical concepts and questions about moral and sequential issues. The test items include age appropriate activities such as counting and comparison of size, length and height. This subscale

also assesses the child's knowledge of the days of the week, ability to tell the time and understanding of right and wrong.

Coding: A 2-3 digit number representing the quotient from practical reasoning subscale.

General quotient

Definition: The general quotient of the GMDS shows how the child's total score varies around the total mean, with a mean of 100 and a standard deviation of 15.

Coding: A 2-3 digit number representing the general quotient.

Other developmental tests administered

Definition: Other developmental tests administered, including clinical developmental assessments.

Coding:

99: unknown.

0: no other developmental tests administered.

-1: yes, other developmental tests administered.

Date of test

Definition: Date on which the other development tests were administered.

Coding: DD / MM / YYYY

Name of test administered

Definition: The name of the other development tests administered.

Coding: Free text field representing developmental test name.

Subscales of other developmental tests

Definition: Total number of the subscales for other developmental tests administered.

Coding: Number representing the total subscales of other developmental tests administered.

Score of other developmental tests

Definition: Score of other developmental tests administered.

Coding: Number representing the score of other developmental tests administered.

Level of development (months)

Definition: Level of development in months determined by other developmental tests administered.

Coding: Number representing level of development in months from the other developmental tests administered.

Reason for incomplete or no formal assessment

Definition: Main reason for incomplete or no formal developmental assessment at two to three years corrected age.

Coding:

- 0: unknown.
- 1: child too severely delayed.
- 2: child had a behavioural disorder.
- 3: child had a neurosensory impairment.
- 4: child was unwell.
- 5: child was uncooperative.
- 6: first language of child was not English.
- 7: formal assessment not offered at place of follow-up assessment.
- 8: other.

Guide for use: only one outcome to be used.

Clinical assessment of cognitive development

Definition: Assessment of cognitive development by a health care professional at two to three years corrected age for infants whose cognitive development was not assessed by a formal developmental test.

Coding:

- 0: unknown.
- 1: normal cognitive development or mild cognitive delay.
- 2: moderate cognitive delay.
- 3: severe cognitive delay.
- 4: cognitive delay but severity of delay unknown.
- 5: cognitive development not clinically assessed.

Clinical assessment of language development

Definition: Assessment of language development by a health care professional at two to three years corrected age for infants whose language development was not assessed by a formal developmental test.

Coding:

- 0: unknown.
- 1: normal language development or mild cognitive delay.
- 2: moderate language delay.
- 3: severe language delay.
- 4: language delay but severity of delay unknown.
- 5: language development not clinically assessed.

Clinical assessment of motor development

Definition: Assessment of motor development by a health care professional at two to three years corrected age for infants whose motor development was not assessed by a formal developmental test.

Coding:

- 0: unknown.
- 1: normal motor development or mild cognitive delay.
- 2: moderate motor delay.
- 3: severe motor delay.
- 4: motor delay but severity of delay unknown.
- 5: motor development not clinically assessed.

Other disability

Definition: Other disabilities.

Coding:

- 99: unknown.
- 0: no other disabilities.
- 1: yes, other disabilities.

Description of other disabilities

Definition: Description of other disabilities. Include ICD-10 code if known.

Coding: Free text field representing description of other disabilities and ICD-10 codes if known.

Glossary

Antepartum fetal death: fetal death occurring before the onset of labour.

Apgar score: numerical score used to indicate the baby's condition at 1 minute and 5 minutes after birth. Between 0 and 2 points are given for each of five characteristics: heart rate, breathing, colour, muscle tone and reflex irritability, and the total score is between 0 and 10.

Baby's length of stay: number of days between date of birth and date of separation from the hospital of birth (calculated by subtracting the date of birth from the date of separation).

Bayley Scales of Infant and Toddler

Development- third edition: assesses the motor (fine and gross), language (receptive and expressive), and cognitive development of infants and toddlers.

Birth status: status of the baby immediately after birth.

Birthweight: the first weight of the baby (stillborn or liveborn) obtained after birth (usually measured to the nearest 5 grams and obtained within one hour of birth).

Caesarean section: operative birth by surgical incision through the abdominal wall and uterus.

Cerebral palsy: a developmental disability that results from damage to or dysfunction of the developing brain.

Clinical assessment of development: professional opinion of a healthcare professional regarding the presence and severity of developmental delays for specific domains (cognitive, language and motor development), made in the absence of formal developmental testing.

Corrected age: the age a preterm baby would be if they had been born on their due date.

Early neonatal death: death of a liveborn baby within seven days of birth.

Extremely low birthweight: birthweight of less than 1,000 grams.

Extremely preterm birth: birth before 28 weeks of gestation

Fetal death (stillbirth): death prior to the complete expulsion or extraction from its mother of a product of conception of 20 or more completed weeks of gestation or of 400 grams or more birthweight. The death is indicated by the fact that after such separation the fetus does not breathe or show any other evidence of life, such as

beating of the heart, pulsation of the umbilical cord or definite movement of voluntary muscles.

Forceps: assisted birth using a metallic obstetric instrument.

Formal developmental assessment: includes neurological examination by a developmental paediatrician or physiotherapist, vision by an ophthalmologist or optometrist, hearing by an audiologist, and a developmental test using the Bayley Scales of Infant Development-III, Griffiths Mental Development Scales or another developmental test performed by a psychologist, developmental paediatrician, physiotherapist, or other qualified person.

Gestational age: the duration of pregnancy in completed weeks calculated from the date of the first day of a woman's last menstrual period and her baby's date of birth, or via ultrasound, or derived from clinical assessment during pregnancy or from examination of the baby after birth.

Griffiths Mental Development Scales: assesses the mental development of young children across five subscales; locomotor, personal-social, language, eye and hand co-ordination, performance and practical reasoning

Gross Motor Function Classification System (GMFCS): classifies the movement ability of children with cerebral palsy

Hyaline membrane disease: a disorder of the respiratory system.

Instrumental delivery: vaginal delivery using forceps or vacuum extraction.

Intrapartum fetal death: fetal death occurring during labour.

Intrauterine growth restriction: a fetus whose estimated weight is below the 10th percentile for its gestational age.

Late neonatal death: death of a liveborn baby after seven completed days and before 28 completed days.

Live birth: the complete expulsion or extraction from its mother of a product of conception, irrespective of the duration of the pregnancy, which, after such separation, breathes or shows any other evidence of life, such as beating of the heart, pulsation of the umbilical cord, or definite movement of voluntary muscles, whether or not the umbilical cord has been cut or the placenta is attached; each product of such a birth is considered liveborn (WHO definition).

Low birthweight: birthweight of less than 2,500 grams.

Maternal age: mother's age in completed years at the birth of her baby.

Mode of separation: status at separation of patient (discharge/transfer/death) and place to which patient is released (where applicable).

Neonatal care levels: Level I care is for normal healthy term babies, some of whom may need short-term observation during the first few hours of life.

Level II refers to a nursery that generally has babies born at 32–36 weeks gestation weighing around 1,500 to 2,500 grams at birth. It includes care for babies who require intravenous therapy or antibiotics, and/or those who are convalescing after intensive care, and/or those who need their heart rate or breathing monitored, and/or those who need short-term oxygen therapy.

Level III or intensive care refers to the care of newborn infants who require more specialised care and treatment. It includes most babies born at less than 32 weeks gestation or less than 1,500 grams birthweight, and others who may require such interventions as intravenous feeding, and/or surgery, and/or cardiorespiratory monitoring for management of apnoea or seizures, and/or require assisted ventilation, and/or supplemental oxygen over 40% or long-term oxygen.

Neonatal death: death of a liveborn baby within 28 days of birth.

Neonatal morbidity: any condition or disease of the baby diagnosed after birth and before separation from care.

Perinatal death: a fetal or neonatal death of at least 20 weeks gestation or at least 400 grams birthweight.

Plurality: the number of births resulting from a pregnancy.

Post menstrual age is calculated by taking the gestational age plus postnatal age – e.g. when a baby born at 25 weeks gestation is 15 weeks old,

they are 40 weeks PMA (also known as term equivalent age).

Post neonatal death: death of a liveborn baby after 28 days and within one year of birth.

Post term birth: birth at 42 or more weeks of gestation.

Presentation at birth: presenting part of the fetus at birth.

Preterm birth: birth before 37 weeks of gestation.

Resuscitation of baby: active measures taken shortly after birth to assist the baby's ventilation and heartbeat, or to treat depressed respiratory effort and to correct metabolic disturbances.

Retinopathy of prematurity (ROP): a disorder of the developing eye.

Sex ratio: number of male liveborn babies per 100 female liveborn babies.

Spontaneous vaginal: birth without intervention in which the baby's head is the presenting part.

Stanford-Binet Intelligence Scales: assesses the cognitive ability of children, adolescents and adults across five subscales; fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing and working memory.

Stillbirth: see Fetal death (stillbirth).

Teenage mother: mother aged less than 20 years at the birth of her baby.

Vacuum extraction: assisted birth using a suction cap applied to the baby's head.

Vaginal breech: vaginal birth in which the baby's buttocks is the presenting part.

Very low birthweight: birthweight of less than 1,500 grams.

Very preterm birth: birth before 32 weeks of gestation.

Wechsler Preschool and Primary Scale of Intelligence: assesses the cognitive development of young children across five subscales; verbal comprehension, visual spatial, fluid reasoning, working memory, and processing speed.

References

- Australian Bureau of Statistics 2018. *Births, Australia, 2017*. Cat. no. 3301.0. Canberra: ABS.
- Chow SSW, Creighton P, Kander V, Haslam R, Lui K 2018. *Report of the Australian and New Zealand Neonatal Network 2016*. Sydney: ANZNN < www.anznn.net >.
- The Committee for the Classification of Retinopathy of Prematurity 1984. An international classification of retinopathy of prematurity. *Archives of Ophthalmology* 102(8):1130–1134.
- Conde-Agudelo A & Romero R 2009. Antenatal magnesium sulfate for the prevention of cerebral palsy in preterm infants less than 34 weeks' gestation: a systematic review and metaanalysis. *American Journal of Obstetrics & Gynecology* 200(6):595–609.
- Crowther CA, Hiller JE, Doyle LW, Haslam RR for the Australasian Collaborative Trial of Magnesium Sulphate (ACTO MgSO₄) Collaborative Group 2003. Effect of magnesium sulphate given for neuroprotection before preterm birth: a randomised controlled trial. *JAMA: The Journal of the American Medical Association* 290(20):2669–2676.
- Doyle LW, Roberts G, Anderson PJ & the Victorian Infant Collaborative Group 2010. Outcomes at age 2 years of infants < 28 weeks' gestational age born in Victoria 2005. *Journal of Paediatrics* 156(1):49–53
- Doyle LW, Roberts G, Anderson PJ & the Victorian Infant Collaborative Group 2011. Changing long-term outcomes for infants 500–999 g birth weight in Victoria, 1997–2005. *Archives of Disease in Childhood – Fetal and Neonatal edition* 96(6):F443–447
- Finer NN & Barrington KJ 2006. Nitric oxide for respiratory failure in infants born at or near term. *Cochrane Database of Systematic Reviews* 18(4):CD000399.
- Hediger ML, Overpeck MD, Maurer KR, Kuczmarski RJ, McGlynn A & Davis WW 1998. Growth of infants and young children born small or large for gestational age: findings from the Third National Health and Nutrition Examination Survey. *Archives of Pediatrics & Adolescent Medicine* 152(12):1225–1231.
- Oskoui M, Coutinho F, Dykeman J, Jette N & Pringsheim T 2013. An update on the prevalence of cerebral palsy: a systematic review and meta-analysis. *Developmental Medicine & Child Neurology* 55(6):509–519
- Papile LA, Burstein J, Burstein R & Hoffer H 1978. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500gm. *Journal of Paediatrics* 92(4):529–34.
- Robertson CMT, Howarth TM, Bork DLR & Dinu IA 2009. Permanent bilateral sensory and neural hearing loss of children after neonatal intensive care because of extreme prematurity: a thirty-year study. *Pediatrics* 123(5):e797–807.
- Rouse DJ 2009. Magnesium sulfate for the prevention of cerebral palsy. *American Journal of Obstetrics & Gynecology*. 200(6):610–612.
- Statistics New Zealand 2018. *Demographic tables 2017*. Wellington: Statistics New Zealand < www.stats.govt.nz >.
- WHO Multicentre Growth Reference Study Group. *WHO Child Growth Standards: Length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development*. Geneva: World Health Organization, 2006.
- Wilkinson D, Andersen C, O'Donnell CP & De Paoli AG 2011. High flow nasal cannula for respiratory support in preterm infants. *Cochrane Database of Systematic Reviews* 11(5): CD006405.

List of Tables

TABLE 1: Level III registrants born at each completed week of gestation, ANZNN 2017	7
TABLE 2: Level III registrants in each birthweight group, ANZNN 2017	8
TABLE 3: Age group of mothers of level III registrants by gestational age, ANZNN 2017	9
TABLE 4: Mother's presenting antenatal problem for level III registrants by gestational age, ANZNN 2017 10	
TABLE 5: Antenatal corticosteroid use for mothers of level III registrants by gestational age, ANZNN 2017 12	
TABLE 6: Magnesium sulphate use for mothers of level III registrants by gestational age, ANZNN 2017	12
TABLE 7: Plurality of level III registrants by gestational age, ANZNN 2017	13
TABLE 8: Method of birth for level III registrants by gestational age, ANZNN 2017	14
TABLE 9: Level of hospital of birth for level III registrants by gestational age, ANZNN 2017	14
TABLE 10: Mode of transport to level III NICU after birth for level III registrants by gestational age, ANZNN 2017	15
TABLE 11: Apgar scores at birth for level III registrants by gestational age, ANZNN 2017	16
TABLE 12: Admission body temperature for level III registrants by gestational age, ANZNN 2017	17
TABLE 13: Indication for respiratory support for level III registrants by gestational age, ANZNN 2017	18
TABLE 14: Exogenous surfactant use for level III registrants by gestational age, ANZNN 2017	19
TABLE 15: Duration of assisted ventilation use for level III registrants by gestational age, ANZNN 2017	20
TABLE 16: Assisted ventilation for level III registrants by gestational age, ANZNN 2017	20
TABLE 17: Respiratory support (airway support or supplemental oxygen therapy) for level III registrants who survived to day 28 by gestational age, ANZNN 2017	22
TABLE 18: Nasal high flow respiratory support for level III registrants by gestational age, ANZNN 2017 22	
TABLE 19: Parenteral nutrition for level III registrants by gestational age, ANZNN 2017	23
TABLE 20: Chronic lung disease at 36 weeks post menstrual age for level III registrants by gestational age, ANZNN 2017	24
TABLE 21: Pulmonary air leak for level III registrants by gestational age, ANZNN 2017	24
TABLE 22: Neonatal sepsis for level III registrants by gestational age, ANZNN 2017	25
TABLE 23: Retinopathy of prematurity for level III registrants by gestational age, ANZNN 2017	26

TABLE 24: Intraventricular haemorrhage for level III registrants born before 32 weeks and survived to day 3, by gestational age, ANZNN 2017	27
TABLE 25: Late cerebral ultrasound results for level III registrants born before 32 weeks by gestational age, ANZNN 2017	28
TABLE 26: Necrotising enterocolitis in level III registrants by year of birth, ANZNN 2008–2017	29
TABLE 27: Characteristics of level III registrants who underwent surgery by gestational age, ANZNN 2017 30	
TABLE 28: Transfer after registration of level III registrants by level of destination hospital and gestational age, ANZNN 2017	31
TABLE 29: Length of stay for level III registrants who survived until discharge home by gestational age, ANZNN 2017	32
TABLE 30: Survival to discharge home for level III registrants by gestational age, ANZNN 2017	33
TABLE 31: Level II registrants by gestational age, ANZNN 2017	35
TABLE 32: Level II registrants by birthweight, ANZNN 2017	35
TABLE 33: Mothers of level II registrants presenting antenatal problem by gestational age, ANZNN 2017 36	
TABLE 34: Antenatal corticosteroid use by mothers of level II registrants by gestational age, ANZNN 2017. 37	
TABLE 35: Method of delivery for level II registrants by gestational age, ANZNN 2017	37
TABLE 36: Indication for respiratory support for level II registrants by gestational age, ANZNN 2017	38
TABLE 37: Duration of assisted ventilation use for level II registrants by gestational age, ANZNN 2017	39
TABLE 38: Survival to discharge home for level II registrants by gestational age, ANZNN 2017	40
TABLE 39: Births, survival and 2–3 year follow-up of extremely preterm and/or extremely low birthweight infants by gestational age, ANZNN 2011–2014 births	42
TABLE 40: Births, survival and 2–3 year follow-up of extremely preterm and/or extremely low birthweight infants by birthweight, ANZNN 2011–2014 births... 42	
TABLE 41: Cerebral palsy at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births.....	44
TABLE 42: Cognitive delay at 2–3 year follow-up by gestational age for Bayley, Griffiths, WPPSI and Stanford–Binet assessments, ANZNN 2011–2014 births	46
TABLE 43: Language delay at 2–3 year follow-up by gestational age for Bayley and Griffiths assessments, ANZNN 2011–2014 births.....	46

TABLE 44: Motor delay at 2–3 year follow-up by gestational age for Bayley and Griffiths assessments, ANZNN 2011–2014 births.....	47
TABLE 45: Severity of functional impairment at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births.....	48
TABLE 46: Infants with or without moderate to severe functional impairment at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births.....	49
TABLE 47: Weight for age at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births.....	50
TABLE 48: Length/height for age at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births.....	50
TABLE 49: Head circumference for age at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births.....	51
TABLE 50: Weight for length/height at 2–3 year follow-up by gestational age, ANZNN 2011–2014 births.....	51
TABLE 51: Antenatal corticosteroid use for level III registrants by birthweight, ANZNN 2017.....	62
TABLE 52: Plurality of level III registrants by birthweight, ANZNN 2017.....	62
TABLE 53: Method of birth for level III registrants by birthweight, ANZNN 2017.....	63
TABLE 54: Level of hospital of birth for level III registrants by birthweight, ANZNN 2017.....	63
TABLE 55: Mode of transport for level III registrants to level III unit after birth by birthweight, ANZNN 2017.....	64

TABLE 56: Exogenous surfactant use for level III registrants by birthweight, ANZNN 2017.....	64
TABLE 57: Assisted ventilation for level III registrants by birthweight, ANZNN 2017.....	65
TABLE 58: Duration of assisted ventilation use for level III registrants by birthweight, ANZNN 2017.....	65
TABLE 59: Chronic lung disease at 36 weeks post menstrual age for level III registrants by birthweight, ANZNN 2017.....	66
TABLE 60: Respiratory support (airway support or supplemental oxygen therapy) for level III registrants who survived to day 28 by birthweight, ANZNN 2017.....	66
TABLE 61: Transfer after registration of level III registrants by level of destination hospital by birthweight, ANZNN 2017.....	67
TABLE 62: Retinopathy of prematurity for level III registrants by birthweight, ANZNN 2017.....	67
TABLE 63: Intraventricular haemorrhage for level III registrants who survived to day 3 by birthweight, ANZNN 2017 ^(a)	68
TABLE 64: Neonatal sepsis for level III registrants by birthweight, ANZNN 2017.....	68
TABLE 65: Length of stay for level III registrants who survived until discharge home by birthweight, ANZNN 2017.....	69
TABLE 66: Survival to discharge home for level III registrants by birthweight, ANZNN 2017.....	69

List of Figures

FIGURE 1: Structure of the ANZNN.....	2
FIGURE 2: Proportion of liveborn babies in Australia and New Zealand who were ANZNN level III registrants, by year of birth, ANZNN 2008–2017.....	6
FIGURE 3: Number of level III registrants born at each neonatal intensive care unit, ANZNN 2017	7
FIGURE 4: Level III registrants by registration criteria, ANZNN 2013–2017	8
FIGURE 5: Presenting antenatal problem for mothers of level III registrants by gestational age, ANZNN 2017	11
FIGURE 6: Retinopathy of prematurity for level III registrants by gestational age, ANZNN 2017	26
FIGURE 7: Intraventricular haemorrhage in level III registrants born at less than 32 weeks gestation and survived to day 3, by gestational age, ANZNN 2017	28
FIGURE 8: Survival of level III registrants to discharge home (with 95% CI) by gestational age, ANZNN 2017	34
FIGURE 9: Survival of level III registrants to discharge home (with 95% CI) by birthweight group, ANZNN 2017	34
FIGURE 10: ANZNN 2–3 year follow-up cohort of extremely preterm infants, 2011–2014 births	41
FIGURE 11: Trends in gestational age at birth of level III registrants, ANZNN 2008–2017.....	53
FIGURE 12: Trends in the use of corticosteroids for mothers of babies less than 32 weeks gestation, ANZNN 2008–2017	54
FIGURE 13: Trends in multiple births of level III registrants by gestational age, ANZNN 2008–2017	54
FIGURE 14: Trends in method of birth for level III registrants by year of birth, ANZNN 2008–2017.....	55
FIGURE 15: Trends in referral source to level III NICU by year of birth, ANZNN 2008–2017.....	55

FIGURE 16: Trends in mode of transport to level III NICU, ANZNN 2008–2017	56
FIGURE 17: Trends in mode of assisted ventilation for level III registrants, ANZNN 2008–2017	56
FIGURE 18: Trends in provision of intermittent positive pressure ventilation and continuous positive airway pressure by year of birth for level III registrants ventilated, ANZNN 2008–2017	57
FIGURE 19: Trends in the use of continuous positive airway pressure as the only form of ventilation by gestational age for level III registrants, ANZNN 2008, 2011, 2014–2017.....	57
FIGURE 20: Trends in provision of high frequency oscillatory ventilation (with 95% CI) for level III registrants born before 28 weeks and at 28 or more weeks gestation, ANZNN 2008–2017	58
FIGURE 21: Trends in nitric oxide (with 95% CI) provision for level III registrants born before 28 weeks and 28–31 weeks gestation, ANZNN 2008–2017.....	58
FIGURE 22: Trends in chronic lung disease (with 95% CI) for level III registrants who survived to 36 weeks post menstrual age, ANZNN 2008–2017	59
FIGURE 23: Trends in stage 3 or 4 retinopathy of prematurity and treated retinopathy among babies born before 31 weeks gestation and/or birthweight of less than 1,250 grams who survived to 36 weeks post menstrual age for level III registrants, ANZNN 2008–2017	59
FIGURE 24: Trends in grade 3 or 4 intraventricular haemorrhage (with 95% CI) in babies born at less than 32 weeks gestation who survived to day 3 for level III registrants, ANZNN 2008–2017	60
FIGURE 25: Trends in incidence of early sepsis for level III registrants by gestational age, ANZNN 2013–2017	60
FIGURE 26: Trends in incidence of late sepsis for level III registrants by gestational age, ANZNN 2013–2017	61

